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Chapter a
General introduction 
and 
Outline of this thesis
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General introduction
Ovarian cancer
Ovarian cancer is an insidious disease that is most frequent in middle aged and 
elderly women. This disease affects approximately  in 70 women in the Western 
world and is the fourth leading cause of cancer-related deaths in women (). The 
yearly incidence of ovarian cancer in the Netherlands is approximately ,00 
cases (). Ovarian cancer symptoms are late in onset, and are often vague and 
non-specific (nausea, early satiety and bloating), so that they are taken initially 
for benign gastrointestinal disorders not worthy of medical consultation. For 
this reason and due to the lack of efficient screening methods, ovarian cancer is 
often diagnosed when it is already at an advanced stage of disease. At physical 
examination a palpable abdominal mass may be found, with ascites and enlarged 
inguinal or supraclaviculair lymph nodes. Further examination consists of 
transvaginal ultrasonography (TVU) and tumor marker CA  measurements 
in serum (). TVU may reveal complex ovarian cyst(s) with both solid and cystic 
components, sometimes with septations and internal echoes as well as ascites in 
some cases. Elevated CA  levels (cut-off >  U/mL) are found in 80% of the 
patients with advanced stage ovarian cancer (,). A risk of malignancy index can 
be used to determine the probability of ovarian cancer in suspected patients based 
on TVU findings, menopausal state and CA  levels (4). Abdominal and pelvic 
malignancies can be further assessed with computed tomography and magnetic 
resonance imaging.
The definitive diagnosis of ovarian cancer and the dissemination of the disease is 
usually determined at staging laparotomy followed by (immuno-)histopathological 
examination of the resected specimens.
Standard treatment
Standard treatment of ovarian cancer consists of surgical exploration for staging 
and tumor debulking, followed by chemotherapy. Ovarian cancer is staged 
according to the Fédération Interationale de Gynécologie et d’Obstetrique (FIGO) 
system (Table ). 
Surgical staging and cytoreductive surgery
The intent of primary surgery is to establish a diagnosis, assess the extent of disease 
and remove as much gross tumor as possible. Surgical staging includes total 
abdominal hysterectomy and bilateral salpingo-oophorectomy. The contents 

Table . FIGO stages (,6,7)
 Stage I Tumor limited to the ovaries %
Stage Ia One ovary involved; without ascites, surface involvement or 
capsule rupture
89.
Stage Ib Both ovaries involved; without ascites, surface involvement 
or capsule rupture
64.8
Stage Ic§ Tumor either stage IA or IB with ascites or surface involve-
ment or capsule rupture or positive peritoneal washings
78.
  Stage II Ovarian tumor with pelvic extension  
Stage IIa Extension and/or metastases to the uterus and/or tubes. 79.
Stage IIb Extension to other pelvic tissues. 64.
Stage IIc§ Tumor either stage IIA or IIB with ascites or surface involve-
ment or capsule rupture or positive peritoneal washings
68.
 Stage III Tumor involving the upper abdomen or lymphnodes
Stage IIIa Microscopical disease outside the pelvis with negative nodes 49.
Stage IIIb Gross deposits ≤  cm in diameter and negative nodes 40.8
Stage IIIc Gross deposits > cm in diameter or nodal involvement 8.9
 Stage IV Distant organ involvement, including pleural space or hepatic or splenic 
parenchyma. 
.4
§To evaluate the impact on prognosis of the different criteria for allotting cases to stage Ic or 
IIc it would be of value to know if rupture of the capsule was (a) spontaneous or (b) caused 
by surgeon, and if the source of malignant cells detected was (a) peritoneal washings or (b) 
ascites.
of the peritoneal cavity, including all organs and peritoneal surfaces, are 
systematically inspected and any suspicious areas are biopsied. Unless these areas 
are confirmed on frozen section to demonstrate malignancy, an omentectomy and 
peritoneal biopsies from the right and left pelvic peritoneum, cul-de-sac, bladder, 
paracoli gutters, and diaphragm are performed. When frozen section shows 
a malignancy, cytoreductive surgery is performed aiming to remove as much 
tumor tissue as possible. In ovarian cancer patients with FIGO stages Ia to IIa, 
primary treatment is completed after complete surgical staging and consecutive 
chemotherapy is not necessary. Important prognostic factors are stage of disease at 
diagnosis and the extent to which the tumor is eradicated at surgery. The amount 
of residual tumor after cytoreductive surgery correlates inversely with progression-
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free and overall survival (). Patients with low stage disease and/or a residual 
tumor mass of  cm or less in diameter have higher survival rates than patients 
with advanced stage disease or suboptimal tumor debulking (6). Recent studies 
show that complete tumor resection has better overall survival rates than optimal 
cytoreduction (residual tumor of  cm or less). In early stage disease, where the 
tumor is confined to the ovaries, surgical resection can provide cure. However, in 
most cases the disease has already progressed to an advanced stage at the time of 
diagnosis due to subclinical presentation of early stage disease and limitations in 
screening methods. Combining this with the high mortality rate associated with 
ovarian cancer, the disease is nicknamed ‘the silent lady killer’.
Chemotherapy
The majority of epithelial ovarian cancer patients will require postoperative 
adjuvant chemotherapy. The standard chemotherapy regimen after debulking 
surgery consists of a combination of carboplatin or cisplatin with taxol (8,9). This 
will be administered -weekly for at least 6 cycles. 
Patients with tumor bulk that does not appear to be surgically cytoreducible to no 
macroscopic residual disease will start with  cycles of chemotherapy followed by 
interval debulking and completion of chemotherapy after surgery. 
Recent studies show that patients with FIGO stage III ovarian cancer have benefit 
from intraperitoneal (i.p.) chemotherapy in combination with intravenous (i.v.) 
chemotherapy after complete or optimal debulking (residual tumor < cm) as 
compared to iv chemotherapy alone (0). However i.p. chemotherapy does result in 
higher toxicity rates and is not recommended after bowel surgery. Further research 
is performed to optimize this treatment strategy e.g. number of cycles, different 
chemotherapeutic drugs, optimal dosing schedule. So far, i.p. chemotherapy is not yet 
incorporated in the standard treatment of ovarian cancer patients in the Netherlands.
Follow-up
The first two years patients will be seen in an out-patient setting every  months, the 
third year every 4 months, and later on twice a year. After five years patients will be 
seen once a year. Physical examination, including TVU and CA  measurements 
is routine at each visit.
Despite intensive treatment, the majority of patients develop recurrent disease, 
particularly in the abdominal cavity, of which most patients die. The incapacity 
to control the disease within the peritoneal cavity is a major cause of treatment 
failure in ovarian cancer patients. 
4
As shown in Figure , the incidence and mortality rates of ovarian cancer in the 
Netherlands have remained stable for the last 0 years. The mortality rate is high, 
and progress in lowering it will depend on new treatment strategies that are able 
to eradicate residual and recurrent disease. Targeting ovarian cancer cells with 
monoclonal antibodies (Mab) labeled with radioisotopes, or toxic substances or 
immunotherapy with unlabeled (‘cold’) antibodies is a possible treatment strategy 
to eradicate residual disease. Mab may destroy tumor cells directly, by delivering a 
toxic radiolabel, or indirectly, by inducing an immune response against the tumor. 
Several antigens expressed on ovarian carcinoma cells have been targeted and 
studied with monoclonal antibody-based therapy. An overview of the different 
tumor-associated antigen (TAA) targeted in ovarian cancer clinical trials is given 
in chapter b of this thesis. 
Figure . Incidence and mortality rates of ovarian cancer in the Netherlands ().
Incidence
Mortality
Year
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Outline of this thesis
Ovarian cancer remains one of the major causes of death in women in the 
Western world and cure is seldom achieved. New strategies, such as monoclonal 
antibody-based therapies (reviewed in chapter b) are needed in the treatment of 
ovarian cancer patients. In this thesis we studied the use of intraperitoneal (i.p.) 
radioimmunotherapy (RIT) for the treatment of ovarian cancer, with specific 
focus on the immunological effect of i.p. RIT with 90Y-muHMFG. MuHMFG is a 
murine monoclonal antibody directed to the antigen MUC, expressed on ovarian 
cancer cells. The studies described in the present thesis are based on a large 
international phase III clinical trial in which ovarian cancer patients in complete 
clinical remission were randomized between i.p. 90Y-muHMFG and standard 
treatment or standard treatment alone (). The clinical trial was not able to show 
a survival benefit between the two treatment arms. 
However, as the study drug was administered into the peritoneal cavity, a regional 
effect of 90Y-muHMFG on tumor growth could occur. In chapter  we analyzed 
the pattern of disease recurrence in the two treatment arms, and found an 
improved control of i.p. disease in patients that received 90Y-muHMFG compared 
to patients receiving the standard treatment. For the patients receiving the study 
drug, the benefit of a longer time to i.p. recurrence was offset by a shorter time to 
extraperitoneal recurrences. 
New treatment modalities may be accompanied by unexpected side-effects which 
may interfere with the success of the treatment. Extraperitoneal leakage associated 
to i.p. administration of 90Y-muHMFG, as well as recommendations to optimize 
the procedure, are examined and discussed in chapter . 
The use of Mabs of murine origin in humans induces the production of human 
anti-mouse antibodies (HAMA), discussed in chapter b. HAMA directed to 
the constant region of the murine antibody (Ab) (anti-isotypic Ab) may interfere 
with the measurement of the tumor marker CA  that is used to monitor the 
course of disease in ovarian cancer patients. In chapter 4 we studied the potential 
interference of HAMA in the CA measurements in patients of the phase III 
clinical trial (). 
HAMA can also be directed to the variable region of the administered antibody 
generating an idiotypic network, as reviewed in chapter b. Intraperitoneal 
administration of muHMFG in ovarian cancer patients may induce an anti-
idiotypic response (Ab) which may result in the production of anti-anti-idiotypic 
Ab (Ab) directed towards the antigen present on the tumor cell. This Ab may 
6
result in activation of the immune system against tumor cells.
We developed ELISAs to measure HMFG specific HAMA-IgG and HAMA-IgM 
directed to the constant and/or variable region of the muHMFG (chapter ). In 
chapter 6 we correlated these HAMA-IgG and HAMA-IgM levels in patients 
of the phase III trial with disease-free and overall survival. To further evaluate 
the existence and cascade-like immune response resulting in specific idiotypic 
antibodies we measured anti-MUC IgG Ab (Ab) in the same study population, 
and also correlated these results to disease-free and overall survival (chapter 7). 
In chapter 8 the findings of the present thesis are summarized and discussed and 
recommendations for further research are presented.
The main objectives of this thesis are:
. To evaluate the effect of a single i.p. 90Y-muHMFG injection on location of 
disease recurrence in ovarian cancer patients in complete clinical remission 
(chapter ).
. To describe possible side-effects of i.p. 90Y-muHMFG therapy in ovarian cancer 
patients (chapter  and 4).
. To develop a reliable method to measure the human HMFG specific-immune 
response after i.p. 90Y-muHMFG administration (chapter ).
4. To investigate the presence of an idiotypic network we measured muHMFG 
specific antibodies and anti-MUC IgG Ab (Ab) in ovarian cancer patients treated 
with a single i.p. 90Y-muHMFG injection, and analyzed their effect on disease-free 
and overall survival (chapter 6 and 7).
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Abstract
The prognosis for patients with ovarian cancer is still poor and more effective 
therapeutic modalities are needed. (Radio)immunotherapy using monoclonal 
antibodies (Mabs) could be one of these approaches. Here, we review the status 
of (radio)immunotherapy using Mabs for the treatment of ovarian cancer. The 
Pubmed database was searched for clinical trials investigating the effect of 
(radio)immunotherapy in ovarian cancer published until October  007. Keywords 
for the search were: ovarian cancer, monoclonal antibodies, CA , gp8, HER, 
HMFG, MUC, TAG 7 and VEGF. A total of 44 trials on immunotherapy with 
unconjugated Mabs, Mabs vaccination and radioimmunotherapy directed towards 
the antigens CA , gp8, HER, MUC, TAG 7 or VEGF in patients with 
ovarian cancer were found, reviewed and discussed. Out of these trials,  studied 
immunotherapy with unconjugated Mabs, five vaccination with Mabs and 6 trials 
studied radioimmunotherapy. The lack of large randomized prospective trials 
with Mabs directed to tumor-associated antigens expressed on ovarian cancer 
cells preclude any firm conclusion on the potential of Mabs use in the treatment 
of ovarian cancer. Oregovomab, directed against CA , and bevacizumab, 
targeting VEGF, are two unconjugated Mabs closest to clinical introduction for 
the treatment of ovarian cancer. Vaccination with Mab ACA  seems promising 
but these findings need to be confirmed in controlled randomized trials. Sole RIT 
should be investigated with the appropriate radionuclide and a Mab with high 
affinity for the specific tumor-associated antigen in the appropriate patient group 
to determine whether it may have a therapeutic effect. Additionally, appending 
radioimmunotherapy with anti-TAG 7 or anti-MUC to other treatment 
strategies such as chemotherapy could also be a strategy worthwhile investigating. 
The potential of Mabs to complement current treatment paradigms, is encouraging 
and may bring a significant improvement to the overall therapeutic outcomes 
currently being achieved in ovarian cancer.

Introduction
Ovarian cancer is the fourth leading cause of cancer-related death in women, 
and accounts for the highest mortality rate of all gynecological malignancies 
(). Its poor prognosis is mainly the result of the clinically occult nature of this 
disease. The peritoneal cavity in which the ovaries are localized provides a perfect 
environment for undisturbed subclinical growth. Furthermore, early detection is 
difficult because of the general asymptomatic presentation of the disease (). In the 
majority (68%) of the patients, ovarian cancer is diagnosed with at least extensive 
abdominal spread (). Standard treatment for advanced stage ovarian cancer is 
tumor debulking surgery and adjuvant chemotherapy. Although most ovarian 
cancers are sensitive to platinum-based chemotherapy, the prognosis remains 
poor. The -years survival of patients with advanced disease, FIGO stage IIIc and 
IV is respectively 9% and % (,4).
There is a need for new treatment modalities. Antibody-based therapy 
such as immunotherapy with unconjugated antibodies, vaccination and 
radioimmunotherapy (RIT) could be treatment modalities useful for this disease. In 
most patients ovarian cancer growth is confined to the peritoneal cavity. One of the 
advantages of (radio)immunotherapy is the possibility of regional administration, 
thereby limiting systemic side-effects. Besides this, a series of ovarian cancer-
associated antigens have been identified during the past few decades which 
may serve as potential targets for antibody-based (radio)immunotherapy. These 
developments, which use monoclonal antibodies (Mabs) as ‘magic bullets’ are 
attractive alternative options for the treatment of ovarian cancer. 
In recent clinical studies in non-Hodgkin lymphoma patients, antibody-based 
therapy has shown remarkable response rates and, for this reason became a 
standard element in the treatment of these malignancies (,6). Similar results were 
obtained with antibody-based therapies in several solid malignancies (7-9). The aim 
of the present review is to provide background information on Mab-based therapy 
in general and to give an overview of published clinical trials with unconjugated 
Mabs, vaccination and/or RIT with Mabs for the treatment of ovarian cancer.
Background 
The therapeutic appeal of antibodies can be traced back more than a century ago, 
when mice were first investigated as a possible source of antibodies. Scientists 
injected mice with infectious agents in order to stimulate the production of 
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antibodies against the micro-organisms. It was hypothesized that patients suffering 
from the same type of infection could be treated with an injection of infected 
rodents’ serum. However, these crude preparations were ineffective, and the sera 
sparked adverse immune reactions in some patients (0). 
The idea to us antibodies as ‘magic bullet’ was first postulated by Paul Ehrlich at the 
end of the 9th century (). Ehrlich proposed the concept that immune cells secrete 
‘Seitenketten’, which we now know as antibodies, in response to foreign antigens. He 
postulated that these antibodies could be used to specifically attack a wide variety 
of pathogens, using them as ‘magic bullets’ to target the site of disease. In 97 
Kőhler and Milstein discovered a method for producing monoclonal antibodies 
by in vitro fusion of immune spleen cells and immortal murine myeloma cells (). 
This discovery has allowed for the production of large amounts of identical and 
specific antibodies for the diagnosis and treatment of cancer, as well as several 
other diseases. More recently, genetic engineering has enabled the development 
of chimeric and humanized antibodies, in order to reduce the immunogenicity 
of the antibodies. Antibodies and IgG fragments were further linked with toxins, 
radionuclides, enzymes, chemotherapeutic agents and cytokines for diagnostic 
and therapeutic purposes (). Subsequently, various Mabs against ovarian cancer-
associated antigens have been developed to try to improve diagnosis and therapy.
Antibody features
Antibodies or immunoglobulins are a group of glycoproteins present in serum 
and tissue of all mammals. They are produced by B-lymphocytes in response to a 
pathogenic challenge and trigger the immune system to react against this pathogen. 
The immunoglobulin is composed of two identical light chains and two identical 
heavy chains linked together by disulphide bonds. An immunoglobulin G (IgG) 
molecule consists of two Fab domains, containing antigen-binding site, and one Fc 
domain, which is responsible for activation of the immune system (Figure ).
There are five distinct classes of immunoglobulins, IgG, IgA, IgM, IgD, IgE, of 
which IgG is most commonly used in diagnostic and therapeutic applications. 
IgG antibodies have a molecular weight of 0 kDa and are characterized by a 
slow clearance from the blood resulting in long circulatory half-life (>  days). 
When targeting a tumor these antibodies show a heterogeneous intra-tumoral 
distribution (4). 
Smaller antibody fragments have been produced in order to achieve more rapid 
blood clearance. Proteolytic degradation of IgG with pepsin results in antibody 
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Figure . Monoclonal antibody structures mainly used in (radio)immunotherapy.
 A. Whole (murine) IgG. v; variable regions, c; constant regions. B. F(ab’) fragment.  
 C. F(ab’) fragment. D. Chimeric IgG, the constant regions of the murine Mab have  
 been replaced by their human analogues (black). E. humanized IgG (90-9% human). 
fragments; F(ab’) (MW 00 kDa) and Fab’ (MW 0 kDa),  respectively (also see 
Figure ). Tumor uptake of these fragments is faster and more homogenous than 
whole IgG molecules, but the absolute tumor uptake is lower and retention time 
is shorter as compared to that of intact Mab (). Furthermore, an important 
difference between intact Mabs and Mab fragments is their route of clearance 
from the body. Intact Mabs are catabolized in the liver and spleen, whereas Mab 
fragments are mainly excreted via the kidneys (6). Consequently, the application 
of radiolabeled Mab fragments for therapy will result in an increased renal radiation 
dose. 
Antibody-based therapy
The anti-tumor effects induced by injecting Mabs are generated by different 
mechanisms. Upon binding of the Fc receptor of the injected Mabs to the effector 
cells, the Fc region triggers an antibody-dependent cell-mediated cytotoxicity 
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(ADCC) response resulting in lysis of the target cells (7). 
Furthermore, activation of the complement system could thus, induce complement 
dependent cytotoxicity (CDC) of tumor cells. Some Mabs induce apoptosis while other 
Mabs may block growth factor receptors on cancer cells and/or may sensitize cancer 
cells for example for chemotherapy and radiotherapy (7). Moreover, Mabs may act as 
anti-angiogenic agents, such as bevacizumab that blocks vascular endothelial growth 
factors (VEGF) and thus inhibits angiogenesis (7). Furthermore, a humoral immune 
response may be induced if the injected Mab is recognized as a foreign protein. This 
humoral response can either be an anti-isotypic and/or an anti-idiotypic response. 
Anti-isotypic antibodies are directed towards antigenic determinants on the constant 
regions of the murine immunoglobulin molecule. Anti-idiotypic antibody response 
(Ab) is directed against the hypervariable regions of the injected Mab. The presence 
of anti-idiotypic antibodies theoretically can evoke a second immune response by 
producing anti-anti-idiotypic antibodies (Ab). The antigen binding region of these 
Ab antibodies is directed towards the antigen binding region of Ab and resembles 
the antibody (Ab) that elicited the original anti-idiotypic antibody response (8). 
This cascade-like manner, in which each antibody generation induces the production 
of another set of antibodies was first described by Jerne and is called ‘The Jerne 
network theory’ (Figure ) (9).
Assuming that the idiotypic network of Jerne does exist, vaccination with Ab or Ab 
may be an attractive treatment strategy. Immunization with Ab, specifically directed 
towards the tumor-associated antigen, or Ab, resembling the antigen, may result in 
the production of Ab, which recognizes the corresponding original antigen. If so, 
complex formation between the antigen present on the tumor cell surface and the 
induced Ab may induce ADCC, CDC and/or apoptosis of tumor cells.
The use of Mabs in RIT is based on the idea of specifically targeting the tumor cells 
that express the tumor-associated antigens. Hereby, the radiation dose is delivered 
locally, optimizing the dose at the tumor site and minimizing radiation damage to 
the healthy tissues.
The three Mab-based treatment strategies with Mab, i.e. unconjugated Mabs 
therapy, vaccination with Mabs and RIT will be discussed below.
Immunogenicity
The activation of the immune system by Mabs may be beneficial for the recipient 
but also have negative effects. Injected murine Mabs may evoke a humoral 
immune response in which human anti-mouse antibodies (HAMA) are produced 
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(0). About 0-7% of patients with solid tumors develop HAMA after exposure 
to mouse Mabs, depending on the Mab and the antibody form (IgG or fragments) 
(). Complex formation between the injected antibody and HAMA may result in a 
faster clearance of the antibody, increased hepatic and splenic uptake and reduced 
tumor uptake when Mabs are repeatedly administered (). The magnitude and 
duration of the HAMA response in serum shows great variability and is more likely 
to occur after repeated injection of Mabs (0,). HAMA can persist in blood for 
several months after exposure to mouse immunoglobulin. B-memory cells that 
produce these specific antibodies presumably remain present for years and will be 
re-activated upon re-exposure to the antigenic stimulus (,4). 
Hence, the development of HAMA has been considered a disadvantage in the 
treatment with Mabs (). Interestingly, HAMA development has also been 
associated with a positive outcome on survival, by inducing the production of 
anti-anti-idiotypic antibodies (Ab) (-8). Induction of Ab following injection 
of Mabs to tumor-associated antigens (TAA), has been associated with cancer 
regression in animal models and cancer patients (6,8). To avoid the negative 
side effects of HAMA development after treatment with Mabs, chimeric and 
Figure . The variable region of the murine monoclonal antibody binds with the antigen. 
The variable region of the murine monoclonal antibody (Ab) contains unique structures, 
which stimulate the production of various anti-antibodies (Ab). Some Ab express the 
variable-region structures (internal image) which mimic the antigen (MUC) and therefore 
can stimulate the production of antibodies similar to the monoclonal antibody (Ab). Ab 
may be similar to Ab and thus may react with MUC. Each antibody generation induces the 
production of still another and larger set of anti-antibodies in a similar cascade-like manner.
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MUC Ab AbAb
7
humanized antibodies have been developed. Chimeric antibodies are Mabs in 
which the constant domains of the human IgG molecule are combined with the 
murine variable regions by transgenic fusion of the immunoglobulin genes (see 
Figure ) (9). The application of chimeric antibodies indeed reduced HAMA 
responses substantially, but did not eliminate them completely in most cases. Next, 
humanized antibodies were developed in which the 6 complementarity determining 
regions (CDRs) of the heavy and light chains and a limited number of structural 
amino acids of the murine Mab were grafted, by recombinant technology, to the 
CDR-depleted human IgG scaffold (see Figure ) (0,). 
Toxicity
Despite earlier concerns, adverse events as a result of the development of HAMA 
during and after immunotherapy or radioimmunotherapy have not proven to 
be significant (). Remarkably few anaphylactic reactions have been reported, 
suggesting that they are quite uncommon.(0,) However, adverse reactions 
after Mab therapy due to a developed HAMA may occur, and the following 
reactions have been reported: allergic reactions, anaphylactic shock, generalized 
pain, hyponatremia, fever, rigors and chills, rash, paresthesias, weakness, chronic 
refractory postural hypotension, serum sickness, cytokine release syndrome and 
tumor lysis syndrome (-). When adverse events do occur they generally occur 
after the first Mab administration (,4). The studies reported to date indicate 
that depending on the Mab, the majority of the Mab-based therapies can be safely 
applied with minimal adverse effects (). 
Clinical trials
A search for antibody-based trials for the treatment of ovarian cancer was performed 
in the Pubmed and Medline databases until October st, 007. The following 
keywords were used for the search: monoclonal antibodies, ovarian cancer, CA, 
HER, gp8, HMFG, MUC, TAG 7 and VEGF. The search was limited by only 
including clinical trials in humans and written in the English language.
A total of 44 Mab based trials in ovarian cancer patients have been published, 4 
of which are phase I/II and two phase III trials dealing with patients receiving 
Mab. Mabs were administered using the intravenous (i.v.), intramuscular (i.m.), 
intradermal, intraperitoneal (i.p.) and subcutaneous (s.c.) route. To date,  
different antibodies have been used directed against  different tumor-associated 
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antigens and one anti-angiogenesis antigen (VEGF). Of the 44 clinical trials,  
trials studied immunotherapy with unconjugated Mab (7,6-7), five trials 
studied vaccination with Mabs (8,9,60,6,6), while 6 trials studied RIT (6-
78). Two of the RIT trials used a combination of cytotoxic chemotherapy and 
RIT (64,7). A combination of unconjugated Mabs combined with cytotoxic 
chemotherapy administration was assessed in four trials (4,47,,7). Because 
of the high propensity to stay confined to the peritoneal cavity until very late 
in the course of the disease, many trials on radiolabeled Mab in ovarian cancer 
patients used the i.p. route for administration (9/44) (8,4,44, 0,,6,64,66-
7,7-78). In 0 studies the Mab was administered iv (6,7,9,40,4,4,4-49,-
,7,60,6,7,79), two studies injected i.m. (9,6), while two other studies used 
both i.v. and i.p. routes of administration (7,8), one study administered through 
i.p., i.v. and intradermal routes (8) and one study only used s.c. route of Mabs 
administration (6). The median number of patients included was 9 (range -447). 
Fourteen trials included patients with ovarian cancer stages Ic through IV. The 
majority of trials (/44) included patients with residual, refractory or recurrent 
ovarian cancer. Five trials included patients in complete clinical remission and 
three trials included patients after debulking and/or chemotherapy. Mabs therapy 
targeting the CA  antigen was used in 4 trials of which four RIT trials and 
three vaccination trials (Table ). Anti folate receptor Mabs (gp8) were used in 
seven trials of which one evaluated RIT (Table ). Anti-HER Mabs were used 
in five trials (Table ). Seven trials evaluated anti-MUC Mabs of which six were 
RIT trials, and one a vaccination trial (Table 4). Anti-TAG 7 Mabs were used in 
five RIT trials (Table ). Anti-VEGF Mabs were used in six immunotherapy trials 
(Table 6). The following sections discuss these trials according to the antigen that 
was targeted.
Cancer antigen (CA) 125
The tumor associated-cancer antigen CA  is detectable on tumor cells in over 
90% of the patients with advanced epithelial ovarian cancer (80). An overview 
of Mab trials directed towards CA  is shown in Table . OC  was the first 
antibody directed to CA  and was used in radioimmunoscintigraphy (RIS) trials 
administering OC labeled with a diagnostic dose of -Iodium in ovarian cancer 
patients (7). A RIS study by Muto et al. (7) also used I-labeled OC- for RIS in 
patients with recurrent ovarian cancer. Interestingly, it was found that patients who 
developed HAMA and/or Ab had a prolonged median survival. Another phase II 
study in ovarian cancer patients treated with i.p. I-OC-F(ab’), (0 mCi) for 
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consolidation did not show a beneficial therapeutic effect (69).
MAb-B4. also known as oregovomab and OvaRex® is a more recently develop 
murine Mab also directed to CA . One of the first RIS studies with 99mTc-
B4. showed an unexpected prolonged survival in 6 ovarian cancer patients 
receiving RIS compared to a control group (69,80). The improved clinical outcome 
was suggested to be due to the induction of the idiotypic cascade by this Mab 
(Ab) (6). Further investigation of the immune response showed activation of 
both a humoral and a cellular CA  specific responses. A double-blind, placebo-
controlled trial in which 4 epithelial ovarian cancer patients were treated with 
repeated iv B4. injections as consolidation therapy confirmed the induction 
of HAMA and Ab (7). However, the study did not demonstrate a prolonged 
time to relapse (TTR). Comparing the group of patients who developed human 
anti-B4. antibodies (Ab responder group) to the Ab non-responder group, 
there was a difference in TTR of respectively, 8.8 months and 6. months (cut-
off Ab response at 00 ng/ml). The induction of an immunological response 
monitored as HAMA and Ab response was also associated with a significant 
advantage in disease-free survival in other studies using B4. (4,46,,4,7). 
Gordon et al. (48) studied the combination of chemotherapy and immunotherapy 
with oregovomab in patients with recurrent epithelial ovarian cancer. They found 
that oregovomab in combination with standard chemotherapy was well-tolerated 
and induced multiple antigen-specific immune responses, which had a significant 
survival benefit in immune responders of the 0 patients participating in the trial. 
The administration of murine B4. to patients led to the induction of HAMA, 
CA  specific antibodies, T helper cells, and cytotoxic T cells, generating both a 
cellular and humoral response to the tumor antigen (4,8). 
ACA  is a murine anti-idiotypic antibody (Ab) that mimics the epitope of the 
CA  antigen. Theoretically vaccination of patients with this Mab could induce 
the generation of Ab. ACA has shown to induce a humoral as well as a cellular 
anti-CA -specific immune response in animals and humans (60,6,8). In a 
phase I/II trial conducted by Wagner et al. (6) 4 patients with recurrent ovarian 
cancer received four i.m. immunizations with anti-idiotypic Mab ACA-. In this 
trial Ab was detected in 67% of the patients. The mean survival of patients with 
an Ab response was 9.9 (± .) months, compared to only . (± 4.) months 
for those without an immune response. These results suggest that vaccination 
with the ACA  antibody could have a significant impact on clinical outcome. A 
continuation of this research by Reinartz et al. (9) included 9 advanced ovarian 
cancer patients who received an average of 9.7 ACA i.m. injections. In 68% of 
0
Table . Clinical trials in ovarian cancer with Mab directed towards antigen CA .
Reference MAb No. of 
patients
Dosage Response Special features
Method et al. 
() 00
B4. 0 
consolidation
 mg repeated, 
i.v.
- Immune response cor-
related with improved 
clinical outcomes
Ehlen et al. 
(46) 00
B4.  recurrent  mg repeated, 
i.v.
 SD
0 PD
SD in patients with ro-
bust immune response
Berek et al. 
(7) 004
B4. 4 CCR  mg repeated, 
iv
- No difference in time to 
relapse
Gordon et al. 
(48) 004
B4. 0 recurrent  mg repeated, 
i.v.
 CR
 PR
 SD
9 PD
Improved survival in 
patients with T-cell 
response to CA 
Ehlen et al. 
(4) 00
B4. 4  consoli-
dation
 mg repeated, 
i.v. 
- Specific immune 
response longer median 
time to progression
Pfisterer et al. 
(6) 006
ACA  6 recurrent  mg repeated, 
s.c. 
 PD Premature termination
Schultes et al. 
(4) 998
B4. 7  mg repeated, 
i.v.
- Ab responders longer 
survival
Reinartz et al. 
(9) 004
ACA  9  mg repeated, 
i.m.
- Specific immune re-
sponse resulted in longer 
survival
Wagner et al. 
(6) 00
ACA  4 recurrent  mg repeated, 
i.m.
- Specific immune re-
sponse resulted in longer 
survival 
Wagner et al. 
(60) 997
ACA  6 advanced 
& recurrent
 mg repeated, 
i.v.
- CA -specific immune 
responders showed 
longer PFS
Mobus et al. 
(7) 00
99Tc-B4. 44 recurrent  mg repeated, 
i.v.
6 CR HAMA responders 
longer survival
Mahe et al. 
(69) 999
I-OC 6 residual 60 mg, i.p.  SD
4 PD
-
Baum et al. 
(6) 994
In-OC
99Tc-B4.
 repeated, i.v. 7 CCR 
or SD
Anti-idiotypic HAMA 
responders longer 
survival
Muto et al. 
(7) 99 
I-OC 9 refractory 0-6 mg, i.p.  CR
8 PD
-
CR, complete remission; HAMA, human anti-mouse antibodies; Hu, human; IFB, interferon; i.v., 
intravenous; i.p., intraperitoneal; i.m., intramuscular; PD, progressive disease; PFS, progression-free 
survival; PR, partial response;s.c., subcutaneous; SD, stable disease.
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the patients an Ab reaction occurred, which was associated with a significantly 
longer survival (.4 months) as compared to patients who were Ab negative (4.9 
months). CA  specific antibodies (Ab) and ADCC of CA  positive tumor cells 
in vitro was observed in 0.4% and 6.9% of the patients respectively. Although this 
study had an uncontrolled set-up, this data strongly supports a relationship between 
the development of Ab and overall survival time of ovarian cancer patients with 
disease recurrence. So far, a causal relation between Ab and disease outcome has 
not yet been confirmed. Recently, Pfisterer et al. (6) performed a phase I trial in 6 
recurrent ovarian cancer patients on the effect of subcutaneous administration of 
ACA  which was prematurely terminated due to patient withdrawal or disease 
progression. However, sc administration of ACA  did seem safe and was well-
tolerated also in highly frequent dosage schedules (6).
The results of the studies cited above indicate the need for further investigation 
on the efficacy of antibody-based therapy directed against the CA  antigen 
in randomized clinical trials. Immunotherapy with oregovomab seems to be an 
attractive alternative as consolidation therapy in ovarian cancer patients. 
Folate receptor
The Mab MOv8 binds to the membrane folate receptor (gp8) which is 
overexpressed in approximately 90% of epithelial ovarian cancers (8). MOv8 is 
directed to the alpha isoform of the folate receptor. Van Zanten-Przybysz et al. (6) 
treated five patients  with recurrent or residual disease with four i.v. injections of 0 
mg chimeric MOv8 (cMOv8). This strategy had minor side effects but showed 
little if any effect on survival (6). In several phase I/II studies the administration of 
radiolabeled cMOv8 by i.v. and i.p. routes proved to be able to deliver therapeutic 
radiation doses to the tumor with minor side effects (6,84-86). Crippa et al. (66) 
administered a single-dose of i.p. I-MOv8 (700MBq) to 6 ovarian cancer 
patients with minimal disease several weeks after second-look evaluation. Tumor 
response assessed at third-look laparotomy indicated a complete response in five 
patients, stable disease in six patients and five patients with tumor progression. 
However this was not a controlled, randomized trial and results should be 
interpreted with caution.  
OC/TR is a bispecific Mab that reacts with the folate binding protein on ovarian 
cancer cells on the one hand and with the CD antigen on T-lymphocytes on the 
other (Table ) (87). The bispecific Mab thus combines the cytolytic potential of 
in vitro expanded T-lymphocytes and the tumor selectivity of the Mab OC/TR 
targeting the folate binding protein on ovarian cancer cells (88). The bispecific 

OC/TR Mab was used to coat the T-lymphocytes in vitro before administration to 
patients. Bolhuis et al. (8) treated  ovarian cancer patients with T-lymphocytes 
retargeted with chimeric OC/TR and administered the Mab-coated T- lymphocytes 
directly into the peritoneal cavity. Five patients were in complete clinical remission 
(CCR), three had partial regression, two had stable disease and three patients 
had progressive disease. Two phase II studies in patients with advanced stage 
ovarian cancer using retargeted T-lymphocytes with chimeric OC/TR showed 
antitumor activity in 0% of the patients (4,). Further research with OC/TR 
in combination with retargeted T-lymphocytes showed similar results with local 
immunomodulation after i.p. administration in ovarian cancer patients, but without 
systemic effects (89). In contrast to earlier findings, the development of HAMA 
Table . Clinical trials in ovarian cancer with Mab directed towards antigen folate 
receptor (gp8).
Reference Mab No of 
patients
Dosage Rsponse Special features
Zanten-Przybysz
et al. (6) 00
cMov8  0 mg
Repeated, 
i.v.
SD
PD
Patiente with recurrent 
or residual disease
Crippa et al. 
(66) 99
I-Mov8 6 4 mg, i.p. CR
6SD
PD
Third-look laparoscopy 
for tumor response
Miotti et al.
(7) 999
OC/TR  Different 
i.p. sched-
ules
i.p.&i.v.
- High HAMA levels as-
sociated with improved 
clinical response
Lamers et al. 
() 997
OC/TR  
residual
Different 
schedules, 
i.p.
4 PR
 SD
 CR
OC/TR re-targeted 
with T-lymfocytes and 
IL-
Lamers et al. 
(0) 99
OC/TR 8 Different 
schedules, 
i.p.
- OC/TR re-targeted 
with T-lymfocytes and 
IL-
Canevari et al. 
(4) 99
OC/TR 8 Repeated, 
i.p.
 CR
 PR
7 SD
OC/TR re-targeted 
with T-lymfocytes
Bolhuis et al. 
(8) 99
OC/TR  Repeated, 
i.p.
 CR
 PR
 SD
 PD
OC/TR re-targeted 
with T-lymfocytes
See legend Figure .
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was even suggested to be beneficial for survival in patients after i.p. therapy with 
OC/TR (7). In  patients treated with i.p. or i.v. OC/TR, those with progressive 
disease and HAMA levels of ≥ 0 ng/mL had a significant higher median survival 
as compared to patients with progressive disease with HAMA < 0ng/mL (7). 
The effect of HAMA development on survival after therapy with OC/TR treated 
with T-lymphocytes thus remains controversial.
An overview of trials using Mab directed towards gp8 is shown in Table 
. In conclusion, the trials with chimeric OC/TR showed that locoregional 
immunotherapy with OC/TR in ovarian cancer may result in tumor regression. 
However larger randomized controlled trials should be conducted to confirm 
these findings.
HER2
HER, a member of the epidermal growth factor receptor family plays an important 
role in the deregulation of proliferation of breast and ovarian cancer cells (90). 
Ovarian tumors that overexpress the proto-oncogene HER have a particularly 
poor survival (9,9). Table  contains an overview of trials using Mab directed 
towards HER in ovarian cancer patients. Trastuzumab also known as Herceptin®, 
is a humanized antibody derived from 4D, a murine Mab, that recognizes an 
epitope on the extracellular domain of HER. This Mab has been approved 
by the U.S. Food and Drugs Administration (FDA) for the treatment of women 
with metastatic breast cancer with HER overexpression, given either alone or 
in combination with paclitaxel (9). Only 0% of the ovarian cancer patients 
overexpress HER on their tumor. Thus, treatment with HER antibodies would 
potentially benefit only a small proportion of patients with epithelial ovarian cancer. 
The Gynecologic Oncology Group evaluated trastuzumab in a phase I/II trial in 
patients with recurrent or refractory ovarian cancer overexpressing HER (9). A 
total of 4 patients received i.v. trastuzumab (4 mg/kg) with a median treatment 
of 8 weeks resulting in an overall response rate of less than 0% and a median 
progression-free interval of  months (9). Based on clinical data in breast cancer, 
the combination of trastuzumab with cytotoxic agents may have a higher impact 
on survival of patients with minimal residual ovarian cancer (94). Future strategies 
should focus on the use of the drug in combination with cytotoxic agents.
Pertuzumab is another new antibody directed to the HER antigen (Table )(9). 
This recombinant humanized monoclonal antibody C4 (IgG) binds to HER and 
is directed against a different epitope than trastuzumab. Pertuzumab inhibits 
tumor growth after binding by inhibiting ligand-activated HER dimerization with 
4
HER (6). Agus et al. (6) performed a phase I study in which patients with solid 
tumors received i.v. pertuzumab (mg/kg) every  weeks. Three ovarian cancer 
patients participated in this pilot study of which one had a partial response (6). 
A phase II open-label, multicenter study using pertuzumab has been executed 
in advanced or refractory ovarian cancer patients by Gordon et al. (49) They 
explored two different dosages of i.v. pertuzumab in  patients with recurrent 
ovarian cancer, resulting in a disappointing low response rate of 4. % defined on 
RECIST criteria (96) and CT scans. The majority of patients had diarrhea as side 
effects and 4% of the patients experienced cardiotoxicity. The results of these two 
studies did not show any effectiveness of pertuzumab. Recently, a phase II trial in 
7 platinum-resistant ovarian cancer patients with repeated administration of the 
Mab Matuzumab, that binds the ligand-binding portion of the EGFR receptor, did 
not show any effectiveness as a single agent therapy (). 
MDX-H0 is a bispecific antibody that cross-links the Fcγ receptor I on macrophages 
to the HER antigen on tumor cells (Table ) (97). MDX-H0 effectively redirects 
Fc gamma receptor I positive effector cells such as monocytes and macrophages to 
tumor cells that overexpress HER. Several trials demonstrated that MDX-H0 
is well-tolerated and also immunologically active (97,98). De Gramont et al. (44) 
combined monocyte-derived activated killer (MAK) cells with the bispecific Mab 
Table . Clinical trials in ovarian cancer with Mab directed towards antigen HER.
Reference Mab No of 
patients
Dosage Response Special Features
Seiden et al. 
() 007
EMD700 7
recurrent
800 mg 
weekly, i.v.
- Well tolerated, no clini-
cal effect of matuzumab
Gordon et 
al. (49) 006
Hu C4 
recurrent
Two sched-
ules, i.v.
 PR
8SD
0 CA
 ½ reduction
Response rate of 4.%
Agus et al. 
(6) 00
Hu C4  mg/kg, i.v.  SD
 PR
 PD
-
Bookman et 
al. (9) 00
Hu 4D 4 4 mg/kg, i.v.  CR
 PR
Start with 4 mg followed 
with  mg/kg weekly
De Gramont
et al. (44)
00
MDX-H0 4 Repeated, 
i.v.
6 CR
 PD
 SD
Combined monocyte-
derived activated killer 
(MAK) cells with the 
bispecific Mab
See legend Figure .
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MDX-H0 in an attempt to direct the MAK killer effect in patients towards HER 
antigen expressing tumor cells. Patients with HER overexpression were treated 
with MAK cells and Mab MDX-H0 while HER negative patients only received 
MAK cells. A total of eight ovarian cancer patients in CCR with microscopic or 
macroscopic residual disease after debulking and chemotherapy received MAK 
cells combined with MDX-H0 (44). Of these eight patients only three remained 
in CCR, while four patients had progressive disease and one patient had stable 
disease as diagnosed at third-look laparotomy. The full therapeutic potential of 
MAK cells as consolidation therapy in ovarian cancer is currently being evaluated 
in a large randomized, comparative trial (44).
In summary, various anti-HER antibodies have been used in trials with ovarian 
cancer patients, however one should keep in mind that only a minority of ovarian 
cancers express HER and thus anti-HER therapies will only be useful in a small 
portion of the patients.
MUC1 antigen 
In 90% of the epithelial ovarian tumors the MUC antigen is overexpressed on 
the cell-surface (99). For an overview of anti-MUC Mabs trials see Table 4. The 
murine IgG monoclonal human milk fat globule  (HMFG) antibody, with 
specificity to an epitope on the protein backbone of MUC, was developed by the 
Imperial Cancer Research Fund. Vaccination with the Mab HMFG in ovarian 
cancer patients is reported by Nicholson et al. (8) A phase I trial of 6 ovarian 
cancer patients receiving a priming dose of  mg HMFG administered either 
i.p. or i.v. followed by up to six intradermal doses of HMFG showed that the 
treatment was safe and well tolerated by patients with induction of an immune 
response resulting in production of Ab and Ab in some patients (8). 
Immunoscintigraphy with radiolabeled HMFG and HMFG, an antibody 
similar to HMFG directed to MUC, successfully detected MUC positive 
tumors in patients with primary and metastatic lesions of ovarian, breast and 
gastro-intestinal cancer with minor adverse events (00-0). The therapeutic 
application of radiolabeled HMFG in ovarian cancer has been mainly studied 
following i.p. administration. In phase I/II trials conducted in the 990s with 
90Yttrium-labeled HMFG (up to  mCi per patient) showed that the agent is 
generally well-tolerated when injected i.p. (68,77,06). Furthermore, radiolabeled 
i.p. HMFG induced an immune response resulting in proliferation of T-cells and 
the production of Ab and Ab (07-0). Nicholson et al. (74) reported that the 
survival of  ovarian cancer patients in CCR who received 90Y-HMFG (8 mCi) 
6
was prolonged compared to matched historical controls with a five-year survival 
of respectively 70% versus %. The same conclusions were drawn by Epenetos et 
al. (67) who found a survival rate of 78% after more than 0 years of follow-up in 
 ovarian cancer patients in CCR who had received a single injection of  mg i.p. 
90Y-HMFG(- mCi) (67). Based on these promising results two phase III trials 
haven been undertaken. The first one by Nicholson et al. (7) included 07 ovarian 
cancer patients in CCR who were randomized between a single i.p. administration 
of  mg 90Y-HMFG (0 mCi) and standard treatment. With a median follow-
up of 40 months, this study was not able to detect any survival advantage in 
patients treated with 90Y-HMFG. The second phase III study, the Study of MAb 
RadioimmunoTherapy (SMART) was a multicenter, randomized prospective trial 
of i.p. 90Y-HMFG (8 to 0 mCi, 4 patients) versus standard treatment ( 
control patients) in ovarian cancer patients in CCR (78). Patients were followed 
for a median time of . years. This study did not show an improvement in time to 
relapse or overall survival (78). Reported side effects of i.p. HMFG were nausea, 
fatigue, arthralgia, myalgia, thrombocytopenia and neutropenia (78). Although 
there was no significant difference in time to relapse and overall survival in the 
SMART study, interestingly, there was a significant difference in pattern of disease 
Table 4. Clinical trials in ovarian cancer with Mab directed towards antigen MUC.
Reference Mab No of patients Dosage Response Special Features
Nicholson et 
al. (8) 004
HMFG 6 residual or 
relapse or CCR
Different 
schedules
i.p. & i.v.
 PD i.v. or i.p. priming 
 followed by 6 intrader-
mal vaccination
Verheijen et 
al. (78) 006
90Y-HMFG 447 CCR  mg, i.p. 0 PD No survival benefit
 
Nicholson et   
al. (7) 000
90Y-HMFG 07 CCR  mg, i.p. - No survival benefit
 
Epenetos et  
al. (67) 000 
90Y-HMFG  CCR
 residual 
disease
 mg, i.p. - Survival: 78% at 0 years 
follow-up 
Nicholson et  
al. (74) 998
90Y-HMFG  after
debulking
 mg, i.p. - 0 yr survival patients 
70%, control % 
Hird et al. 
(68) 99
90Y-HMFG   mg, i.p. - patients have longer 
survival compared to 
historical  controls
Stewart et   
al. (77) 990
90Y-HMFG 
+ AUA
 8 mg,i.p.  PD
 SD
AUA to  kd cell sur-
face antigen expressed 
in 7% ovca  
See legend Figure .
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recurrence (). Time to i.p. relapse was significantly longer in patients that were 
treated with i.p. 90Y-HMFG, whereas significantly more extraperitoneal relapses 
were seen in the treatment arm compared to the standard arm (49% vs. 4%). Most 
of the extraperitoneal relapses were seen in the lymph nodes (78%), the majority 
of which was situated in the para-aortic region. This observation suggests that i.p. 
90Y-HMFG leads to i.p. disease control in ovarian cancer patients in CCR (). 
Further analysis of the data gathered in the SMART study considering the immune 
response of participating patients is still ongoing. In the SMART study the HMFG 
dose was relatively high and the radionuclide 90Y may not be the most appropriate 
for therapy in patients with minimal residual disease. An overview of all discussed 
trials using Mab directed towards MUC antigen is given in Table 4.
A humanized variant of the murine HMFG has been developed and is currently 
under investigation for breast cancer (www.antisoma.com). This humanized antibody 
may also be a potential drug for immunotherapy or RIT in ovarian cancer.
Tumor-associated glycoprotein (TAG) 72
The Mab B7. targets the tumor-associated glycoprotein, TAG 7 which is expressed 
on most adenocarcinomas including gastrointestinal and ovarian cancers (). 
Research on RIT with i.p. B7. was done in a phase I trial in which 8 refractory 
ovarian cancer patients received repeated i.p.  to 0 mg 90Y-B7. ( to 40 mCi) 
in combination with calcium disodium versenate (EDTA) (). In this study the 
90Y label was bound in an instable chelate resulting in higher bone uptake of the 
radionuclide, the rationale of adding EDTA was to investigate the ability of EDTA 
to suppress the bone uptake of 90Y label and, thus reduce the radiation dose to the 
bone marrow, preventing myelosuppression. Results of this trial demonstrated the 
myeloprotective ability of EDTA and clinical responses in four patients. 
Further research on the development of new antibodies directed against TAG 7 
resulted in a series of second-generation antibodies of which CC-49 was selected 
(Table ). Mab CC49 and Mab B7. recognize different epitopes on TAG 7 and 
CC49 has a 0-fold higher affinity fir TAG 7 (4). A phase I trial of 0 mg i.p. 77Lu-
CC49 (0-0 mCi/m) in  refractory ovarian cancer patients demonstrated good 
tolerability and even antitumor activity (70). Tumor response as assessed during 
third-look laparotomy or laparoscopy resulted in one partial response in a patient 
with gross disease, six patients had progressive disease, four stable disease and one 
delayed recurrence of disease in patients with microscopic disease (70). Subsequently, 
Alvarez et al. (6) performed a phase I/II trial of 0 mg i.p. 77Lu-CC49 (-4 mCi/m) 
in 7 patients with recurrent ovarian cancer. Follow-up with physical examination 
8
and CT scan showed that most patients with gross disease experienced disease 
progression while prolonged disease-free survival was again seen in patients with 
microscopic disease. Bone marrow toxicity was noted as the dose-limiting effect of 
77Lu-CC49 (6). Meredith et al. (7) administered i.p. 77Lu-CC49 (40-4 mCi/m) in 
combination with interferon alpha (IFNα) and paclitaxel in patients with recurrent 
or persistent ovarian cancer. This combined strategy was based on the findings that 
IFNα enhanced the expression of TAG 7 tumor antigen and improves localization 
of radiolabeled antibody in the tumor (). The study of Meredith et al. (7) led to 
partial responses in four of the 7 treated patients and stable disease in four out of 
7 patients without measurable disease, assessed during third-look laparotomy or 
laparoscopy. A combination of  i.p. 0 mg 90Y-CC49 (4-4. mCi/m), subcutaneous 
IFNαb and i.p. paclitaxel in 0 persistent or recurrent ovarian cancer patients showed 
good feasibility and was well-tolerated (64). Tumor response as assessed with CT 
scan during follow-up revealed a partial response in two patients with measurable 
disease. Out of the patients with non-measurable disease, four patients remained 
disease-free of which three longer than 8 months (64).
The combination of i.p. 90Y-CC49 with chemotherapy seems to be well-tolerated, but 
larger prospective and randomized trials are needed to demonstrate whether this 
therapy is effective.
Table . Clinical trials in ovarian cancer with Mab directed towards antigen TAG 7.
Reference Mab No of 
patients
Dosage Response Special Features
Alvarez et al.
(64) 00
90Y-CC49 0 recurrent or 
persistent
 mg, i.p.  SD
 PR
4 ND
Combination with 
subcutanous IFN 
and i.p. paclitaxel
Meredith et al.
(7) 00
77Lu-CC49 44 recurrent or 
persistent
Repeated, i.p. 4 SD
4 PR
Combi IFN 
 subcutaneous and 
i.p. Taxol
Alvarez et al.
(6) 997
77Lu-CC49 7 refractory 0 mg, i.p. 7 SD
 PR
-
Meredith et al.
(70) 996
77Lu-CC49  refractory 0 mg, i.p.  PR
 CR
 PD
 SD
-
Rosenblum et    
al.(76) 999
90Y-B7. 8 recurrent or
refractory
-0 mg, i.p.  CR
 PR
0 SD
-
See legend Figure .
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Vascular endothelial growth factor (VEGF) is a mediator of angiogenesis 
and is expressed in most ovarian cancers (6). Bevacizumab is a humanized 
antibody directed against VEGF (overview of trials in Table 6) (7,8). A well 
characterized activity of VEGF is to promote the growth of vascular endothelial 
cells. Bevacizumab binds all five isoforms of VEGF, which prevent interaction with 
the VEGF receptors. Binding of bevacizumab inhibits formation of new blood 
vessels and a decrease in vessel diameter, density and permeability. This results in
normalization of tumor vasculature (7,8). Through this mechanism, 
bevacizumab might increase the delivery of drugs (7,8). Trials investigating 
bevacizumab as monotherapy failed to prove effectiveness. However, randomized 
trials in breast, colon and lung cancers have shown that the addition of bevacizumab 
to standard chemotherapeutic regimens results in statistically significant 
improvements in both progression-free and overall survival (7). In 004 the FDA 
approved the use of bevacizumab as adjuvant therapy with -fluorouracil-based 
chemotherapy in advanced stage colorectal cancer. In October 006, bevacizumab 
was also approved by the FDA for the treatment of advanced lung cancer in 
conjunction with paclitaxel and carboplatin-based chemotherapy. These approvals 
established the therapeutic potential of anti-angiogenesis treatments. The 
pathobiology of ovarian cancer and its i.p. metastatic spread is similar to metastatic 
colorectal cancer and suggests that ovarian cancer may also be amenable to anti-
angiogenic intervention. 
Cannistra et al. (4) investigated the single-agent activity of bevacizumab ( mg/
kg) in 44 platinum-resistant heavily pre-treated ovarian cancer patients. Seven of 
the 44 patients had a partial response, as defined on RECIST guidelines (96), with 
a progression-free survival (PFS) at 4. months for all patients. The Gynecologic 
Oncology Group (GOG 70-D trial) assessed the response rates and 6-month 
progression-free survival (PFS) of iv bevacizumab ( mg/kg) three-weekly in a 
cohort of 6 refractory or recurrent ovarian cancer patients (40). Three patients 
were in complete clinical remission, 8 patients had partial remission, 4 patients 
had stable disease and 7 patients had progressive disease. In 8.7% of the patients 
there was stable disease for more than 6 months. Cohn et al. (4) treated 0 ovarian 
cancer patients with a combination of weekly taxane and biweekly bevacizumab 
(0 mg/kg) therapy, which led to temporarily improvement on cancer-related 
symptoms (e.g. diminishing ascites, lowering CA  levels) without toxicity. Monk 
et al. () found similar results in  refractory ovarian cancer patients treated with 
the same combination therapy (bevacizumab  mg/kg) resulting in one complete 
40
remission, 4 partial responses and in 6% of the patients stable disease (disease 
progression was defined on RECIST guidelines (96)). 
A combination of oral cyclophosphamide and bevacizumab (0 mg/kg) in 9 
recurrent ovarian cancer patients resulted in 6 partial responses,7 patients with 
stable disease and 6 with disease progression. About 47% of the patients had stable 
disease at 6 months (47). A retrospective analysis with different bevacizumab 
doses in combination with cytotoxic chemotherapeutic agents in  recurrent or 
refractory ovarian cancer patients showed similar results, with partial remissions in 
%, stable disease in 44% and a PFS of 6 months in % of the patients (7). These 
results with bevacizumab in combination with cytotoxic therapy are promising as 
additional therapy to standard treatment for ovarian cancer and warrant further 
investigation. Two phase III trials in front-line ovarian cancer therapy are currently 
in progress (9).
Table 6. Clinical trials in ovarian cancer with Mab directed towards antigen VEGF.
Reference Mab No of 
patients
Dosage Response Special Features
Wright et al.
(7) 006
bevacuzimab  recurrent  mg/kg, 
i.v.
8 PR
0 SD
 PD
In combination with 
cytotoxic chemotherapy
Cohn et al.
(4) 006
bevacuzimab 0 refractory 0 mg/
kg, i.v.
8 PR
0 SD
 PD
In combination with 
cytotoxic chemotherapy
Monk et al.
() 006
bevacuzimab  refractory  mg/
kg, i.v.
8 PR
 PD
Partial in combination 
with cytotoxic chemo-
therapy
Cannistra et   
al. (4) 006
bevacuzimab 44 refractory  mg/
kg, i.v.
0 PFS
7 PR
0 SD
7.4 % PFS of 6 months
Garcia et al. 
(47) 00
bevacuzimab 9 recurrent 0 mg/
kg, i.v.
6 PR
7 SD
6 PD
In combination with 
cytotoxic chemotherapy
47 % PFS of 6 months
Burger et al. 
(40) 00
bevacuzimab 6 recurrent  mg/
kg, i.v.
 CR
8 PR
4 SD
7 PD
8.7% had stable disease 
for more than 6 months
See legend Figure .
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Conclusion 
In contrast to hematological malignancies and certain solid malignancies (breast, 
colorectal and lung), Mab-based therapy modalities have not yet convincingly 
proven to be efficacious in the treatment of ovarian cancer. Antibodies are 
multifunctional molecules that can target tumor cells, stimulate the immune 
system to attack tumor cells and engage receptor pathways effective in tumor cell 
destruction. 
Of the discussed Mabs, oregovomab directed to the CA  antigen and 
bevacizumab targeting VEGF are two unconjugated Mabs closest to potential 
clinical introduction for the treatment of ovarian cancer. Oregovomab has proven 
to be effective in large trials with patients with recurrent disease or as consolidation 
strategy. Anti-VEGF Mabs in combination with chemotherapy has proven to be 
effective in other malignancies and the initial trials of this combination in ovarian 
cancer patients show similar results. 
Considering the reviewed vaccination regimens, vaccination with the Mab ACA 
 inducing the production of anti-tumor antibodies seems promising, but 
further research in controlled randomized trials should be performed to affirm 
these findings. 
Sole RIT should be investigated with the appropriate radionuclide in combination 
with Mabs with high affinity for the tumor-associated antigen in the appropriate 
group of patients to see whether it may have effect. Additionally, appending 
RIT with CC49 or HMFG to other treatment strategies such as chemotherapy 
or lymphadenectomy could also be a strategy worthwhile investigating. 
Intraperitoneal RIT seems to be effective for local disease control and this should 
be the administration route of preference. However controlled randomized trials 
still need to affirm these treatment modalities.
The lack of large randomized prospective trials with the specific Mabs preclude any 
firm conclusion on the potential of Mabs use in the treatment of ovarian cancer 
although several antibodies have shown to induce significant humoral and cellular 
immune responses with anti-tumor activity. The potential of Mabs to complement 
current treatment in ovarian cancer is encouraging and may bring a significant 
improvement to the overall therapeutic outcomes currently being achieved in this 
disease.
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Abstract
Objective: This study analyzes the site of disease recurrence in ovarian cancer 
patients to assess the influence of a single i.p. administration of 90Y-muHMFG on 
the pattern of disease recurrence.
Methods: In a large phase III trial trial ovarian cancer patients in complete clinical 
remission with FIGO stage Ic-IV were randomized between standard treatment 
plus a single intraperitoneal (i.p.) 90Y-labeled muHMFG versus standard treatment 
alone after negative second-look laparoscopy. Case report forms of all patients with 
disease recurrence were reviewed to determine site and date of recurrent disease.
Results: In total 447 patients were included in the study with a median follow-up of 
. years. Relapse was seen in 04/4 in the active and 98/ in the control arm. 
Significantly fewer intraperitoneal (p < 0.0) and more extraperitoneal (p<0.0) 
relapses occurred in the active treatment arm. Time to intraperitoneal recurrence 
was significantly longer (p = 0.009) and time to extraperitoneal recurrence was 
significantly shorter for the active treatment arm (p < 0.00). The impact of i.p. 
radioimmunotherapy on intraperitoneal relapse-free survival could only be seen 
in the subgroup of patients with residual disease after primary surgery (HR, 0.; 
9% CI, 0.8 to 0.; p = 0.00). 
Conclusion: Although there is no survival benefit for i.p. radioimmunotherapy 
as consolidation treatment for epithelial ovarian cancer, we found an improved 
control of intraperitoneal disease, that was offset by increased extraperitoneal 
recurrences. 
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Introduction
The prognosis of women with advanced stage ovarian cancer remains poor despite 
40 years of research into systemic therapies. Epithelial ovarian cancer is the fifth 
leading cause of cancer deaths and the most lethal gynecologic cancer in the 
United States (). The introduction of platinum and subsequently taxane based 
chemotherapy has resulted in longer progression free (.- months) and overall 
(-44 months) survivals, yet at least 0-7% of these women have persistent or 
recurrent disease with long-term survival (> years) achieved in only % (,). In 
the majority (8%) of the patients recurrence is seen within the peritoneal cavity, 
and in approximately % it occurs in the retroperitoneal lymph nodes (4,).
The rationale for intraperitoneal therapy in ovarian cancer is based on the 
predominately or solely peritoneal location of ovarian cancer during the early part 
of the natural history of the disease and the significant pharmacologic advantage 
of delivering anti-tumor agents directly into the accessible but confined space of 
the peritoneal cavity. Three randomized trials in ovarian cancer patients affirmed 
this assumption by demonstrating improved survival with intraperitoneal (i.p.) 
chemotherapy as compared to similar or identical agents delivered systemically 
(6-8). Recently, the National Cancer Institute proposed to make i.p. chemotherapy 
part of the standard treatment in ovarian cancer (9).
In the recently published study of monoclonal antibody radioimmunotherapy 
trial, patients with advanced stage ovarian cancer in complete clinical remission 
were randomized to a single i.p. administration of yttrium-90-labeled murine 
monoclonal antibody HMFG (90Y-muHMFG) plus standard treatment versus 
standard treatment alone (0). A total of 447 patients were included in the study of 
which 4 received i.p. 90Y-muHMFG plus standard treatment (active treatment 
group) and  patients only received standard treatment. During follow-up (range 
-6 years) 70 patients died and 04 patients experienced relapse in the active arm 
of the study compared to 6 deceased patients and 98 patients with relapse who 
only received standard treatment. Cox proportional hazard analysis of survival 
and time to relapse demonstrated no difference between the two treatment arms. 
A single i.p. administration of 90Y-muHMFG in patients with epithelial ovarian 
cancer who had a negative second-look laparoscopy (SLL) did not extend survival 
or time to relapse. 
In the present study the site of disease recurrence in women participating in the 
international phase III trial of i.p. 90Y-muHMFG was analyzed to assess the influence 
of a single i.p. administration of 90Y-muHMFG on the pattern of recurrence.
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Material and Methods
Between February 998 and January 00 patients who met the eligibility criteria of 
the international phase III trial (0) were enrolled in the study from 74 centers in 7 
countries. Written consent was obtained from all patients. The study was approved 
by the appropriate scientific and ethical authorities and conducted in compliance 
with good clinical practice (guidelines of the European Medicines Agency) and 
the standards of the Declaration of Helsinki. Patients with histologically proven 
epithelial ovarian cancer FIGO stage Ic-IV and macroscopically negative SLL 
were randomized : between standard treatment plus i.p. 90Y-muHMFG and 
standard treatment alone. Patients in the i.p. arm received a single i.p. dose of 
 mg of the 90Y-muHMFG (maximum dose 0 MBq) between 4 and 8 weeks 
after delivery of their final cycle of chemotherapy. Institutions were permitted to 
deliver other standard consolidation therapies after the study to patients in both 
treatment arms (0). Follow-up of all patients was identical with the exception that 
standard treatment patients attended follow-up visits only at weeks , 4 and 8 and 
patients in the active treatment arm weekly for the first six weeks and at week 8. 
Further follow-up occurred at three-monthly intervals for 6 months and then at 6 
monthly intervals until study completion. At each visit, patients underwent clinical 
and laboratory examinations. Clinical disease recurrence had to be confirmed by 
one or more of the following independent objective assessments: radiological 
findings on CT scan, histological evidence of recurrence from materials obtained 
at surgical procedures including histological and/or cytological sampling. Date of 
recurrence was the date of the first CT scan, histology sample or cytology sample 
that confirmed disease recurrence.
Patients had a pre-entry CT scan with follow-up scans on a yearly basis as long as 
they remained in remission and on study. All pre-entry and follow-up CT copies 
were reviewed by a central reader (independent expert radiologists in the USA and 
Europe) at a central reading facility. The study was closed in March 004 when 
 deaths had occurred. At the end of the study, a final CT scan was obtained 
for all surviving patients whose previous scan had occurred more than three 
months before the end of study date. Histologically and/or cytologically diagnosed 
recurrence of disease was also reviewed by the central histopathology facility. 
The case report forms of all patients with disease recurrence were reviewed after 
disclosure of the international phase III trial. Operation reports, CT-scans, MRI scans, 
chest X-rays, histopathology and cytopathology reports, and physical examination 
documents were analyzed to determine site and date of disease recurrence.
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Time to disease recurrence was measured as the number of days between SLL and 
the date of documented disease recurrence up to the end of study date. Patients 
who had not developed recurrent disease at study closure were censored as of that 
date.
Recurrence categories
Patients with disease recurrence were categorized into four main groups: 
intraperitoneal recurrence, extraperitoneal recurrence, combination of intra- and 
extraperitoneal recurrence and unknown site of recurrence. Patients assigned to 
the intraperitoneal relapse group demonstrated peritoneal and/or diaphragm 
involvement as the only site of recurrence. The metastases in this group are the 
result of direct intraperitoneal tumor spread. Patients with evidence of recurrent 
disease confined to extraperitoneal sites were subdivided into those with nodal 
and distant patterns of recurrence. Nodal involvement included disease recurrence 
in pelvic, para-aortic, inguinal, axillary and/or mediastinal lymph nodes. Patients 
categorized as having distant metastases included all women with extraperitoneal 
relapse sites, which were not located in lymph nodes, e.g. liver (intraparenchymal), 
lung, brain and abdominal wall. When both intraperitoneal and extraperitoneal 
sites of disease were documented at time of initial recurrence, patients were 
assigned to the combination relapse group. Patients with recurrent disease but 
no documented site or unknown site of disease recurrence were assigned to the 
unknown site group.
Statistical analysis
All statistical calculations were performed using SPSS .0. software packet 
(SPSS Inc., Chicago). Differences between characteristics were compared using 
the Wilcoxon rank sum test. All statistical tests were performed at the 0.0 level of 
significance and were two-sided. The recurrence-free survival rates were calculated 
by the Kaplan–Meier method and the difference was determined by log rank test. 
Patients who developed recurrent disease at a different site than analyzed in the 
Kaplan Meier method were censored in that analysis. The Cox proportional hazards 
regression model was used to identify prognostic factors. Step-backward regression 
was used to build a valid statistical model for the association of prognostic factors 
with relapse-specific time to relapse among patients. 
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Results
In total 447 patients were included in the study with a median follow-up of . 
years. Patient characteristics are summarized in Table . The active and passive 
treatment arms consisted of 4 patients with a median age of 4.4 years and  
patients with a median age of .7 years, respectively. Differences in age, FIGO 
stage and histologic tumor subtype were not statistically significant.
Recurrent disease was documented in 04/4 patients assigned to active therapy 
and in 98/ patients in the control arm. Of the 04 patients with disease 
recurrence in the active treatment arm, seven patients had incomplete records, 
leaving 97 patients eligible for evaluation. In the standard treatment arm, four 
patients of the 98 patients with recurrent disease had missing data and 94 patients 
were eligible for evaluation. 
The distribution of initial disease recurrence sites is summarized in Table . Solely 
intraperitoneal relapses were diagnosed significantly more frequent in the standard 
treatment arm (69/94) than in the active treatment arm (40/97, p < 0.0). Pure 
extraperitoneal recurrence occurred in 47 of the 97 (48.%) patients in the active 
treatment arm compared to  of the 94 (4%) patients assigned to the standard 
treatment arm (p < 0.0). Most of the extraperitoneal relapses in the active 
treatment arm were lymphatic, 6 of the 47 (77%), with the majority in the 
para-aortic region, ( of the 6). In the standard treatment arm only ten of the 
extraperitoneal recurrences occurred in the lymph nodes. In total 0 of the 97 
(%) patients assigned to the active treatment arm had either intraperitoneal 
(40 patients) or simultaneous intraperitoneal and extraperitoneal recurrence (0 
patients) as compared to 8 of the 94 (89%) patients assigned to the control arm 
(69 intraperitoneal and  a combination of intraperitoneal and extraperitoneal 
disease recurrence). 
Kaplan-Meier plots of time to intraperitoneal and extraperitoneal disease 
recurrence are shown in Figures  and , respectively. The mean interval from 
SLL to the diagnosis of intraperitoneal recurrence was .4 months (SEM =  
months) for the active and 46.4 months (SEM = .6 months) for the standard 
treatment group. For the extraperitoneal recurrences mean interval time from SLL 
to extraperitoneal recurrence was  months (SEM =  months) for the active and 
6.6 months (SEM= .6 months) for the standard treatment group. 
Time to intraperitoneal recurrence was significantly longer for the active 
treatment arm (logrank test, p = 0.009) and time to extraperitoneal recurrence 
was significantly shorter for the active treatment arm (logrank test, p < 0.00). 
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The mean time from SLL to diagnosis of a combination of intraperitoneal and 
extraperitoneal disease recurrence in the active treatment group was 6 months 
(SEM =  month) and 64 months (SEM = of . months) for the standard treatment 
group. The mean time from SLL to unknown recurrence in the active and standard 
treatment group were, 64 months (SEM =  month) and 67 months (SEM =  
month), respectively.
Multivariate regression analysis evaluating factors that could influence site of 
disease recurrence demonstrated that for both recurrence sites (intraperitoneal 
and extraperitoneal) patients with FIGO stage III or greater were at significantly 
higher risk for recurrence than patients with FIGO stage II or less (Table ). 
Patients with residual disease after primary surgery were at significantly increased 
risk of intraperitoneal disease recurrence compared to patients without residual 
disease. For an overview see Table . The impact of i.p. radioimmunotherapy 
on intraperitoneal relapse-free survival could only be seen in the subgroup of 
Table . Patient characteristics
Active treatment
N = 4  (%)
Standard treatment
N =  (%)
Median age (years) 4.4 .7
         Range -76 -79
FIGO stage
         Ic - IIc 7.6 0.4
         ≥ III 7.4 69.6
Histology
         Serous 64. 7.
         Endometrioid .0 .6
         Clear cell 0.0 .
         Undifferentiated 4. .0
         Other .4 .7
Residual disease after surgery
         Yes 44. .9
         No 47.8 .
         Unknown 8.0 9.0
 Abbreviations: FIGO, International federation of Gynecology and 
 Obstetrics; SLL, second-look laparoscopy.
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patients with residual disease after primary surgery, as relapse-free survival in 
patients with residual disease was significantly better in the active treatment 
arm (HR, 0.; 9% CI, 0.8 to 0.; p = 0.00). For patients without residual 
disease after primary surgery, consolidation treatment with 90Y-muHMFG did 
not influence intraperitoneal relapse-free survival. Kaplan-Meier plots of time to 
intraperitoneal disease recurrence in patients with and without residual disease 
are shown in Figure .
Discussion
In this retrospective analysis there is a significant difference in pattern of disease 
recurrence between patients who received a single intraperitoneal treatment with 
90Y-muHMFG and those in the control arm. Patients in the active treatment arm 
Table . Overview of recurrence sites
Location Active treatment
(n = 4)
Standard treatment
(n = )
Intraperitoneal 40 69 
Extraperitoneal 47  
      Nodal                    36                    10
       Pelvic 5  -
       Para-aortic* 22 4
       Inguinal 3    -
       Axillary 1 2
       Other 6 4
       Distant                   11                    3
       Liver 7 1
       Brain† 3 -
       Lung - 2
       Other 2 -
Combination 0  
      Intraperitoneal and nodal 2 9
      Intraperitoneal and distant 8 3
Unknown 7 4
Total 04 98
*One patient had a combination of liver and para-aortic metastasis
† One patient had a combination of liver and brain metastasis.
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Figure . Kaplan-Meier Curve of time to intraperitoneal relapse.
Figure . Kaplan-Meier Curve of time to extraperitoneal relapse.
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had significantly fewer intraperitoneal recurrences compared to the standard arm 
and time to intraperitoneal recurrence of disease was significantly longer for the 
active treatment group. Conversely, in the active treatment group, extraperitoneal 
recurrences were more frequent and presented earlier.
This study provides useful natural history data regarding patterns of disease recurrence 
in a large group of ovarian cancer patients who achieved a complete clinical remission 
after primary cytoreduction and platinum-based chemotherapy confirmed by negative 
second-look laparoscopy. In our study 44% of the patients in the standard treatment 
arm had experienced a relapse by the end of study date. Bolis et al. and Gaducci 
et al. found similar relapse rates (,) while studies with slightly longer follow-up 
have reported higher recurrence rates, % and 64% (4,,). In our control group, 
89% of the women demonstrated intraperitoneal disease at time of first recurrence, 
which is similar albeit modestly higher than intraperitoneal recurrence rates reported 
elsewhere (,4). On the other hand, the incidence of recurrent disease localized in 
the retroperitoneal lymph nodes was lower in this study than reported elsewhere 
(,4). The discrepancy is likely due to inclusion of women with lower stage disease in 
our study since the risk of lymph node involvement rises with advanced stage disease 
Figure . Kaplan-Meier curves of intraperitoneal relapse-free survival in (A) patients 
 without residual disease and (B) all patients with residual disease after primary surgery. 
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to more than 0% (4,). The study population of the international phase III trial (0) 
comprised patients with FIGO stage Ic-IV while studies performed by Gaducci et al. 
and Rubin et al. were limited to patients with FIGO stage III and IV (,4). 
Significantly fewer intraperitoneal recurrences were seen in the active treatment 
arm. An explanation for this observation could be that exposing the peritoneal 
cavity to a single dose of 90Y-muHMFG successfully eradicated residual 
microscopic tumor deposits. Another option could be that intraperitoneal beta 
radiation may negatively influence peritoneal vascularity and causes fibrosis, which 
again may negatively affect peritoneal tumor implants. Furthermore, by using a 
murine monoclonal antibody specifically directed against an antigen expressed on 
ovarian tumor cells, an induced immunologic response against the tumor might 
also contribute to the destruction of microscopic i.p. tumor deposits.
The increased incidence of extraperitoneal relapse in the active treatment arm 
as compared to the standard treatment arm is both striking and difficult to 
explain. This is not what one would expect after intraperitoneal therapy with 90Y-
muHMFG if treatment resulted in eradication of tumor at the predominant site 
of persistent disease. By administering 90Y-muHMFG straight into the peritoneal 
cavity, a positive regional effect seems to occur, while simultaneously the 90Yttrium 
causes reversible myelosuppression, as described in the previous publication on 
the international phase III trial (0). This myelosuppressant effect may explain the 
apparent high number of extraperitoneal relapse sites in the active treatment arm. 
The possibility that such therapy may induce detrimental systemic effects should 
be considered and explored further. More likely, our findings may indicate that 
extraperitoneal dissemination of ovarian cancer occurs more often than previously 
assumed; development of intraperitoneal disease recurrence may mask the 
presence of systemic and/or nodal metastasis since the majority of patients treated 
with standard therapeutic strategies experience predominantly intraperitoneal 
failure and disease progression.
We found a difference in pattern of disease recurrence in ovarian cancer patients in 
complete clinical remission treated with a single i.p. 90Y-muHMFG administration 
compared to the standard treatment group, even though the international phase III 
study did not find any overall difference in progression free survival. Intraperitoneal 
radioimmunotherapy with 90Y-muHMFG improved tumor control in the 
intraperitoneal cavity, but at the same time was associated with (the detection of ) 
more extraperitoneal recurrences. This shift in recurrence ultimately resulted in 
comparable mean progression free survival times in both arms of the  international 
phase III trial (0). 
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Findings from this study should be evaluated in the appropriate context. 
Specifically, the analysis of pattern of disease recurrence was not specifically noted 
as a primary or secondary endpoint of the study and hence these data were not 
collected prospectively or independently audited. In addition, the protocol did 
not specifically indicate that comprehensive staging was required at the time of 
disease recurrence and hence the search for extraperitoneal disease was of variable 
intensity across this international study. Nevertheless data were evaluable for 
over 90% of the cases. Furthermore, the confirmation of extraperitoneal disease 
including extraperitoneal lymphadenopathy in patients with cancer is not an exact 
science and most women did not have surgical or pathologic confirmation of 
disease recurrence in extraperitoneal or intraperitoneal sites. Finally, the detection 
method of disease recurrence is similar to the one used during follow-up of 
patients in daily practice with the same limitations. The CT-scan modality has 
a poor sensitivity for detection of small tumor implants, especially on the small 
intestine or mesentery, but improvement of the CT modality has allowed detection 
of 8-0% of the peritoneal implants as small as  mm in diameter (6).
In conclusion, this retrospective analysis of a large prospective and randomized 
trial identifies a difference in pattern of disease recurrence in patients with ovarian 
cancer assigned to receive a single i.p. administration of 90Y-muHMFG with no 
significant effect on total overall and progression-free survival due to the higher 
incidence of extraperitoneal disease recurrence. 
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Abstract
We conducted a single arm study to determine the biodistribution of 
intraperitoneally administered 90Yttrium-labeled murine monoclonal antibody 
HMFG (90Y-muHMFG) in patients with advanced stage ovarian cancer. Seventeen 
patients in complete clinical remission for epithelial ovarian cancer were included. 
After completion of chemotherapy, a mixture of Indium labeled muHMFG 
(imaging) and 90Y-muHMFG (therapy) was intraperitoneally administered via a 
surgically placed, indwelling intraperitoneal catheter. Planar and Single Photon 
Emission Computed Tomography (SPECT) images were recorded to determine 
the distribution of the study medication during the first 6 days post-injection. 
Out of the first three patients, two patients had extraperitoneal leakage up to 
0% of the injected dose within 4 hours after injection of the study medication. 
Extraperitoneal leakage was mainly seen in the retroperitoneal spaces covering the 
upper and lower quadrant of the abdomen. After adjustments in the procedure, 
leakage was observed in two of the remaining 4 patients. Extraperitoneal leakage 
of intraperitoneally administered therapy does occur. Such leakage would reduce 
the locally delivered dose of a drug and could potentially have a negative impact on 
therapeutic efficacy. Given the potential attraction of developing intraperitoneal 
treatments for intra-abdominal cancer, the observations in this study need to be 
taken into consideration.
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Introduction
Despite advances in the treatment of ovarian cancer, it is still the most deadly of the 
gynecologic malignancies. In the majority of cases it is diagnosed at an advanced 
stage, when -year survival is -0% (). Although there is a high response rate 
to cytoreductive surgery followed by platinum-based chemotherapy, the majority 
of patients develop recurrent disease, particularly in the abdominal cavity. Failure 
to control intra-abdominal disease remains the primary reason for poor overall 
outcome. 
Intraperitoneal (i.p.) delivery of anti-neoplastic therapy was first explored in the 
90s, and over the last five decades several forms of intraperitoneal therapy, e.g. 
i.p. chemotherapy, i.p. radioimmunotherapy, i.p. radioactive P- phosphate and 
i.p. unlabeled monoclonal antibody therapy, have been investigated in patients 
with ovarian, colorectal and gastric cancer (). Advantages of intraperitoneal 
therapy are the achievement of higher local drug concentrations which can greatly 
exceed drug concentrations in the plasma, reduced systemic toxicity, prolonged 
tumor exposure with an assumed greater effect on tumor reduction and a slow 
systemic uptake from the peritoneal cavity (,4). The different i.p.  therapy forms 
have shown variable results. 
Despite advantages of an intraperitoneal approach i.p. studies have not yet led 
to a standardization of i.p. therapy in ovarian cancer. At least three randomized 
studies have shown a survival benefit for the use of i.p chemotherapy in ovarian 
cancer patients with residual disease smaller than  cm in diameter after debulking 
surgery (-7). However, toxicity and difficulties inherent to this approach have 
until recently precluded the acceptance into clinical practice (4,8,9).
In a phase III, randomized clinical trial, a novel approach using intraperitoneal 
injection of the HMFG murine monoclonal antibody radiolabeled with 90-
Yttrium was studied (0). HMFG is directed towards the MUC gene, which is 
a large, heavily glycosylated mucin expressed on the apical surface of the majority 
of secretory epithelial cells (). In 90% of the epithelial ovarian cancers, MUC 
is overexpressed on the cells surface and it is antigenically distinct from normal 
tissue mucin as a result of underglycosylation or aberrant glycosylation of this 
protein in cancerous tissue (,).
Parallel to the phase III study (0), we conducted an open, single arm study to 
determine the biodistribution of the intraperitoneally administered therapeutic 
agent 90Yttrium-labeled murine HMFG (90Y-muHMFG).
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Patients and Methods 
Between July 00 and July 004, patients in complete clinical remission following 
cytoreductive surgery and platinum-based chemotherapy for a prior histological 
proven diagnosis of epithelial ovarian cancer FIGO stages Ic –IV, were enrolled in 
the Monoclonal antibody Imaging and Dosimetry Assessment Study (MIDAS). The 
study was approved by the Institutional Review Board of the Radboud University 
Nijmegen Medical Centre. Written informed consent was obtained from all patients 
prior to study entry. Eligibility criteria consisted of proven epithelial ovarian cancer 
including primary peritoneal serous carcinoma with ovarian involvement, entry 
within 4-8 weeks from final administration of chemotherapy, a life expectancy of at 
least  months, age over 8 years and adequate bone marrow (leukocyte count ≥  
x 09/L, platelet count ≥ 00 x 09/L, hemoglobin 0g/dl), renal (serum creatinine 
≤ 77 μmol/L or 0 mg/L) and hepatic function (alanine aminotransferase and 
aspartate aminotransferase not higher than twice the upper limit of normal).
Patients were excluded from inclusion in the study if they had known metastases at 
the time of second-look laparoscopy (SLL) or had prior/concomitant malignancy 
other than basal cell carcinoma of the skin. Further exclusion criteria were, 
serious concomitant physical or psychiatric disease, previous exposure to murine 
antibodies or the presence of human anti-mouse antibodies (HAMA) as detected 
by the central laboratory, and participation in any other experimental treatment 
program. 
During SLL the trocar for the laparoscope was placed inferior and the trocar 
for the laparoscopic probe inferior and lateral to the umbilicus. If there was 
any visible evidence of malignant disease at SLL the patient was excluded from 
the study. At negative SLL the patient was further enrolled in the study and the 
peritoneal dialysis catheter was placed at the same place as the trocar for the 
laparoscopic probe and was fixated to the abdominal wall. Administration of the 
study medication was performed one day after SLL through the peritoneal dialysis 
catheter. Before administering radiolabelled antibody, 99mTechnetium (99mTc) 
colloid was injected intraperitoneally to verify an adequate fluid distribution 
within the peritoneal cavity. Significant loculation of the intraperitoneal cavity - 
that might preclude adequate distribution of the study medication – was excluded 
by initial intraperitoneal administration of 99mTc-colloid. After administration 
of 99mTc-colloid-colloid, the patient was moved frequently to ensure adequate 
intra-abdominal distribution. Subsequently, anterior and posterior planar images 
were recorded to check adequate distribution of the radiopharmaceutical to all 
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four abdominal quadrants. When distribution was seen in at least  out of the 
4 abdominal quadrants, 0. liter saline solution, heated to body temperature, 
was infused. Thereafter, a single therapeutic dose of 90Y-muHMFG (Antisoma, 
London, UK, 90Y activity dose 666 MBq/m of body-surface area with a maximum 
dose but not exceeding 0 MBq) spiked with an imaging dose of 8 MBq of 
Indium-muHMFGwas injected through the ‘Y’ connector or two-way tap in 0-
60 sec. Although obviously not necessary for imaging and dosimetry studies, it was 
decided to offer the therapeutic 90Y-muHMFG to patients participating in this 
study, as patients were subjected to all invasive procedures as the patients in the 
active treatment arm of the phase III trial that was recruiting in parallel. During 
and after infusion of the radiopharmaceuticals, the saline solution continued to 
flow until the intraperitoneal space was filled with . L saline solution. After 
administration of the study medication the catheter was removed and the skin was 
closed. To enhance distribution of the study medication in the peritoneal cavity, 
the patient was asked to move gently during the first hour after administration. 
Planar and Single Photon Emission Computed Tomography (SPECT) images were 
recorded to determine the distribution of the study medication. On the anterior and 
posterior images, regions of interest (ROI) were drawn around the extraperitoneal 
leakage, (corrected for background by an ROI drawn in the adjacent soft tissues 
in which no leakage was observed) and over the whole body. When drawing the 
ROIs over the extraperitonel leakage, inclusion of intra-abdominal activity was 
carefully avoided. At all time points, the measured counts in ROIs were corrected 
for physical decay of Indium. SPECT was performed twice at 48 and 68 hours 
post-injection for dosimetric calculations (data not shown), but not used for the 
assessment of leakage. The percentage leakage was calculated using the geometric 
means of the decay-corrected counts in the formula:   
√ ((ROIleakage, ant - ROIbkgr, ant ) x (ROIleakage, post - ROIbkgr, post ))
               √ (ROIWB, ant, t=0  x ROIWB, post,t=0 )
Blood sampling and imaging was performed , 6, 4, 48, 7, 96, 0 and 68 
hours after injection of the study medication with a range of +/- 4 hours. Blood 
samples were collected, weighed, and counted in a  γ-counter. By simultaneous 
measurement of a known aliquot of the injected dose, the percentage injected dose 
per gram (%ID/g) was determined for each sample.
For safety purposes, patients had a weekly follow-up for 6 weeks, at week 8, at 
week  and  monthly thereafter, up to one year post treatment. The follow-up 
consisted of physical examination, and blood and urine sampling to determine 
total activity that was excreted.
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Statistical analyses
Data analyses were performed using SPSS .0. software packet (SPSS Inc., 
Chicago). Differences between characteristics were tested two-sided with the 
independent t-test. P values ≤ 0.0 were considered significant. 
Results
A total of 7 patients received the i.p study medication of the MIDAS study (Table 
). In the first three patients, two cases of substantial leakage from the peritoneal 
cavity to extraperitoneal spaces were observed. Patient no.  showed moderate 
extraperitoneal leakage of approximately % of the injected study medication into 
the right lower quadrant of the abdomen. Patient no.  had a major extraperitoneal 
leakage of 0% of the injected activity into the right upper and lower quadrant 
of the abdomen (Fig. ). These observations resulted in an adjustment of the 
protocol. After the first three patients the protocol was revised and adjusted with 
Table   Baseline characteristics of patients treated with intraperitoneal 90Y-muHMFG.
Patient FIGO stage Age 
(years)
Histopathology (serous/endometroid/other)
 IIIc  Papillary adenocarcinoma
 IIIc  Serous carcinoma
 IIIc 7 Endometroid carcinoma
4 IIIc 70 Serous carcinoma
 IIIb  Serous carcinoma
6 IIIc 4 Papillary adenocarcinoma
7 IIIb  Unspecified adenocarcinoma
8 IIb 49 Serous carcinoma
9 IIIc 8 Serous carcinoma
0 IIIb 6 Endometroid  carcinoma
 III  Serous carcinoma
 IIIc 7 Serous carcinoma
 IIIb 68 Serous carcinoma
4 IIIa 6 Serous carcinoma
 IIIb 67 Serous carcinoma
6 IV  Serous carcinoma
7 IIIb  Mixed endometroid and  serous carcinoma
FIGO, International Federation of Gynecology and Obstetrics.
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the following measures: firstly, the trocar incision for the laparoscopic probe and 
catheter was dsplaced from the lateral to the medial side of the abdomen. Secondly, 
the peritoneal dialysis catheter was replaced by a Foley catheter to ensure that the 
abdominal opening would be closed firmly; the balloon of the Foley catheter was 
inflated, pulled back and secured against the abdominal wall with sutures before 
administration of the study medication. Thirdly, the infusion of distribution fluid 
was limited to a maximum volume of  liter. Finally, instead of removing the catheter 
immediately after administration of the study medication, the catheter remained 
in situ for a minimum of 4 hours after administration of the study medication. 
  Figure . Whole body images of patient no.  at 4 hours post injection of Indium-
  muHMFG: major extraperitoneal leakage (0% of the injected activity leaked into the 
  right upper and lower quadrant of the abdomen).
Anterior        Posterior
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After introduction of these four adjustment measures, no leakage was observed 
in  of the 4 remaining patients. Patient no.  showed a very minor leakage of 
.% of the injected dose into the left lower quadrant of the abdomen and in patient 
no. 7 a moderate extraperitoneal leakage of 9% into the right flank and lower 
quadrant of the abdomen was seen. 
The minimum time at which extraperitoneal leakage first was seen, was as early 
as 4 hours after injection of the study medication as defined on planar images. 
All 4 patients with extraperitoneal leakage had signs of leakage at 4 hours after 
injection of the study medication. In none of these 4 patients local side effects due 
to increased radiation outside the peritoneal cavity, were observed.
Radioactivity in blood serum has been measured at time points , 6, 4, 48, 7, 
96 and 68 hours post-injection of the study medication. As shown in Figure , 
the three patients with substantial leakage (nos. , , and 7) had a 0% lower 
peak activity in their blood at 48 hours after i.p injection. Furthermore, subsequent 
blood clearance of the radioactivity from 48 to 68 hours after study drug 
administration was slower than in the group without leakage, indicating a slow 
release and reabsorption from the extraperitoneal compartment to the blood. 
There was a significant difference in the level of blood radioactivity (area under the 
curve) between the group of patients without leakage (. ± 0.4) and the three 
patients with substantial leakage (0.0 ± 0.), p< 0.00).
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Figure . Radioactivity in the blood after intraperitoneal administration of 
Indium-muHMFG. There is a significant difference between the blood levels of 
In-muHMFG in patients with leakage (Leakage +) and patients without leakage 
(Leakage -). Data are expressed as means of the two groups.
Leakage -
Leakage +
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Discussion
Four of the 7 patients demonstrated leakage after i.p administration of study 
medication. After adjusting the surgical procedure and the infusion method, leakage 
was reduced, but not completely prevented. Leakage of the study medication did 
not result in local toxicity due to radiation exposure.
Until now no studies or case-reports about leakage of i.p administered medication 
to extraperitoneal spaces, which was not subcutaneous, have been described in 
the literature. Balink et al. (4) reported a case of leakage into the subcutaneous 
tissue at the catheter site after i.p therapy with P during the treatment of 
malignant ascites. They detected the leakage because of regional side effects after 
administration of the study medication. As shown in this study, leakage of i.p 
study medication does not always cause side effects. This depends on the amount 
of leakage, the site of leakage and the composition of the study medication. 
Different chemotherapeutic agents that have been used intraperitoneally are 
classified as vesicant and irritant drugs, which may cause inflammation and or 
tissue destruction ().
Major catheter problems, such as malfunction, did not occur in our study, but 
these have been reported in other studies. Several studies reported that 0-0% 
of the patients treated with intraperitonel chemotherapy, had catheter problems. 
Reported complications are malfunction of the catheter (inflow obstruction), 
infection, bowel perforation, ileus, abdominal pain and an increased morbidity 
(6-9). Almost all these complications were reported in studies which used 
repeated administration of the drugs. Because 90Y-muHMFG was given as a single 
dose we used an administration procedure, which was less invasive. Placement 
of the catheter during surgery and quick removal of the catheter after drugs 
administration prevented extra surgical interventions and catheter complication. 
For repeated administration the technique we described is not appropriate as it 
was designed for one-time administration of i.p therapy.
Recommendations for the use and placement of i.p catheters for repeated 
drugs administration have been given by Markman and Walker (0) and were 
the following: ) insertion of a fully implantable port attached to a single lumen 
venous silicone catheter on the inferior thorax at the midclavicular line. ) the 
catheter should be tunneled subcutaneously, above the fascia, 6 cm lateral to the 
umbilicus and pulled into the peritoneal cavity through a small hole the size of the 
catheter. ) closure of the wound and peritoneal defect in several layers to prevent 
leakage (0). 
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In our study, we restricted the use of distribution fluid in the intraperitoneal 
cavity to  liter at maximum after the first  patients. Several intraperitoneal 
chemotherapy studies use .- liter distribution fluid at maximum to facilitate 
distribution of medication (-7, -). The rationale behind minimizing the 
volume of distribution fluid was a potentially lower intraperitoneal pressure and 
hence minimize risk of leakage. Dedrick and Flessner (6) demonstrated that an 
increase in irrigated area may be achieved in many patients by individualizing 
the distribution fluid volume and through consideration of the patient’s position. 
Obviously, as in the current study both the surgical protocol and the distribution 
volume were modified, it is unclear which alteration had more impact on the 
reduction of leakage. 
The main problem with regional therapy is the limited depth of penetration of the 
drugs directly into the tumor by free surface diffusion. Experimental and clinical 
data support the conclusions that the high concentrations of drugs observed after 
delivery directly into the peritoneal cavity will only be relevant for patients with 
microscopic disease or very small volume macroscopic cancer e.g. largest residual 
mass less than 0.- cm in diameter (7,8). In this context the existence of leakage 
during i.p therapy is of importance for the outcome of the treatment. Leakage may 
result in lower concentrations in the intraperitoneal cavity and thereby potentially 
diminish effects of the drug. If the surfaces of tumor nodules are not or are 
inadequately exposed to the drug containing solution, the rationale for regional 
administration is compromised and treatment failures could result. A recently 
published large international randomized trial of i.p 90Y-muHMFG in ovarian 
cancer patients did not show a survival benefit between the active treatment and 
the standard treatment arm (0). This might at least in part be due to leakage after 
i.p therapy, possibly resulting in diminished therapeutic effectiveness.
Besides working as a regional therapy, i.p therapy could also be effective in the 
systemic treatment of any extraperitoneal tumor localizations. Capillary uptake 
of the drug from the peritoneal cavity allows therapeutic concentrations to be 
achieved systematically, resulting in the control of extraperitoneal disease. As 
shown in Figure , the group with leakage shows a lower concentration in blood 
as compared to the group without leakage. The concentration in the peritoneal 
cavity is lower, which causes a lower gradient for diffusion of the radioactivity and 
clearance out of the peritoneal cavity. Thus, when leakage occurs it may affect not 
only the intraperitoneal therapy but also possible systemic effects.
Some phase III trials have documented the clinical benefit of i.p cisplatin-based 
chemotherapy in the first-line treatment of optimally cytoreduced patients (-7). 
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The results of i.p chemotherapeutic therapy when extraperitoneal leakage occurs 
are not yet known. The effect on efficacy and the local side effects largely depends 
on reabsorption from the extraperitoneal tissues. 
In conclusion, extraperitoneal leakage of intraperitoneally administered 
medication may occur, which may result in decreased efficacy and potentially also 
in local side effects. In view of the recently published clinical announcement of 
the National Cancer Institute to prefer a combination of i.p and i.v. chemotherapy 
over i.v. chemotherapy alone in the first-line treatment of ovarian cancer (9) and 
future developments of intraperitoneal treatment of intra-abdominal cancer, the 
observations in this study need to be taken into consideration. 
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Abstract
Objective: To investigate the influence of human anti-mouse antibodies (HAMA) 
on serial CA  measurements in serum of patients with epithelial ovarian cancer 
following single intraperitoneal (i.p.) therapy with Yttrium-90-labeled human 
milk fat globule  murine monoclonal antibody (90Y-muHMFG) as part of a large 
international randomized phase III trial. 
Methods: We monitored CA  concentrations in longitudinally collected serum 
samples from 4 patients after i.p. 90Y-muHMFG (study group) and from  
patients who received standard treatment (control group). Serum samples of  
study patients with increased CA  concentrations were selected and subjected to 
affinity chromatography to study HAMA interference in CA  measurements.
Results: CA  serum concentrations at weeks , 4 and 8 were significantly higher 
in the study group than in the control group. In the first eight weeks after i.p. 90Y-
muHMFG administration significantly more patients of the study group (44/4) 
demonstrated CA  concentrations above the upper limit of normal of  U/mL, 
as compared to those of the control group (7/). Affinity chromatography of 
serum with high CA  values in the first 8 weeks confirmed HAMA interference 
in CA  measurements while after 4 weeks this HAMA interference could no 
longer be detected.
Conclusions: This is the first study to demonstrate that clinical trials applying 
murine monoclonal antibodies may be flawed by a transient HAMA effect, which 
should be considered when monitoring ovarian cancer patients with CA  
measurements.
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Introduction
There has been extensive experience with the serum tumor marker CA  in the 
detection and management of ovarian cancer. Up till now this tumor marker is the 
best available marker for monitoring epithelial ovarian cancer (). Rising values 
of CA  during follow up of ovarian cancer patients correlates with disease 
progression in approximately 90% of the cases and persistent CA  elevation 
correlates with persistent disease (). 
The prognosis of ovarian cancer is still poor and in need of new treatment 
modalities (). Radioimmunotherapy and immunotherapy which use monoclonal 
antibodies (Mab) could be such modalities. The murine human milk fat globule  
(muHMFG) directed towards the MUC antigen, which is overexpressed in 90% 
of the epithelial ovarian cancers, is a Mab used in clinical trials in ovarian cancer 
patients (4). The injection of this mouse Mab induces the development of human 
anti-mouse antibodies (HAMA) (). HAMA are reported to interfere in CA  
measurements (6-).
In the present study, serial CA  measurements of ovarian cancer patients 
participating in a large international randomized phase III trial () treated with 
a single intraperitoneal (i.p.) yttrium-90-labeled murine HMFG (90Y-muHMFG) 
injection (study group) were compared with serial CA  measurements of patients 
who received standard treatment (control group). In addition, we investigated 
whether differences in CA  concentrations existed and if so, to what extent 
these were caused by the development of HAMA.
Material and Methods 
Patients eligibility
In an international phase III trial (), comprising 74 institutes, ovarian cancer 
patients in complete clinical remission FIGO stage Ic-IV were randomly assigned 
to standard consolidation treatment plus i.p. 90Y-muHMFG (study group) and 
standard treatment alone (control group). Patients with a macroscopically negative 
second look laparoscopy were eligible to receive a single i.p. dose of  mg of the 
radiolabeled Mab (maximum dose 0 MBq) or standard treatment between 4 
and 8 weeks after receiving their final cycle of chemotherapy. Patients with HAMA 
serum concentrations (ELISA, Roche Diagnostics, Basel, Switzerland) greater than 
0 ng/mL at the start of the study were excluded. The study was approved by the 
scientific and ethical authorities of the participating institutes and was conducted 
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in compliance with the standards of the Declaration of Helsinki. Serum samples 
for CA  measurements of the control and the study group were taken on the 
following time points: prior to i.p. 90Y-muHMFG administration (week 0), and 
at week , 4 and 8 after 90Y-muHMFG administration and at three-monthly 
intervals up to the closure of the study. To study HAMA interference in CA  
measurements we tested serum samples of  study patients. 
CA  measurements were performed with the commercially available CA  assay 
(AxSYM, Abbott Laboratories, Chicago, Illinois, USA) with a minimum detectable 
concentration of  U/mL. This assay is based on Microparticle Enzyme Immunoassay 
technology and uses the murine monoclonal antibody OC  as catching antibody. 
An upper limit of normal CA  values of  U/mL was used ().
HAMA measurements were performed using a commercially available ELISA 
(Roche Diagnostics, Basel, Switzerland) in which HAMA is bound to mouse-IgG-
biotin and to the peroxidase-conjugated detection antibody. This complex binds 
via the biotin-labeled antibody to the streptavidin-coated surface of the microplate. 
Following the washing step, complex bound peroxidase (HRP) reacts with the 
substrate tetramethylbenzidine and the product is quantified at 40 nm. The limit 
of detection is . ng/mL anti-mouse IgG.
Chromatography procedure
To determine whether the developed HAMA interfere in the CA  assay, affinity 
chromatography (Fast Protein Liquid Chromatography, FPLC) was performed 
on a number of serum samples with high CA  values as described earlier (8). 
Patient serum (0 μL) was applied to a HiTrap Protein G column (GE Healthcare, 
Uppsala, Sweden). The total passage fraction was collected using a 0.0 M phosphate 
buffer pH 7.0 at a flow rate of 0. mL/min. The Protein G-bound IgG was eluted 
with  ml of 0. M glycine-HCl buffer, pH .7. Directly after elution the pH was 
neutralized using 0 μL of  M Tris-HCl, pH 9.0. The isolated HAMA-IgG in the 
4.-fold diluted eluent fraction was quantified with the CA  AxSYM assay and 
expressed in terms of apparent CA  concentrations. CA  concentration in 
the passage fraction was also measured. Due to the 4.-fold sample dilution of both 
fractions, CA  concentrations could be quantified with a minimum detectable 
concentration of 8.4 U/mL. In each chromatography run we processed a positive 
control sample with a known concentration of CA . Moreover, we have tested 
CA  values in  serum samples obtained at week 8 of the control group of the 
present study. These control samples always contained ≥ of 80% of the CA  
measured before chromatography in the effluent fraction (i.e passing the column) 
86
of the column and CA  values measured in the eluate fractions (eluted from the 
column) were invariably below the detection limit of the CA  assay.
Statistical analysis
Differences in patient characteristics and CA  profiles were tested with the 
Mann Whitney U test with the level of significance set at < 0.0. Correlations 
between HAMA and CA  levels during follow up were analyzed with Spearman’s 
correlation test.
Results
The study group consisted of 4 patients who received i.p. 90Y-muHMFG and 
the control group comprised  patients only receiving standard treatment. Prior 
to Mab administration none of the patients had HAMA levels above 0 ng/mL. 
Following i.p. 90Y-muHMFG administration, 98.% of the study group patients 
developed HAMA levels above 0 ng/mL. Only four patients failed to develop a 
HAMA response (< 0 ng/mL). In the control group none of the patients developed 
a HAMA response.
Prior to i.p. 90Y-muHMFG administration at week 0, there was no significant 
difference (p = 0.9) between CA  values of the study (n = 4) and the control 
group (n = ). At week , 4 and 8 after 90Y-muHMFG administration CA  
values of the study group were significantly (p < 0.0) higher as compared to 
the control group. The difference in CA  values between the study and the 
control group could no longer be observed at 4 weeks and later following i.p. 
90Y-muHMFG administration. Significantly more patients of the study group 
(44/4) had CA  values of > U/mL (Figure ) during the first eight weeks 
as compared to the control group (7/). None of the control patients had CA 
 values greater than twice the upper limit of normal CA  values (i.e. ≥ 46 
U/mL) on  consecutive time points during the first 8 weeks, while 4 patients of 
the study group showed CA  values ≥ 46 U/mL. 
To study whether elevated serum CA  values in the study group were caused 
by HAMA interference in the assay, serum samples of these patients were tested 
for the presence of HAMA by affinity chromatography. The results are shown 
in Table . Serum samples of patients with high CA  values during the first 8 
weeks and between week  and the end of follow-up were measured for HAMA 
interference on consecutive time points (patients  to ). In all three patients a 
signal in the CA  assay was detectable in the eluent after chromatography of 
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Table . Results of affinity chromatography in samples of patients with elevated CA  
 values (U/mL).
Patient no Week Before 
chromotography
After 
chromotography
Eluent HAMA IgGd
a  88  
   8 47
 4 4 ND 6
 6 0 ND 0
 4  ND 8
 6 8 89 ND
a  0  8
 4 74 7 
 4 47 6 
 8  0 ND
 6 87  ND
 48 86 8 ND
a  6 7 8
  84 6 
 4 64 6 
 6 0  
   ND ND
 6 87 48 ND
4b  6 00 00
   8 
6  89 78 76
7   90 
8  89 9 8
9  46  6
0  67  97
  88 47 
 4 76 4 ND
 4 6 ND 7
4c 4 94 60 0
 4 49 78 ND
6 48 8 60 ND
7 60 66 8 7
8 84  7 ND
9 84 8 0 ND
0 68 46 47 ND
 68 70 0 ND
 68 46 47 ND
aPatients  to  had elevated CA  values during the first 8 weeks and elevated CA  values 
between week  and the end of follow-up after 90Y-muHMFG administration. bPatients 4 to  
only had elevated CA  values during the first 8 weeks and c patients 4 to  had only elevated 
CA  values not earlier than  weeks after IP 90 Y-muHMFG administration.d Eluent HAMA-
IgG expressed in CA  values (U/mL).
ND, not detectable < 8.4 U/mL.
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samples taken within the first 8 weeks, indicating interference of HAMA in the 
original sample. In serum samples obtained after twelve weeks no CA  positive 
signal was detectable in the eluent and thus the measured CA  values could 
be considered as true. HAMA interference could also be demonstrated in serum 
samples from patients who showed CA  serum elevations only in the first 8 
weeks (patients 4 to ), except for patient . CA  values were lower after 
affinity chromatography and the eluent fraction clearly showed a positive CA 
 signal. FPLC eluent fractions of serum from patients who had CA  serum 
elevations not earlier than twelve weeks after i.p. administration (patients 4 to 
) did not show any significant CA  positive signal, indicating that the CA 
 values measured prior to chromatography could be considered as true. These 
findings were confirmed when performing correlation analysis between HAMA 
and CA  concentrations at each time point. During the first 8 weeks HAMA 
was positively correlated to CA . In week 4 there was correlation coefficient of 
0.66 (p < 0.00) and in week 8 of 0.69 (p < 0.00). After 8 weeks there was no 
significant correlation between HAMA and CA .
We subjected several samples of patients of the control group to the same HAMA 
chromatography procedure. More than 80% of the original CA  concentration
was recovered in the effluent fraction, whereas in the eluent fractions 
the CA  were below the detection limit of the assay. These results 
indicate the absence of interference in the control samples investigated.
Figure . Number of patients who developed CA  values above the upper limit of 
normal (> U/mL) during the first 60 weeks. More patients in the study group (n = 4) 
developed CA  values >  U/mL as compared to the control group (n = ).
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Discussion
Our study shows the presence of HAMA interference in CA  measurements 
in ovarian cancer patients after a single i.p. 90Y-muHMFG administration. This 
interference is transient as it could no longer be detected in serum samples taken 
4 weeks after 90Y-muHMFG administration. Interference of HAMA in the CA 
 assay has been described previously (6-). However, the transient nature of 
the HAMA interference after a single i.p. Mab injection in our view has not been 
reported before. Our data show that the interference is no longer present 4 weeks 
after administration of 90Y-muHMFG and the observed CA  value can be used 
reliably in monitoring ovarian cancer patients. 
Thirty-seven control patients showed elevated CA  values (> U/mL) during 
the first 8 weeks after second-look laparoscopy. These elevations were not caused 
by interfering HAMA, as the patients with HAMA higher than 0 ng/mL at 
the start of the study were excluded from investigations. As described in earlier 
reports, these CA  elevations were probably the result of the second-look 
laparoscopy in which the peritoneum was manipulated and damaged resulting in 
an increase in serum CA  concentrations (4-). Furthermore, increased CA 
 concentrations have also been described to be caused by other benign diseases 
including multivisceral tuberculosis, Meigs and pseudo-Meigs syndrome, ovarian 
hyperstimulation syndrome, liver cirrhosis, tuberculosis peritonitis, uremia and 
renal failure, nephritic syndrome, fulminant hepatic failure and pancreatitis (6).
CA  is a predictive marker during monitoring of ovarian cancer. During the 
first 8 weeks, 4 patients in the study group developed CA  values greater than 
twice the upper limit of normal 46 U/mL) on  consecutive time points, which is 
one of the criteria for defining disease progression (). Patients with repeated CA 
 values ≥46 U/mL could have undergone needless diagnostic or therapeutic 
interventions for disease progression, as the elevated CA  levels were caused by 
HAMA interference in the assay. 
It has to be noted that the concentration of CA  in serum, eluent and passage 
fraction cannot be quantitatively compared with each other. A lower CA  
concentration is measured in the passage fraction as compared to the serum 
sample due to recovery loss during the procedure. Moreover, the passage fraction 
was measured in a buffer solution, which may cause a matrix effect, affecting CA 
 measurements.
HAMA interference in other commercially available CA  assays has also been 
reported and the magnitude of the interference in these assays differs widely 
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(9,7,8). Furthermore, other assays, e.g. those for rheumatoid factor, digoxine, 
TSH and cortisol, also are reported to be affected by HAMA interference (9-). 
The present results indicate that caution should be taken when interpreting assay 
results in blood of patients recently treated with monoclonal antibodies. Alternative 
techniques or commercial products to neutralize the effects of HAMA include 
heating of the specimen when the antigen being measured is heat stable, adding 
nonimmune mouse IgG or adding commercially available blocking agents (,4). 
Moreover, the susceptibility of HAMA interference in assays may be reduced by 
using Fab of F(ab) fragments instead of intact immuglobulin antibodies. Another 
option explored by our group combines immunoglobulines originating from 
different animals in order to reduce the possibility of bridging the catching and 
detecting antibodies (4). 
In the present study a transient HAMA interference is observed in serum samples 
of patients who had received a single i.p.90Y-muHMFG injection. Most likely, 
in experimental clinical trials using other murine Mab and other routes and/or 
frequency of administration other types of HAMA response are induced which 
may result in a shorter or a longer duration of assay interference. 
In conclusion, the results of this study indicate a transient HAMA interference in 
CA  measurements during the first 8 weeks after a single i.p. 90Y-muHMFG 
administration and that after  to 6 months CA  values are again reliable. When 
using i.p. 90Y-muHMFG in the treatment of ovarian cancer one should be aware 
that elevated CA  values during the first 8 weeks after administration may be 
due to HAMA interference and verification of the elevated CA concentrations 
should be performed.
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Abstract 
The aim of this study was to develop and validate ELISAs for quantification of HAMA-
IgM and HAMA-IgG in serum of patients with ovarian cancer who enrolled in a 
large international randomized phase III trial of intraperitoneal Yttrium-90-labeled 
HMFG murine monoclonal antibody therapy. The capture antibody of these two 
assays was the murine antibody HMFG, while mouse anti-human IgM-HRP or 
mouse anti-human IgG(Fc)-HRP served as tracer antibodies. A pool of HAMA 
positive serum samples was used to prepare a series of assay standards and another 
pool served as reference preparation. The analytical sensitivity of the HAMA-IgM 
assay was . arbitrary units per mL (AU/mL) and 4.7 AU/mL for the HAMA-IgG 
ELISA. Diluted serum samples showed good parallelism with the HAMA-IgM and 
HAMA-IgG standard-dose response curves. Within-assay coefficient of variation 
was 7.% for HAMA-IgM and 6.% for HAMA-IgG. Between-assay variation was 
4.% for HAMA-IgM and .% for HAMA-IgG. The developed HAMA-IgM and 
HAMA-IgG ELISAs show satisfactory reliability criteria (sensitivity, parallelism 
and precision) and are suitable for monitoring of HAMA-IgM and HAMA-IgG 
responses in ovarian cancer patients. These ELISAs will be used to monitor the 
development of HAMAs in patients who received radioimmunotherapy with 
murine HMFG.
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Introduction
Human adenocarcinomas overexpress the transmembrane glycoprotein mucin  
(MUC), which is normally expressed on the apical surface of glandular epithelial 
cells. More than 90% of the epithelial ovarian cancers express high levels of 
MUC (). In addition, MUC in cancerous tissue is antigenically different from 
MUC in normal tissue, as a result of aberrant glycosylation, thereby exposing 
an immunodominant repetitive amino acid sequence (). The murine monoclonal 
antibody (MAb) human milk fat globule  (HMFG) recognizes a repetitive 
specific epitope of the MUC antigen on the surface of ovarian cancer cells (). 
Radiolabeled murine HMFG can be used for targeting of ovarian cancer cells and 
may even eradicate minimal residual disease (4-6).
Patients that receive murine MAb for cancer diagnosis or therapy may develop 
human anti-mouse antibodies (HAMA) that are directed against the constant 
and/or the variable regions of mouse MAb. About 0-00% of patients with solid 
tumors develop HAMA after exposure to a murine MAb, whereas only about 0% 
of patients with B-cell malignancies treated with MAb develop HAMA, likely due 
to disease-related deficiencies in the immune system of the patients (7-9). HAMA 
can be divided in different antibody isotypes; IgG, IgM, IgA or rarely IgE (0). The 
majority of the antibodies that is produced comprise the IgM and the IgG isotype.
Interestingly, the development of HAMA has been correlated with a longer survival 
in patients with ovarian cancer and B-cell malignancies (7,8,,). Furthermore, 
the clinical consequences of HAMA development may include an enhanced 
clearance of the injected MAb and reduced tumor targeting of the administered 
MAb at repeated injection. These effects are caused by complex formation of the 
injected antibody with developed HAMA in the circulation (0). It is well-known 
that the presence of HAMA in blood may interfere in assays for measurement of 
serum tumor markers such as CA  (). 
We participated in a large international randomized phase III trial of intraperitoneal 
(i.p.) therapy with Yttrium-90-labeled (90Y)-muHMFG, a murine monoclonal 
antibody, in patients with epithelial ovarian cancer after a surgically defined complete 
remission. In an earlier study of our group, we reported that commercially available 
HAMA assays provide unspecific results to accurately identify immune responses 
after monoclonal antibody therapy (4). The present study aims to develop and 
validate two specifically designed ELISAs for the quantitative determination of 
HAMA-IgM and HAMA-IgG in serum of these patients. 
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Materials and Methods
Patients and serum samples 
Serial serum samples of ovarian cancer patients participating in the large phase III 
radioimmunotherapy trial of  mg i.p. 90Y-muHMFG were available for HAMA-
IgM and HAMA-IgG measurements. One of the inclusion criteria of the study 
was a HAMA serum concentration of less than 0 ng/mL (HAMA-ELISA, Roche 
Diagnostics GmbH, Basel, Switzerland) prior to receiving i.p. 90Y-muHMFG 
(week 0) or standard treatment. Patients who only received standard treatment 
served as controls. 
Serum samples were taken before 90Y-muHMFG administration and during follow-
up at week , 4, 8 and then in three-monthly intervals for 6 months. Venous blood 
was collected from an antecubal vein, allowed to clot, centrifuged for 0 minutes at 
000 x g, and serum was stored at -70°C until analyzed. To determine HAMA-IgM 
and HAMA-IgG, serum samples were diluted 0, 00 and 000-fold in dilution 
buffer prior to analysis and measured in singleton. Samples exceeding the standard-
dose range were further diluted (000, 0,000 and 00,000-fold) and HAMA-IgM 
and/or HAMA-IgG analysis was repeated.
Equipment
Nunc MaxisorbTM flat-bottomed immuno-plates used in ELISA experiments 
were obtained from VWR International (Amsterdam, The Netherlands). All 
serum samples of the patients were tested with one batch of plates. For washing 
procedures a 96PW plate washer (SLT Lab Instruments GmbH, Salzburg, Austria) 
was used. Absorbance values were measured with an automated ELISA reader 
(Multiskan Ascent, Lab systems, Helsinki, Finland) at 40 nm.
Reagents
Because there were no calibrators or reference samples available, we used a pool 
of blood of 6 known HAMA-positive patients as calibrator. From this pool serial 
dilutions were made to generate standard dose-response curves (00, 400, 800, 
600, 00, 6400 and ,800-fold dilutions for HAMA-IgM and HAMA-IgG 
ELISAs). The HAMA-IgM and HAMA-IgG concentrations of the 00-fold diluted 
pool were set at 000 arbitrary units per mL (AU/mL). To monitor long-term 
assay performance, we prepared a reference sample from a pool of  other HAMA 
positive serum samples. This reference sample was diluted 0, 00 and 000-fold for 
the HAMA-IgM ELISA and 00, 000 and 000-fold for the HAMA-IgG ELISA.
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Antisoma Research Ltd (London, UK) provided the murine human milk fat globule  
monoclonal antibody (muHMFG). Isotype-specific mouse anti-human IgM horse 
radish peroxidase (HRP) (#900-0) and mouse anti-human IgG(Fc)-HRP (#9040-
0) were both obtained from Southern Biotechnology Associates, Inc (Birmingham, 
Alabama, USA). All serum samples of the patients were tested with one batch of 
muHMFG, mouse anti-human IgM-HRP and mouse anti-human IgG (Fc)-HRP. 
The composition of the buffers was as follows: coating buffer,  mM NaCO and 
 mM NaHCO, pH 9.6; phosphate buffered saline (PBS), 40 mM NaCl, .7 mM 
KCl, . mM KHPO4 and 8. mM NaHPO4.HO, pH 7.4; blocking buffer, % 
bovine serum albumine (BSA) in coating buffer; washing buffer, 0.% Tween 0 in 
PBS; dilution buffer, 0.% Tween-0 and % BSA in PBS; substrate solution, pre-
stained tetramethylbenzidine plus(Kem-En-Tec, Copenhagen, Denmark); stop 
reagent, 0. M HSO4.
ELISA immunoassay 
Because no commercial assay is available for the specific detection of HMFG-
induced HAMA-IgM or HAMA-IgG, home-made ELISAs were developed. The 
coating antibody (muHMFG) was diluted in coating buffer, whereas detection 
antibody as well as calibrator, patient samples and reference samples were diluted 
with dilution buffer. The ELISA procedure started with coating of the microtitre 
plates with  µL per well of  μg/mL HMFG (0 mg/mL) in coating buffer 
overnight at 4°C. After washing the plates twice, wells were blocked with 00 µL % 
BSA in coating buffer during  hour at 7°C. Subsequently, the plates were washed 
4 times. All washing steps were performed with 00 µL per well washing buffer. 
Plates not directly used for the ELISA were non-vacuum packed in a plastic bag 
after drying for one hour at 7°C and stored at -0°C. Plates remained stable for at 
least  weeks (data not shown). Wells were incubated with the samples, calibrators 
and reference preparation (00 µL per well) during  hour at 7°C. After incubation 
the plates were washed again 4 times and subsequently incubated with 00 µL 
per well mouse anti-human IgM-HRP (/,000) or with mouse anti-human IgG 
(Fc)-HRP (/,000) for  hour at 7°C. After incubation the plates were washed 4 
times and manually one last time with 00 µL PBS per well. After incubation for 0 
minutes with substrate the reaction was stopped by adding 00 µL 0. M HSO4 to 
each well. The optical density (OD) was measured at 40 nm within  minutes after 
the reaction was stopped. Each run consisted of  HAMA-IgM and  HAMA-IgG 
plates. Results are expressed in AU/mL.
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Table . Accuracy in terms of parallelism of the reference preparation in the HAMA-IgG 
and HAMA-IgM ELISAs. 
Reference sample HAMA-IgG 
(n = 0)
HAMA-IgM 
(n = 0)
Dilutions (fold) 00 000 000 0 00 000
OD (40 nm) .8 .8 0.9 .8 . 0.6
Dose read (AU) 7.0 6.4 70. 49.6 40. .4
Mean concentration 
(AU/ml) 
7,00 6,400 4,000 09,900 0,00 ,400
SD (AU/mL) 4,600 ,00 ,400 0,600 7,000 7,00
CV (%) 0.6 .7 .9 9.7 4. 4.
Abbreviations: CV, coefficient of variation; OD, optical density; SD, standard deviation.
 
Statistical analysis 
Single measurements of serum samples were performed in three different dilutions. 
HAMA-IgM and HAMA-IgG concentrations were calculated, provided that at 
least two out of three optical density measurements of three dilutions fitted on 
the linear part of the standard curve. The standard curves were approximated as 
polynomials Y=a+bX+cX, with X as the analyte concentration and response Y 
as the determined absorbance value. Detection limits were calculated at the 9% 
level of confidence on the basis of general variance of the slopes of the curves. Two-
sided p-values below 0.0 were considered to be statistically significant.
Results
Standard curves and analytical sensitivity
Figure  shows the standard dose-response curves of HAMA-IgM and HAMA-IgG 
assays. The serum pool serving as the standard curve was applied in seven dilutions 
comprising the standard dose-response curve, which was tested in 0 HAMA-
IgM and 0 consecutive HAMA-IgG assay runs. Between-assays coefficients of 
variations of the seven standard samples ranged from 0.% to 4.% for HAMA-
IgM and 0.7% to .4% for HAMA-IgG. The analytical sensitivity, defined as the 
00
minimum of HAMA-IgM and HAMA-IgG concentration evoking a response 
significantly different from zero calibrator (mean zero calibrator + 4 x SE) was . 
AU/mL for the HAMA-IgM, and 4.7 AU/mL for the HAMA-IgG ELISA.
Parallelism and precision 
To study parallelism, serially diluted reference samples (0, 00 and 000-fold for 
HAMA-IgM and 00, 00 and 000-fold for HAMA-IgG) were compared with the 
standard dose-response lines (Table ). The HAMA-IgM concentrations ranged for 
0 x 0 to  x 0 AU/mL (with optical densities between 0.6 and .8). In the 
case of HAMA-IgG the concentrations corrected for the different dilutions ranged 
between 6 x 0 and 4 x 0 AU/mL (with optical densities between 0.9 and 
.8). To measure HAMA-IgM and HAMA-IgG development in patients treated 
with 90Y-muHMFG, we conducted 0 HAMA-IgM runs and 0 consecutive 
assay runs for HAMA-IgG in a period of 9 months. From these data we calculated 
the assay precision. The within-assay variation for the reference preparation was 
7.% for HAMA-IgM and 6.% for HAMA-IgG, while the between-assay precision 
was 4.% for HAMA-IgM and .% for HAMA-IgG. 
Patient samples
To demonstrate the clinical usefulness of the developed assays used for monitoring 
of patients included in the clinical trial, we measured HAMA-IgM and HAMA-IgG 
in serum longitudinally collected from patients treated with i.p. 90Y-muHMFG and 
Figure . Dose-response curves of HAMA-IgG (black triangle) and HAMA-IgM (blank 
triangle) ELISAs.
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from patients who did not receive this treatment. Figure  shows a typical example of 
serum values of these HAMA-IgMs and HAMA-IgGs. In the patient who received 
i.p.90Y-muHMFG HAMA-IgM values peaked in week  to a concentration of 69 
x 0 AU/mL which declined to 98 AU/mL in week 96. The HAMA-IgG pattern 
of the treated patient reached a maximum value of 790 x 0 AU/mL in week  
after i.p. 90Y-muHMFG administration and gradually declined to 80 x 0 AU/mL 
in week 96. In case of the control patient the HAMA-IgM and the HAMA-IgG 
concentrations at the start of the follow-up were 9 AU/mL and 4 AU/mL, 
respectively. These values remained unchanged during the observation period.
Discussion
The present study describes the development of two sandwich-type ELISAs for 
measurement of HMFG-induced HAMA-IgM and HAMA-IgG in serum samples 
of epithelial ovarian cancer patients who received i.p. radioimmunotherapy with 
90Y-muHMFG. The reliability of the assay in terms of sensitivity, parallelism and 
 Figure . HAMA-IgM (A) and HAMA-IgG (B) values of a control patient  and a 
 patient treated with intraperitoneal 90Y-muHMFG.
Time (weeks)
Time (weeks)
H
AM
A-
Ig
M
 x 
0
 
(A
U/
m
L)
H
AM
A-
Ig
G
 x 
0
 
(A
U/
m
L)
A
B
Active
Active
Control
Control
Time (weeks)
0
precision was tested and considered satisfactory for the measurement of serum 
HAMA-IgM and HAMA-IgG in serum samples of patients enrolled in the phase 
III trial. Patients treated with a single i.p. injection of 90Y-muHMFG developed a 
rapid IgM response, followed by an IgG response. The majority of patients showed an 
early peak for HAMA-IgM within the first 4 weeks, which was followed by a HAMA-
IgG peak approximately -4 weeks later. This is in accordance with the kinetics of 
an immune response as described in literature after exposure of humans to murine 
monoclonal antibodies ().
As mentioned earlier it has been suggested that the development of HAMA 
is associated with an improved survival of patients with B-cell malignancy and 
ovarian cancer (7,8,). In line with these studies one could postulate that a single 
i.p. injection with 90Y-muHMFG may lead to a survival benefit as a result of the 
development of anti-idiotypic HAMA-IgM and HAMA-IgG. These anti-idiotypic 
HAMA (Ab) may in turn evoke an immune response followed by the production 
of anti-anti-idiotypic antibodies (Ab). The antigen binding regions of Ab 
are directed towards the ‘internal image’ of Ab and are similar to the antigen 
that elicited the original anti-idiotypic HAMA response i.e., muHMFG (Ab) 
(6). Because this Ab can have Ab-like reactivity, Ab may target the antigen 
presented on the tumor cell. This immunological cascade, in which each generated 
antibody induces the production of another set of antibodies is known as ‘The Jerne 
network theory’ (7). The induction of these tumor-specific antibodies could not 
only further activate the immune system, but these antibodies may also recognize 
and neutralize tumor cells by antibody-dependent cell cytotoxicity (ADCC) and 
complement-dependent cytotoxicity (CDC) ().
The two developed ELISA assays used murine HMFG as catcher antibody. 
Consequently, the major part of the HMFG-induced HAMA measured with these 
ELISAs in serum will be HMFG-specific, as far as it concerns the idiotypic antibody 
response. Therefore, these assays most likely are not suitable for quantification of 
HAMA generated by other murine MAb, although the muHMFG MAb probably 
shares common epitopes with other murine antibodies, which may elicit anti-isotypic 
HAMA responses identical with those originating from muHMFG.
The present paper describes the development and validation of two ELISAs for the 
detection of HMFG specific HAMA-IgG and HAMA-IgM in serum to monitor the 
humoral immune response of patients with epithelial ovarian cancer as part of a large 
international randomized phase III trial. Further research is in progress, specifically 
using these ELISAs, to study the effect of HAMA-IgG and HAMA-IgM antibodies on 
disease-free and overall survival of patients treated with this murine HMFG.
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Abstract
Background: Human anti-mouse antibody (HAMA)-IgM and IgG in ovarian 
cancer patients treated with intraperitoneal (i.p.) 90Y-muHMFG as consolidating 
therapy were analyzed for a relationship with outcome of disease. 
Patients and Methods: Serial serum samples from 08 ovarian cancer patients 
participating in a phase III trial of i.p. 90Y-muHMFG and  controls were 
analyzed for HAMA-IgM and HAMA-IgG. Results were correlated with time to, 
and location of, disease recurrence.
Results: Patients receiving i.p. 90Y-muHMFG developed a rapid HAMA-IgM peak 
(week 4 to 8), followed by a HAMA-IgG peak -4 weeks later. HAMA levels in 
the control group remained unchanged. Early maximum HAMA-IgG peaks were 
associated with early relapse (hazard ratio (HR), 0.97; 9% confidence interval 
(CI) 0.96 to 0.99; p = 0.0). Patients with a HAMA-IgG maximum before or at 
8 weeks were at significantly higher risk for disease recurrence (HR, .6; 9% CI 
. to .; p = 0.0) as compared to patients with a HAMA-IgG maximum after 
8 weeks. 
Conclusion: Besides time point of maximum HAMA-IgG, no evident relation 
could be found between HAMA-IgM or HAMA-IgG development and time to 
relapse or location of recurrence.
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Introduction
Despite advances in the treatment of ovarian cancer, it is still the leading cause 
of death from gynecological malignancies (). New strategies to improve overall 
survival are needed and radioimmunotherapy (RIT) could be one of the options. 
Human adenocarcinomas overexpress the transmembrane glycoprotein MUC, 
which is normally expressed on the apical surface of glandular epithelial cells (). 
Ninety percent of epithelial ovarian cancer expresses high levels of MUC (). 
MUC in cancerous tissue is antigenetically different from the protein in normal 
tissue as a result of aberrant glycosylation, which leads to the exposure of the peptide 
core of the mucin with its immunodominant repetitive amino acid sequence (). 
The murine IgG monoclonal antibody (Mab) HMFG recognizes this specific 
epitope of MUC on the apical surface of ovarian cancer cells (4). Several studies 
have used radiolabeled HMFG for imaging and therapeutic targeting of ovarian 
cancer lesions in the treatment of ovarian cancer (, 6).
Administration of murine Mabs may provoke the development of human 
anti-mouse antibodies (HAMA) (7). Sero-conversion frequencies of HAMA 
development in patients with solid tumors range from 0-7% after exposure 
to murine Mabs (7). Although the consequences of the presence of HAMA are 
usually minor, subsequent treatment of patients using HAMA with monoclonal 
antibodies may be affected by rapid clearance of the administered antibody from 
the blood. Several studies reported an association between the development of 
antibody-specific HAMA and prolonged survival (8-0). Recently, a large phase 
III clinical study targeting ovarian cancer with intraperitoneal (i.p.) 90-yttrium 
labeled murine HMFG (90Y-muHMFG) showed that there was no disease-free 
or overall survival benefit in patients receiving 90Y-muHMFG compared to those 
receiving standard therapy (). However, there was a significant difference in the 
localisation of disease recurrence as patients receiving i.p. 90Y-muHMFG had 
significantly fewer intraperitoneal disease recurrences, and time to this type of 
recurrence was longer than that of patients in the control group ().
These observations led us to investigate whether the development of HAMA 
correlates with localization and time of recurrence in the 90Y-muHMFG-
treated group. For this purpose, we used two recently developed enzyme-linked 
immunosorbent assays (ELISAs) for specific quantification of the HAMA-IgM and 
the IgG response in these patients ().
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Patients and Methods
Study design and population
Serial serum samples of ovarian cancer patients in complete clinical remission 
participating in a phase III trial of i.p. 90Y-muHMFG () were analyzed for the 
presence of HAMA-IgM and HAMA-IgG directed against the muHMFG. Of 
the 4 patients treated with a single i.p. administration of  mg 90Y-muHMFG, 
08 patients were available for analysis. From the  patients who only received 
standard treatment, we randomly selected  patients to serve as controls. The 
patients were recruited in 74 centers in 7 different countries, in three different 
continents (Europe, Oceania and Northern America). Patients enrolled in the 
study after having given written informed consent; procedures were followed in 
accordance with the Declaration of Helsinki. 
Serial serum samples were taken before (week 0, baseline values), at , 4, 8,  weeks 
after 90Y-muHMFG injection, and in three-monthly intervals thereafter until the 
end of follow-up. Venous blood was collected from an antecubal vein, allowed to 
clot, centrifuged for 0 minutes at 000 x g, and serum was stored at -70°C until 
analyzed. Time to disease recurrence was measured as the number of days between 
second-look laparoscopy and the date of documented disease recurrence up to the 
end of the study.
HAMA-IgM and HAMA-IgG ELISAs
Circulating HAMA-IgM and HAMA-IgG antibodies were measured with two 
ELISAs that were developed in our laboratory as previously described (). Briefly, 
coating antibody HMFG (Antisoma Research Ltd, London, UK) and bovine 
serum albumin (BSA) were absorbed onto microtitre plates. Serum samples were 
tested at dilutions of :0, :00 and :000, and immunoglobulins bound to 
HMFG were detected with mouse anti-human IgM (Fc)-HRP or with mouse anti-
human IgG-HRP (Southern Biotechnology Associated, Birmingham, AL, USA). 
Tetramethylbenzidine plus (Kem-En-Tec, Copenhagen, Denmark) was used as 
substrate, and the reaction was quantified at 40 nm in an ELISA reader (Multiskan 
Ascent, Lab systems, Helsinki, Finland). Results were expressed as arbitrary units 
per milliliter (AU/mL).
Statistical methods
Data analysis was performed using SAS 8.0 and SPSS .0. (SPSS Inc Chicago, 
IL, USA). Differences in disease outcome were tested with Wilcoxon rank sum 
0
test. HAMA-IgM and HAMA-IgG values were analysed in a linear mixed model 
correlating the individual patients with relapse and location of relapse. To analyse 
data in a repeated mixed model, the natural logarithm was used to normalize the 
data. Cox proportional hazards regression model was used to identify prognostic 
factors (4). P-values of < 0.0 were considered significant.
Results
Two hundred and eight ovarian cancer patients who received a single i.p. 90Y-
muHMFG injection and  control patients who received standard treatment 
were evaluated for HAMA-IgM and HAMA-IgG responses. At the start of the 
present study, all patients were in complete clinical remission after debulking and 
chemotherapy, as defined at second-look laparoscopy. The median age of the 08 
patients in the study group was 4 years (range -67 years) and  years for the  
control patients (range -79 years). Out of the 08 patients in the study group, 8% 
(9/08) had a FIGO stage I or II and 7% (49/08) had FIGO stage III or IV. In 
the study group of patients, 48% (00/08) of the patients had no residual disease, 
44% (9/08) had residual disease and in 8% (6/08) the residual disease status was 
unknown. Ninety-eight patients in the study group developed relapse during follow-
up with a median time from second-look laparoscopy to relapse of  year (range 0.-
4.7 years). Patients in the study group were monitored for HAMA-IgM and HAMA-
IgG concentration with a median follow-up of 0 months (range  to 7 months).
HAMA-IgM profile
Baseline HAMA-IgM titers in blood, before 90Y-muHMFG administration, had a 
median value of 997 AU/mL (range 69 to ,000 AU/mL) in the study group and 
a median value of ,04 AU/mL (range 07 to ,78 AU/mL) in the control group. 
Baseline values did not differ significantly between study and control groups. HAMA-
IgM results in the study and the control group during follow-up are displayed in 
Figure A. During follow-up HAMA-IgM in the control group remained unchanged 
as compared to baseline HAMA-IgM levels. The maximum HAMA-IgM level in the 
study group (median ,000 AU/ml; range ,0 to  x 06 AU/mL) was reached at 4 
weeks and was 8-fold higher (range 0.6 to 9-fold) than the median baseline values. 
Ninety-four percent (9/08) of patients in the study group reached a maximum 
HAMA-IgM concentration within 8 weeks after i.p. 90Y-muHMFG administration. 
At the end of the follow-up median HAMA-IgM was .4-fold higher (range . to .8-
fold) than baseline levels.
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HAMA-IgG profile
Baseline HAMA-IgG concentration in blood, before 90Y-muHMFG 
administration, had a median value of ,7 AU/mL (range 00 to ,000 AU/
mL) in the study group and ,0 AU/mL (range 77 to 8,06 AU/mL) in the 
control group. There was no significant difference in baseline HAMA-IgG values 
between the two groups. Figure B shows HAMA-IgG concentrations in the 08 
study and  control patients during follow-up. Maximum HAMA-IgG values 
were reached 8 weeks after administration and were 8-fold (median, range  
to 6-fold) higher than their respective baseline levels. In 9% (9/08) of the 
study group patients, HAMA-IgG reached its maximum within 4 weeks after i.p. 
90Y-muHMFG administration. By the end of follow-up the median HAMA-IgG 
concentration was -fold higher (range .8 to 4-fold) than the baseline level. 
During follow-up HAMA-IgG values in the control group had a median value of 
,74 AU/mL with a range 9 to 9,809 AU/mL. HAMA-IgG concentrations in 
the control group were never higher than three times the baseline values.
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Figure . Development of HAMA-IgM (A) and HAMA-IgG (B) in 08 patients who 
received a single i.p. 90Y-muHMFG injection (stripes) and  patients who received 
standard care (blanc) during follow-up. The HAMA-IgM and HAMA-IgG concentra-
tions are displayed on a logarithmic Y axis and the time is stated on a non-linear X-axis. 
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Correlation of HAMA-IgM and HAMA-IgG with disease-free survival
In order to investigate whether the HAMA-IgM and HAMA-IgG response in the
study group is associated with disease recurrence we studied: (i) the time point at 
which HAMA-IgM and HAMA-IgG reached their maximum concentrations, (ii) 
the maximum HAMA-IgM and HAMA-IgG concentrations (peak concentration), 
and (iii) the individual longitudinal HAMA-IgG and HAMA-IgM measurements 
during follow-up, and correlated these three parameters with disease outcome. 
Furthermore, to include time to relapse in our analysis, we compared results of 
HAMA IgM and IgG between patients with an early (≤  year, n = 4) and a late 
(> year, n = 6) relapse. 
No association was found between the time point of maximum HAMA-IgM 
concentration or the peak concentration HAMA-IgM and relapse, time to relapse 
or location of relapse. Linear mixed model showed no association between the 
individual HAMA-IgM responses and disease outcome (data not shown). Patients 
with an early relapse had higher median HAMA-IgM values during week 4 to  
after 90Y-muHMFG administration than did those with a late relapse, but these 
differences were not statistically significant.
Peak HAMA IgG and the individual HAMA IgG responses in a linear mixed model 
approach during follow-up were not associated with relapse, time to relapse or 
location of relapse. Again, median HAMA-IgG values from week 4 to  tended to 
be higher in patients with an early relapse. However, this difference did not reach 
significance.
Univariate analysis showed a significant association between time point of maximum 
HAMA-IgG values, as a continuous variable, and time to relapse (hazard ratio (HR) 
0.97; 9% confidence interval (CI) 0.96 to 0.99; p = 0.0). To dichotomize this 
parameter, the group was divided into patients with maximum HAMA-IgG before or 
at 8 weeks (i.e. the median time) and patients with a maximum after 8 weeks. Patients 
with a HAMA-IgG peak before or at 8 weeks were at significantly higher risk for 
disease recurrence (HR .7; 9% CI 0.8 to 0.89; p = 0.0) as compared to patients 
with a maximum HAMA-IgG peak after 8 weeks. After correction for residual disease 
and FIGO stage, patients with a HAMA-IgG maximum before or at 8 weeks were still 
at significantly higher risk for disease recurrence (HR .6; 9% CI . to .; p = 0.0) 
than those with a HAMA-IgG maximum after 8 weeks in multivariate analysis. The 
Kaplan-Meier plot of disease-free survival is shown in Figure . When adjusting for 
stage, this difference remained significant (p = 0.00). As to be expected, patients with 
FIGO stage III or higher were at significantly higher risk for recurrence than patients 
with FIGO stage II or less (HR .7; 9% CI . to 4.6; p = 0.00).
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Discussion
This study describes the HAMA response in ovarian cancer patients in complete 
clinical remission after primary treatment who received a single i.p. 90Y-muHMFG 
injection. The majority of patients showed a HAMA-IgM peak within the first 4-8 
weeks, which was followed by a HAMA-IgG peak approximately -4 weeks later. 
Patients in the control group did not show a rise in HAMA-IgM or HAMA-IgG 
values. An early maximum HAMA-IgG peak was associated with early relapse 
(p = 0.0). Patients with a HAMA-IgG maximum before or at 8 weeks were at 
significantly higher risk for disease recurrence (HR .6;9% CI . to .; p = 0.0) 
as compared to patients with a HAMA-IgG maximum after 8 weeks.
The murine Mab HMFG was found to be very immunogenic, as reflected in the 
amount of HAMA-IgM and HAMA-IgG after a single i.p. administration. Similar 
results were found in other studies administering HMFG directly into the peritoneal 
cavity resulting in detectable HAMA levels in almost 00% of the patients (-7). 
This is in contrast to intravenous administration of HMFG after which 0-0% of 
the patients develop HAMA (8). Other Mabs seem less immunogenic as reports 
on HAMA response after Mab administration vary widely between 40 to 90% of the 
patients (0,9,0). The development of an early HAMA-IgM peak within the first 
4-8 weeks after HMFG administration and a HAMA-IgG peak approximately -4 
weeks later is in accordance with the kinetics of an immune response as described in 
literature after exposure of humans to murine Mab (). As to be expected, patients 
in the control group did not show a rise in HMFG HAMA-IgM or HAMA-IgG 
values, since they did not receive an injection of 90Y-muHMFG.
The development of antibody-specific HAMA after Mabs exposure has been 
associated with unexpectedly prolonged survival in cancer patients (8-0;). 
Azinovic et al. (8) demonstrated that higher antibody specific-HAMA titers were 
associated with longer survival in patients with B-cell malignancies treated with I-
Lym-. Recently, a study which treated refractory indolent non-Hodgkin lymphoma 
patients with I-tositumomab (murine Mab) demonstrated an improved survival 
in the four patients that developed HAMA (). Miotti et al. (9) showed that 88% of 
the patients treated with a bispecific antibody OC/TR for ovarian cancer, developed 
antibody-specific HAMA, but only patients with HAMA titers greater than 0 μg/
mL (6% of the HAMA-positive patients) showed an advantage in terms of survival. 
Earlier studies with i.p. radiolabeled HMFG showed a benefit in survival in ovarian 
cancer patients (6,,6). Unfortunately, the large international multicenter phase III 
trial of i.p. 90Y-muHMFG failed to confirm these findings (). However, recently 
4
we reported that despite the absence of improvement in overall survival observed 
in the trial, there was a reduced intraperitoneal disease recurrence in patients 
treated with i.p. 90Y-muHMFG (). Furthermore, time to intraperitoneal 
disease recurrence in patients in the study group was significantly longer as 
compared to the control group. In the present study, we were unable to find an 
association between HAMA-IgM or HAMA-IgG parameters and localization of 
disease recurrence. The observation of reduced i.p. relapse and delayed i.p. disease 
recurrence is most likely an effect of the radiation dose given intraperitoneally 
by 90-Yttrium with which the muHMFG was labeled, and not due to a HAMA 
immune response.
We found an association between the time point at which the HAMA-IgG reaches 
its maximum and disease recurrence. Patients with an early peak (before or at 8 
weeks) were at higher risk for developing relapse as compared to patients with a 
maximum HAMA-IgG peak after 8 weeks. These results should be interpreted 
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Figure . Kaplan-Meier plot of disease-free survival in study patients with a HAMA-
IgG peak before or at week 8 (HAMA-IgG Tmax ≤ 8 wks, n = 6) or after 8 weeks 
(HAMA-IgG Tmax > 8 wks, n = 8). Patients with a HAMA-IgG maximum before or 
at 8 weeks were at a significantly greater risk than patients with a maximum HAMA-
IgG after 8 weeks.
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with caution for there was a wide dispersion in HAMA-IgG values between the 
patients. Some patients had their peak at week 8 while other patients reached their 
peak at week  with already extremly high HAMA-IgG values at week 8. 
In summarry, HAMA-IgM and HAMA-IgG development after a single i.p. 90Y-
HMFG administration occurred in the majority of patients with a primary HAMA-
IgM peak within the first 4-8 weeks, followed by a HAMA-IgG peak approximately 
-4 weeks later. In multivariate analysis, patients with a HAMA-IgG maximum 
before or at 8 weeks were at significantly higher risk for disease recurrence (HR .6; 
9% CI . to .; p = 0.0) as compared to patients with a HAMA-IgG maximum 
after 8 weeks.
At present, work is in progress to study the development of anti-idiotypic (Ab) 
and anti-anti-idiotypic antibodies (Ab) in ovarian cancer patients in this study. 
The production of these anti-idiotypic antibodies has been associated with a 
beneficial disease outcome in previous studies (4,). Further research into the 
possible induction of the idiotypic network after injection with murine Mab should 
be performed to investigate whether the presence of these antibodies improves 
prognosis in ovarian cancer patients.
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Abstract
We investigated whether epithelial ovarian cancer patients participating in a 
randomized phase III trial comparing single intraperitoneal (i.p.) administration 
of yttrium-90-labeled murine HMFG (90Y-muHMFG) plus standard treatment 
(AT) vs. standard treatment (ST) alone developed IgG Ab to MUC that had an 
impact on disease outcome. Serial serum samples from 08 patients in the AT and 
99 patients in the ST arm were tested for IgG Ab to MUC (anti-MUC IgG). 
Anti-MUC IgG at weeks 4, 8 and  ranked higher in the AT than in the ST arm 
(p < 0.00). The median (range) area under the curve (AUC) of anti-MUC IgG 
for weeks  to  was . (.-9.) and .9 (.7-68.74) for the AT and ST 
arm, respectively (p < 0.00). An anti-MUC IgG AUC >  was associated with 
a benefit in overall survival (OS) and disease-free survival (DFS) in the AT arm in 
univariate (p = 0.04 and 0.06, respectively), but not in multivariate analysis (Cox 
proportional hazards regression model). Kaplan-Meier analysis showed a benefit 
in OS and DFS in patients with an anti-MUC IgG AUC >  in the AT arm (p = 
0.04 and 0.06, respectively), but not in the ST arm. A single i.p. injection with 
muHMFG did not lead to a survival benefit in the randomized trial, but it induced 
Ab to MUC that were associated with an improved disease outcome in patients 
with highest levels of anti-MUC IgG. Immunotherapy against MUC could be 
effective in the treatment of epithelial ovarian cancer.

Introduction
Despite advances in chemotherapy during the past decade, the majority of patients 
with ovarian cancer still develop relapse, and -year survival for patients with 
advanced stage disease is only -0% (,). New treatment regimens are needed 
to improve outcome of disease, and immunotherapy targeting tumor antigens 
could be one of these modalities.
MUC is a large heavily 0-glycosylated transmembrane glycoprotein present on 
the apical surface of normal glandular epithelia (), and overexpressed on 90% of 
adenocarcinomas, including epithelial ovarian cancer (4-6). Carcinoma-associated 
MUC induces immune responses to the tumor (7), and serum antibodies (Ab) 
against MUC have been described in patients with ovarian cancer (8). Natural Ab 
to MUC are associated with a benefit in survival in patients with breast, pancreatic 
and lung carcinoma (9-).
Recently, a large international phase III trial was conducted in epithelial ovarian 
cancer patients in complete clinical remission after surgery and platinum-based 
chemotherapy targeting MUC via intraperitoneal (i.p.) administration of the 
radiolabeled murine monoclonal antibody (Mab) HMFG (90Y-muHMFG) (). 
Ovarian cancer patients with no or minimal (microscopic) residual disease at 
second-look laparoscopy (SLL) were randomized to receive a single i.p. injection 
of 90Y-muHMFG and 0 mg of unlabeled HMFG plus standard treatment (AT) 
or standard treatment (ST) alone. The study did not show a disease-free (DFS) 
or overall survival (OS) benefit in patients treated with 90Y-muHMFG (), but 
administration of Mab to cancer patients for diagnosis or therapy is reported to 
induce anti-idiotypic Ab that recognize the tumor-associated antigen targeted 
by the administered Mab (-7), and that are associated with improved disease 
outcome (-7).
The objective of this study was to analyze the presence of IgG Ab to MUC (anti-
MUC IgG) in serial serum samples obtained from the patients taking part in the 
phase III clinical trial of 90Y-muHMFG (), to investigate whether the drug is 
capable of inducing Ab to MUC, and to analyze whether the presence of these Ab 
has an impact on outcome of disease.
Materials and Methods
Patients and serum samples 
A total of 447 patients with epithelial ovarian cancer FIGO stage Ic-IV and 
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macroscopically negative SLL following initial debulking surgery and 6 courses 
of platinum-based chemotherapy, took part in the clinical trial (), and were 
randomized between standard treatment plus i.p. 90Y-muHMFG (active treatment, 
AT, n = 4) and standard treatment (ST, n = ). Patients randomized to the AT 
arm received a single i.p. dose of  mg 90Y-muHMFG between 4 and 8 weeks after 
their final cycle of chemotherapy. The study drug consisted of 0 mg of unbound 
HMFG and the appropriate amount of Yttrium labelled HMFG to achieve a 
dose of 666 MBq/m (8 mCi/m) of body surface area and not exceeding ,0 
MBq/m (0 mCi/m) in total. All patients were observed at regular intervals; 
assessments conducted during the study included clinical tumor evaluation, 
laboratory analyses, ultrasound, CT or magnetic resonance imaging scan. Patients 
had a preentry CT scan with follow-up scans on a yearly basis as long as they 
remained in remission and on study, and a final CT scan. All patients that recurred 
were treated with chemotherapy, as appropriate for the individual case. The study 
was closed in March 004. Date of recurrence was the date of the first CT scan, 
histology or cytology sample that confirmed disease recurrence. Time to disease 
recurrence (DFS) was measured as the number of days between SLL and the date 
of documented disease recurrence (or death, if death occurred without a prior 
diagnosis of relapse) and, for patients that suffered no relapse, as the number of 
days between SLL and the end of the trial (March 8, 004) or when the patient was 
withdrawn from the study, whichever occurred first. Overall survival time (OS) 
was measured as the number of days between SLL and the date of death from any 
cause; survival times for all other patients were measured as the number of days 
between SLL and the end of the trial (March 8, 004) or when the patient was 
withdrawn from the study, whichever occurred first. The study was approved by 
the appropriate scientific and ethical authorities and was conducted in compliance 
with the Declaration of Helsinki. Written Informed consent was obtained from 
each women before randomization.
Serum samples were collected prior to treatment (week 0) and at weeks , 4, 8, , 
4, 6, 60 and 96 after i.p. 90Y-muHMFG injection from patients receiving AT, and 
at equivalent time points from patients in the ST arm. A total of 60 serial serum 
samples from 08/4 patients in the AT arm, and 0 samples from 99/ 
patients in the ST arm were available for testing for anti-MUC IgG; the number 
of serum samples tested at the individual time points in each of the study arms is 
shown in Figure . Serum was stored at –70 °C until analyzed. 
The clinical characteristics of the patients included in the study are described in 
Table . Equality of distribution of clinical characteristics between the two treatment 
4
arms was retained in the patient population available for the present study (age, 
Mann-Whitney U test, p=0.0; FIGO stage, histology, and residual disease after 
surgery, Pearson χ two-sided, p =0.8, p=0.499, and p=0.46, respectively).
MUC1 antibody assay
Anti-MUC IgG was measured with an enzyme-linked immunosorbent assay 
(ELISA) for binding to a 60-mer peptide corresponding to  tandem repeats of 
the MUC peptide core conjugated to bovine serum albumin (BSA), as previously 
described (8). In summary, the BSA-conjugated MUC peptide or BSA were 
absorbed in alternate rows in 96-well ELISA plates. After overnight incubation 
the wells were incubated with BSA to block non-specific absorption sites. Serum 
samples diluted :00 were incubated overnight and immunoglobulins bound to 
the peptide were detected with horseradish peroxidase-conjugated rabbit anti-
human IgG, diluted :0,000. Tetramethylbenzidine was used as substrate and the 
reaction was quantified at 40 nm in a ELISA reader. Serum samples were tested 
in duplicate. Results, calculated as the mean difference between the readings in 
optical density units in experimental and control wells, were read against a five-
point standard curve constructed with huHMFG (9) (Antisoma Ltd, London, 
UK), a humanized Mab against MUC with the same specificity as the murine 
parental antibody (muHMFG), at concentrations of 8, 4, ,  and 0. μg/mL, and 
expressed in arbitrary units per mL (AU/mL).
CA 15-3 assay
Serum CA - (MUC) was measured in the AT population at weeks 0 and 8 
with a commercial assay (Abbott Diagnostics Division, Chicago, Il, USA) (0). The 
detection limit of the assay is .0 arbitrary units per mL (U/mL) and the reference 
value for normal is < 0 U/mL. Samples from 00 patients were available for 
testing. 
Statistical analysis
Statistical analysis was performed using SPSS software (version 4.0, SPSS Inc, 
Chicago, Illinois). Anti-MUC IgG was analyzed as measured in AU/mL. The 
area under the curve (AUC) for anti-MUC IgG (AU/mL) was calculated for each 
individual patient between week  (the value at week 0 was taken when week  was 
not available), 4, 8, and , extrapolating values from the two adjacent values where 
necessary. The total anti-MUC IgG AUC was calculated by adding the sub areas 
for each time span, i.e. the mean of two consecutive measurements multiplied 
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by  the time in weeks between them. Data distribution was nonparametric. Assay 
results in the different groups were analyzed using the Mann-Whitney U test, a 
p value ≤ 0.006 was considered significant (Bonferroni correction). A correlation 
among assay results was evaluated by the Spearman’s rank correlation coefficient. 
Univariate and multivariate analysis of OS and DFS was performed using the Cox 
proportional hazards regression model (). A cut-off value for anti-MUC IgG 
AUC was defined by analyzing in univariate analysis the association with OS of 
the values that divided the AT population into quintiles (0-0, 0-40, 40-60, 60-
Table . Clinical characteristics of the study population.
Clinical characteristics Total population
 n = 407 (%)
Active treatment
n =  08 (%)                    
Standard treatment
n = 99 (%)
Age (years)
Median
Range

-79
4
-76

-79
FIGO stage
Ic – II
III – IV
 (0)
86 (70)
9 (8)
49 (7)
6 ()
7 (69)
Histology
Serous
Mucinous
Endometrioid
Clear cell
Mixed
Undifferentiated
Other
0(6)
8(4)
6 ()
 (6)
 (6)
 ()
7 (4)
8 (6)
6 ()
6 (7)
 (6)
4 (7)
4 ()
8 (4)
 (6)
 (6)
6 ()
 (6)
 (6)
8 (4)
9 ()
Residual disease after surgery
Yes
No
Unknown
64 (40)
08 ()
 (9)
9 (44)
00 (48)
6 (8)
7 (6)
08 (4)
9 (0)
Relapses 89 (46) 98 (47) 9 (46)
Disease-free survival
Median
Range
(years)
.6
0.4 – .77
.76
0.6 – .8
.
0.4 – .77
Deaths  (0) 67 () 4 (7)
Survival (years)
Median
Range
.9
0.7 – 6.00
.89
0.7 – 6.00
.0
0.6 – .77
Patients treated with 90-Y-muHMFG.  All tumors expressed MUC.
6
80, 80-00 percentiles). Multivariate modeling included the following three binary 
covariates: FIGO stage at diagnosis (≤ II vs. ≥ III), presence of residual disease 
after primary surgery (no vs. yes), and anti-MUC IgG AUC ≤ or > than the cut-
off value. The probability of OS and DFS was analyzed using the Kaplan-Meier 
method (), and univariate comparisons between subgroups were made using a 
two-tailed log-rank test. A -tailed p < 0.0 was considered significant.
Results
Anti-MUC1 IgG
Assay results are displayed in Table  and in Figure . Anti-MUC IgG did not 
differ with time in the ST arm, whereas in the AT arm it was elevated from week 4 
onwards as compared to values obtained at week 0 (Table ). Whereas prior to i.p. 
90Y-muHMFG administration at week 0, and in week  there was no difference in 
anti-MUC IgG between the AT and the ST arm, in weeks 4 to  anti-MUC IgG 
ranked significantly higher in the AT than in the ST arm (Table , Fig. ). 
To define a factor that included time as well as levels of anti-MUC IgG, we 
calculated for each patient in the study the area under the curve (AUC) from week 
0/ to week  for anti-MUC IgG AU/mL (anti-MUC IgG AUC). The median 
(range) of anti-MUC IgG AUC was . (.-9.) and .9 (.7-68.74) for the 
AT and ST arm, respectively, and the values ranked significantly higher (p < 0.00) 
in the AT than in the ST arm (Fig. ). 
CA 15-3 
Median CA - (MUC) serum levels in the AT arm at week 0 and 8 were 
6.9 U/mL (range .6 - 7. U/mL) and . U/mL (range .9 – 0.4 U/mL), 
respectively. CA - ranked significantly higher at week 0 than at week 8 (p < 
0.00). Correlation analysis showed a significant correlation between CA -
 levels at week 0 and 8 (Spearman’s rank correlation coefficient, rs=0.76, p < 
0.00), but no correlation was found between CA - and anti-MUC IgG at 
week 0 (Spearman’s rank correlation coefficient, rs=−0.06, p = 0.40) or week 8 
(Spearman’s rank correlation coefficient, rs=0.00, p = 0.676). 
Anti-MUC1 IgG and outcome of disease
Univariate analysis showed a significant association of FIGO stage and residual 
disease after primary surgery with OS and DFS in the total population and in each 
study arm (results not shown). Anti-MUC IgG AUC entered as a continuous 
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variable was not significantly associated to OS and DFS in the total population 
or in the two study arms, but univariate analysis of anti-MUC IgG AUC values 
that divided the AT population in quintiles showed a trend towards a significant 
association with OS of increasing anti-MUC IgG AUC values (p = 0.06) in the 
patients who received the drug. A significant association with OS and DFS of anti-
MUC IgG AUC >  (80th percentile of the AT population) vs. anti-MUC IgG 
AUC ≤  was present in the AT (p = 0.04 and 0.06, respectively), but not in the 
ST arm (p = 0.8 and 0.6, respectively). Sixteen percent of the total population 
(9.7% of the AT and .6% of the ST arm) had values above this cut-off level 
(Pearson χ, p = 0.00). In the ST arm, a higher percentage of patients with anti-
MUC IgG AUC >  was observed in FIGO stage I than in the other three stages 
(Pearson χ, p = 0.07). In the AT arm, the percentage of FIGO stage I patients 
with anti-MUC IgG AUC >  was very similar to that in the ST arm (0% and 
7.%, respectively), but it was much higher than in the ST arm for the other three 
stages (FIGO stage II, 4.% and .4%; FIGO stage III, 7.% and .8%; FIGO 
stage IV 8.% and 0%, respectively). In the AT arm, distribution of patients with 
anti-MUC IgG AUC (≤  or > ) was not significantly related to stage (Pearson 
χ, p =  0.88). Distribution of patients with anti-MUC IgG AUC ≤  or >  did 
not differ in relation to histiotypes (Pearson χ, p = 0.984).
Multivariate analysis of an association with DFS and OS of FIGO stage, residual 
Table . Serial MUC IgG levels (median, range)  in the standard and active treatment group.
Standard Treatment (ST) Active Treatment (AT) ST vs. AT
Weeks Anti-MUC IgG
 (AU/mL)
P Anti-MUC IgG
 (AU/mL)
P P
0 0.4 (0. – 4.78) 0.6 (0. – .07) n.s.
 0. (0.6 – 4.7) n.s. 0.7 (0. – .89) n.s. n.s.
4 0.7 (0.0 – 6.68) n.s. 0.0 (0.4 – 4.) <0.00 <0.00
8 0.7 (0. – 6.) n.s. 0. (0. – 4.) <0.00 <0.00
 0.6 (0. – 6.9) n.s. 0.48 (0. – .4) <0.00 <0.00
4 0.6 (0. – 6.9) n.s. 0.44 (0.4 – 8.) 0.004 n.s.
6 0. (0.4 – .4) n.s. 0.44 (0. – 4.7) 0.006 n.s.
60 0.4 (0.6 – 4.8) n.s. 0.4 (0. – .70) n.s. n.s.
96 0.4 (0.6 – 7.) n.s. 0.4 (0. – .60) n.s. n.s.
P values of ≤ 0.006 are considered significant (Bonferroni correction).
Mann-Whitney U test, comparison of results at each time point with results at week 0. 
Mann-Whitney U test, comparison of results between ST and AT group at each time 
point. Abbreviations: n.s., not significant.
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disease after primary surgery, and anti-MUC IgG AUC in the total population 
and in the AT and ST arms is shown in Table . In the total population, FIGO stage 
was the only factor significantly associated with DFS and OS. The significance 
of FIGO stage as a prognostic factor for OS was lost in the AT arm (p = 0.4), 
but maintained in the ST arm (p = 0.0). Additional multivariate analyses that 
included interactions between FIGO stage and anti-MUC IgG AUC in each of 
the treatment arms did not reveal significant interaction effects (FIGO stage/anti-
MUC IgG AUC, ST arm, OS, p = 0.80 , DFS p = 0.8; AT arm, OS, p = 0.99, 
DFS, p = 0.78). Kaplan Meier analysis of OS and DFS in the total population 
in relation to anti-MUC IgG AUC ≤  (n = 4) or >  (n = 66) showed no 
significant survival benefit for the patients with a anti-MUC IgG AUC >  (p = 
0.0 and p = 0.09, respectively).  Kaplan-Meier plots of OS in the ST and AT arm 
in relation to anti-MUC IgG AUC are shown in Figure A and B, respectively. 
Whereas no OS benefit was observed in the ST arm in relation to an anti-MUC 
IgG AUC >  (Fig. A), in the AT arm (Fig. B) OS probability was significantly 
higher for patients with an anti-MUC IgG AUC >  than in patients with an 
anti-MUC IgG AUC ≤  (78% vs. 0%, p = 0.04). Although OS probability was 
higher in patients with an anti-MUC IgG AUC > , differences did not remain 
significant (p = 0.097) after adjusting for FIGO stage ≤ II vs. ≥ III (relative risk anti-
MUC IgG AUC > vs. ≤ , 0., CI 0. – .). Kaplan-Meier plots of DFS in 
the ST and AT arm in relation to anti-MUC IgG AUC are shown in Figure C 
and D, respectively. Whereas no difference in DFS was observed in the ST arm 
(Fig. C), patients in the AT arm (Fig. D) with an anti-MUC IgG AUC >  had a 
significantly higher probability of DFS than patients with an anti-MUC IgG AUC 
≤ (9% vs. 0%, p = 0.06). As with OS, differences did not remain significant 
(p = 0.) after adjusting for FIGO stage ≤ II vs. ≥ III, but again DFS probability 
was higher in patients with an anti-MUC IgG AUC >  than in patients with an 
anti-MUC IgG AUC ≤ (relative risk anti-MUC IgG AUC >  vs. ≤ , 0.6, 
CI 0.6 – .09).   
Discussion
The randomized clinical trial provided an unprecedented opportunity to study 
natural humoral immune responses to MUC in a large population of patients 
with epithelial ovarian cancer, and to evaluate the impact of anti-MUC IgG on 
outcome of disease. Ovarian cancer patients can develop natural ab to MUC (8), 
and a recent study related the presence of events predicting occurrence of ab to 
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Figure . Box and whisker plots (median, quartiles, range) of anti-MUC IgG (AU/mL) 
at weeks 0 to 96 for patients in the AT (grey boxes) and ST (white boxes) arm. The dotted 
reference line corresponds to the median values at week 0. The number of serum samples 
available for testing at each time point are indicated in the figure. Results in the ST and 
AT arm were compared with the Mann-Whitney U test, *p <0.00; p values ≤0.006 are 
considered significant (Bonferroni correction). 
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MUC, such as number of ovulatory cycles and use of oral contraceptives, with a 
diminished risk of ovarian cancer (,4). A natural immune response to MUC 
may well play a role in disease prevention, but, contrary to what we observed 
in breast cancer (9), it does not seem to affect the course of disease in ovarian 
cancer, as a number of patients in the ST arm had natural Ab to MUC but no 
clear benefit in DFS or OS was observed. However, similarly to what we observed 
in breast cancer (9), the percentage of patients with elevated anti-MUC IgG is 
higher in early than in late stage of disease, and these Ab may play a role initially in 
controlling disease spread, providing a wider window for early diagnosis. 
Earlier phase I/II studies established the development of anti-idiotypic Ab after 
administration of radiolabeled muHMFG (). More recently, a phase I trial of 
idiotypic vaccination with muHMFG in ovarian cancer reported the development 
of Ab (i.e. anti-idiotypic ab, binding to muHMFG) and anti-MUC Ab (i.e. anti-
anti-idiotypic Ab, Ab, binding to MUC) in the vaccinated patients (). We 
have shown that a single i.p. injection of 0 mg of muHMFG and 90Y-muHMFG 
induces the production of anti-MUC IgG with a maximum at weeks 4, 8 and  
after administration of the drug. Anti-MUC IgG was also present in the control 
arm, but in significant lower levels as compared to the treatment arm, and the 
levels did not differ with time. Furthermore, no difference in anti-MUC IgG 
was observed at time point 0 between the treatment and control arm. Therefore, 
although we did not measure Ab responses, we can infer the induction of an 
idiotypic network resulting in Ab (anti-MUC IgG) responses in the group of 
patients that received the drug. Serum MUC (CA -) may complex with the 
murine Mab and, together with the murine, foreign region of the antibody that 
acts as an adjuvant, these immune complexes may recruit the immune system 
and lead to B-cell activation, maturation and differentiation that result in the 
generation of Ab, some of which are directed to MUC (Ab). Alternatively, the 
destruction of tumor cells caused by the radiolabeled Mab liberates tumor antigen 
that complexes with the monoclonal to induce the immune response. Whereas 
antigen shedding and tumor necrosis are probably responsible for the induction of 
natural immune responses to the tumor, it may not be the primary mechanism here, 
as the patients had no or minimal (microscopic) residual disease at second-look. 
However, killing of tumor cells and, possibly, monocytes and B-cells expressing 
MUC by the radiolabel may provide an inflammatory microenvironment with 
cytokines helping B cells switch Ab isotypes. 
Multivariate analysis showed FIGO stage to be the only prognostic factor 
significantly associated to time to progression and death in the total population. 
≤

Time (years)
Figure . Kaplan Meier curves of overall and disease-free survival in the standard (a and c, 
respectively) and in the active treatment group (b and d, respectively) in relation to anti-
MUC IgG AUC ≤  or > . Fig. b: patients with an anti-MUC IgG AUC ≤  had a mean 
OS time of .98 years (9% CI .70 – 4.7 years); patients with an anti-MUC IgG AUC > , 
had a mean OS time of . years (9% CI 4.7 – .66 years). Fig c: patients with an anti-
MUC IgG AUC  ≤  had a mean DFS of .88 years (9% CI .4 – . years); Fig d: patients 
with an anti-MUC IgG AUC> had a mean DFS of .84 years (9% CI . – 4.4 years).
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FIGO stage remained as the only prognostic factor for OS in the ST arm, but was 
no longer significant in the AT arm, probably due to the influence on survival of 
anti-MUC IgG in the latter. A similar trend could be observed in the association 
of FIGO stage and anti-MUC IgG with DFS. Whereas the humoral immune 
response induced by the drug was associated with a benefit in disease outcome in 
Kaplan-Meier analysis, no difference in disease outcome in relation to anti-MUC 
IgG was observed in the group of patients that did not receive the drug. 
In spite of the beneficial effect of anti-MUC IgG on disease outcome within the 
trial arm receiving the drug observed in the present study, no survival benefit 
was apparent in the original randomized phase III trial (). Either the number of 
patients who developed IgG Ab to MUC after a single administration of the drug 
was not large enough, or the induced immune response was not sufficiently strong 
and sustained to lead to a significant difference in disease outcome between the 
two arms of the trial. The trial was not designed to induce an immune response: 
The main goal was to target intraperitoneal micrometastases with the radiolabeled 
murine HMFG and destroy ovarian cancer cells. Consequently, the level and 
duration of the induced immune response to MUC was weak, and the impact 
on outcome of disease was small. The immune response induced in patients with 
FIGO stage I disease, possibly the group least immunocompromised, was not 
much higher than the natural immune response suggesting a threshold for the 
immune response obtained in this way. It was, however, strong enough to induce an 
immune response in the more advanced stages as, contrary to what was observed 
with the natural immune response, no significant difference in the distribution of 
patients with high anti-MUC IgG between stages was observed in the treatment 
arm. A treatment protocol designed to induce optimal immune responses to the 
antigen could lead to greater benefits in disease outcome. Idiotypic vaccination 
with muHMFG is possible (), however, to avoid the induction of human anti-
mouse antibodies (HAMA) and the consecutive higher clearance and toxicity of 
HMFG after repeated administration, use of huHMFG (0) should be considered. 
HuHMFG is capable of effecting antibody-dependent cell-mediated cytotoxicity 
(ADCC) that is enhanced by cytokines that stimulate NK cells (6,7). HuHMFG 
has been investigated in phase I clinical trials in patients with advanced breast 
cancer: The Ab was well tolerated and  cases of prolonged stable disease were 
seen, supporting its advancement to phase II clinical trials (8). Vaccination of 
patients with breast cancer with MUC peptides induces Ab capable of effecting 
ADCC (6,9,0). Furthermore, our recent studies show that purified IgG samples 
obtained from serum from 9 patients with adenocarcinoma with high levels 
4
of natural anti-MUC IgG bind to MUC expressed on breast cancer cells, and 
mediate ADCC (M.Moreno, unpublished results). Vaccination with MUC 
glycopeptides in an adjuvant setting, alone or in combination with other tumor 
antigens, is a further treatment option to achieve optimal MUC Ab levels that 
could benefit disease outcome ().
The large phase III trial () in which ovarian cancer patients were randomized 
between standard and i.p. 90Y-muHMFG treatment did not show a survival 
benefit for the patients receiving the study drug. In spite of the executed protocol 
being suboptimal for inducing an effective immune response, a number of patients 
in the AT arm developed IgG ab to MUC that led to a benefit in survival and 
disease-free survival for patients who developed high levels of anti-MUC IgG. 
Immunotherapy designed to induce optimal immune response to MUC may have 
an impact in disease outcome in patients with ovarian cancer.
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Discussion
This thesis describes our findings on site and time of disease recurrence and 
induced humoral immune responses in ovarian cancer patients in complete clinical 
remission, who were treated with a single intraperitoneal (i.p.) dose of 666 MBq/
m 90Y-muHMFG. MuHMFG is a murine monoclonal antibody (Ab) directed 
to the antigen MUC, expressed on ovarian cancer cells. The patients participated 
in an international multi-centre randomized phase III clinical trial comparing the 
effect on disease outcome of a single i.p. 90Y-muHMFG administration followed 
by standard treatment to standard treatment alone (). Although the phase III 
trial did not result in improvement of overall survival, we observed that patients 
receiving a single dose of i.p. 90Y-muHMFG had delayed and fewer i.p. relapses 
compared to patients undergoing standard treatment (chapter ). Local disease 
control may have been brought about either by the induction of an immune 
response to muHMFG, or by the radiation dose guided to the i.p. tumor lesions, 
or by a combination of both. 
We hypothesized that the injection of muHMFG leads to the production of anti-
idiotypic Ab (Ab) directed to the hypervariable region of muHMFG, which 
in turn may induce the production of anti-anti-idiotypic Ab (Ab). The antigen 
binding region of Ab is directed to Ab and resembles the hypervariable region of 
muHMFG. These induced Ab are capable of binding with the HMFG-defined 
epitope of the tumor-associated antigen MUC on ovarian cancer cells, directing 
the immune response towards these tumor cells. 
As demonstrated in this thesis a single i.p. dose of 90Y-muHMFG can induce 
muHMFG-specific human anti-mouse antibodies (HAMA) IgG, IgM and anti-
MUC IgG Ab (Ab), possibly reflecting an idiotypic network unleashed as a 
reaction to the foreign Ab, muHMFG. The majority (9%) of patients developed 
HMFG-specific HAMA-IgG and HAMA-IgM indicating induction of a humoral 
immune response. From week 4 to  after 90Y-muHMFG administration, anti-
MUC IgG levels in serum of treated patients were significantly higher as compared 
to baseline levels. We correlated HMFG-specific HAMA-IgG and HAMA-IgM 
with the induced Ab to explore the existence of a cascade-like immune response 
to muHMFG, and thus indirectly to MUC present on ovarian cancer cells. 
No significant correlation was found between the levels of the various immune 
responses. The  maximum anti-HMFG HAMA-IgG levels in serum occurred later 
as compared to maximum levels of anti-MUC IgG, apparently not supporting a 
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cascade-like development of Ab. In chapter 7 we calculated the area under the 
curve (AUC) of anti-MUC IgG from week  to  to define a factor accounting 
for time as well as levels of anti-MUC IgG. Individual HMFG-specific HAMA-
IgG AUC values did not significantly correlate with anti-MUC-IgG values. In 
conclusion, we were unable to determine a significant relation between HMFG-
specific HAMA-IgG and anti-MUC levels.
The lack of correlation between HMFG-specific HAMA IgG and anti-MUC IgG 
levels may be explained by the design of the HMFG-specific HAMA-IgG and 
IgM assays. These tests, described in chapter , measure a mixture of anti-isotypic 
Ab (directed towards the constant region of muHMFG) as well as anti-idiotypic 
Ab (Ab). The mixture of anti-isotypic and anti-idiotypic Ab as measured in our 
HMFG-specific HAMA-IgG and IgM assays was most likely variable from patient 
to patient. Ideally, one prefer to measure exclusively the anti-idiotypic Ab (Ab) 
part of the reaction, and correlate this response with the induced anti-MUC IgG 
to investigate the relation between Ab and Ab. Unfortunately, we were unable 
to develop an assay which specifically measures anti-idiotypic Ab responses. 
However, the presence of Ab in patients that received i.p. 90Y-muHMFG does 
suggest a preceding Ab response by a cascade-like idiotypic immune response to 
muHMFG.
It has been shown that the presence of high levels of pretreatment antibodies to 
MUC is associated with a benefit in survival in lung, pancreatic, and breast cancer 
patients (-4). In chapter 7 of this thesis, we demonstrated that ovarian cancer 
patients with highest levels of anti-MUC IgG had an improved disease-free 
survival. This finding is in accordance with the results described in literature (-4). 
Conversely, recent findings in BRCA/ mutation carriers who are at increased 
risk for developing ovarian cancer, showed that natural antibodies to MUC 
ranked lower in patients with BRCA/ mutation as compared to healthy controls 
(). The latter suggests that induction of anti-MUC IgG is hampered in BRCA 
/ mutation carriers, which may result in a higher life-time risk for developing 
ovarian cancer. 
The multi-centre phase III trial on efficacy of 90Y-muHMFG was unable to 
demonstrate an improvement in disease outcome. However, we did find that 
patients in the active treatment arm receiving i.p. 90Y-muHMFG had delayed 
and less intraperitoneal disease recurrence, suggesting local disease control. To 
determine the role of an induced humoral immune response in local disease control, 
we correlated HMFG-specific HAMA-IgG, IgM and anti-MUC IgG with the site 
of disease recurrence. Analysis of site of relapse and HMFG specific HAMA-IgG, 
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IgM or anti-MUC IgG response did not show any significant correlation between 
antibody titres and site of disease recurrence. Thus, the observed regional effect 
in delayed and fewer intraperitoneal relapse in ovarian cancer patients receiving 
i.p. 90Y-muHMFG is most likely due to the effect of the radiation dose to the 
tumor lesions or perhaps a combination of both the effect of induced Ab and the 
radiation.
The muHMFG antibody used in the phase III trial was labeled with 90Y. This 
radionuclide () is a high energy β-emitter (Emax=. MeV) with high tissue 
penetration. It has been pointed out that when a 90Y-labeled antibody targets a 
cm tumor lesion 70 percent of the energy would be deposited outside the lesion 
(6). This characteristic makes it an unsuitable radionuclide for the treatment of 
minimal disease consisting of tumor nodules of only a few mm. To obtain an 
optimal radiotherapeutic effect in patients with minimal residual disease, medium-
energy β-emitters, e.g. Lutetium-77 and Copper-67, are more effective as the 
electrons of these radionuclides have a shorter penetration range in tissue.
Besides i.p. 90Y-muHMFG ( mg), patients in the phase III trial also received 0 
mg i.p. unconjugated muHMFG (unlabeled) to target tumor cells. Several studies 
have shown that enhancement of the dose of monoclonal antibodies (Mab) can 
negatively affect the efficacy of radioimmunotherapy (RIT). Kranenborg et al. (7) 
demonstrated that tumor uptake of radiolabeled Mab was relatively lower at high 
protein doses as compared to low Mab doses. Similar results were obtained in 
several other studies (8,9). Translating these findings to the phase III trial one may 
argue that tumor targeting could be optimized by administering a lower muHMFG 
protein dose. To further increase the effect of i.p. RIT with radiolabeled muHMFG 
the optimal protein dose should be determined in this setting.
A single dose of i.p. 90Y-muHMFG administered to ovarian cancer patients in 
complete clinical remission achieves a degree of local disease control, and induces 
the production of Ab against MUC that may protect against disease progression. 
The presence of anti-MUC IgG (Ab) suggests the existence of an idiotypic 
network induced by muHMFG. Both the local radiation effect (of the radiolabeled 
antibody) and the cytotoxic effect of the induced Ab were insufficient to favourably 
affect survival.
It should be noted that the phase III trial was not designed to specifically detect site 
of disease recurrence. The trial did not dictate a uniform protocol to trace site of 
disease recurrence and thus we had to analyze these data retrospectively (chapter 
). Furthermore, the search for extraperitoneal disease recurrence turned out to 
4
be of variable intensity which may have biased our results. Apart from delayed 
and fewer intraperitoneal disease recurrence observed in patients receiving 90Y-
muHMFG, the number of patients with extraperitoneal disease recurrence was 
higher in the arm receiving the drug compared to the control arm. This apparent 
paradox may be explained by the pattern of growth and progression of ovarian 
cancer, with growth in the abdominal cavity leading to ascites and involvement 
of other intra-abdominal organs. These serious complications frequently define 
the course of disease and outcome in patients with ovarian cancer. In other words, 
the consequences of locoregional disease spread are so nefarious, that distant 
metastases play a minor role in the final image of the disease. The shift from fewer 
and delayed intraperitoneal relapse to more and earlier extraperitoneal recurrences 
in the active treatment arm ultimately resulted in comparable mean progression 
free survival times in both arms of the international phase III trial ().
Future perspectives
To optimize RIT in ovarian cancer patients in complete clinical remission 
several improvements can be considered. A disadvantage of the treatment with 
muHMFG is the production of HAMA which limits repeated administration of 
the murine Mab and may occasionally induce allergic responses. The presence 
of HAMA induces rapid clearance from the circulation of subsequently infused 
Ab, reducing uptake of the radiolabeled HMFG in the tumor. To overcome these 
problems a humanized successor of muHMFG, has been produced (huHMFG). 
This humanized Mab can be administered repeatedly with minimal side effects, 
as evidenced in a recent phase I clinical trial in breast cancer patients (www.
antisoma.com). Furthermore, several studies have shown that this Mab induces 
tumor cell lysis in vitro (0,). On the other hand the murine Mab is possibly 
more effective in inducing an idiotypic immune response than its humanized 
counterpart, huHMFG, as the foreign constant region of the Mab acts as an 
adjuvant that contributes to recruit the immune system (). Immunotherapy 
trials with monoclonal antibodies aiming to destroy disseminated tumor cells and/
or inducing anti-idiotypic antibodies against the tumor in several types of cancer 
have shown that repeated administration of the specific antibody is required to 
induce an adequate immune response (-7). As a single administration of 
muHMFG was insufficient to induce an immune response that influenced disease 
outcome, repeated administration should be considered. However, the effect of 
repeated administrations of muHMFG will be countered by the rapid clearance 
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of the murine Ab bound to HAMA. Therefore, the use of huHMFG in repeated 
administrations should be superior to muHMFG and will more likely result in the 
production of an optimal and persisting immune response to MUC. 
Wang et al. (8) showed that metastases of primary ovarian carcinomas with 
high MUC expression also express high levels of MUC, and therefore can be 
targeted with anti-MUC therapy. This enables the possibility of tumor control 
outside the peritoneal cavity. A combination of i.p. 90Y-huHMFG to address 
disease in the abdominal cavity, followed by repeated intravenous (i.v.) huHMFG 
administrations to reach tumor deposits outside the abdominal cavity could be a 
new treatment option to reduce tumor burden more effectively.
To improve the therapeutic efficacy of monoclonal antibodies, cytokines have 
been co-administered to activate natural killer (NK) cells and to increase antibody-
dependent cell-mediated cytotoxicity (ADCC). Both mechanisms result in 
the destruction of tumor cells. The administration of IL-, IL- and IL- has 
been shown to activate NK cells and to augment ADCC in vitro (0;9,0). As 
the cytotoxic effect on tumor cells of huHMFG as well as Ab is mediated by 
ADCC, a more effective tumor response may be obtained by co-administration of 
huHMFG and cytokines, hereby intensifying the therapeutic effect (). 
In our studies muHMFG was used to target the tumor-associated antigen (TAA) 
MUC on ovarian cancer cells. Apart from MUC there are several other TAAs 
expressed on ovarian cancer cells (chapter b). In a study of Chauhan et al. () 
multiple TAA staining (CA , TAG-7 and MUC) achieved > 9% labeling 
of ovarian cancer cells in over 98% of the 48 epithelial ovarian cancers tested. 
Treatment with a monoclonal Ab ‘cocktail’ directed towards different tumor-
associated antigens present on ovarian cancer cells may increase the chance to 
target all tumor cells. Furthermore, after debulking and pathological examination 
of the individual tumor specimens, Mab treatment can be optimized by selecting 
those specific Mabs directed against the TAA’s expressed on the particular tumor 
of the patient.
As described above, several potential options to optimize RIT with HMFG are 
available. Improvement of the radiation effect can be accomplished by using a 
radionuclide that emits β-particles of medium energy. Targeting of tumor cells 
may be maximized by administering the optimal antibody protein dose and 
administering humanized Mab (huHMFG), to induce maximum tumor-uptake 
of the Mab and to prevent induction of HAMA. To induce an optimal immune 
response, repeated administrations of the huHMFG could be performed and the 
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co-administration of cytokines could be considered. Additionally, a Mab cocktail, 
tailored to the individual tumors, can be used to target all TAAs present on ovarian 
cancer cells. 
In summary, the studies in this thesis have shown that a single i.p. 90Y-muHMFG 
administration in ovarian cancer patients may reduce and delay intraperitoneal 
relapse, but does not influence disease-free and overall survival. However, i.p. 
administration of muHMFG induces an immune response to MUC, which is 
associated with an improved disease outcome. The effect of repeated systemic 
administrations of huHMFG on disease outcome in patients with ovarian cancer 
(to control disseminated tumor spread), together with repeated intraperitoneal 
administration of radiolabeled huHMFG (to achieve local control) given in an 
adjuvant setting should be tested in randomized prospective trials.
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Summary
Ovarian cancer remains one of the major causes of death in women in the Western 
world and cure is seldom achieved. The yearly incidence of ovarian cancer in the 
Netherlands is approximately ,00 cases. Despite intensive treatment, the majority 
of patients develop recurrent disease, particularly in the abdominal cavity, of which 
most patients die. The incapacity to control this disease within the peritoneal cavity 
is a major cause of treatment failure in ovarian cancer patients. New treatment 
strategies are necessary to optimize therapy in these patients. Antibody-based 
therapy such as immunotherapy with unconjugated antibodies, vaccination and 
radioimmunotherapy could be future treatment modalities useful for this disease. 
Antibodies are multifunctional molecules that can target tumor cells, stimulate 
the immune system to attack tumor cells and engage receptor pathways effective 
in tumor cell destruction. In chapter b we reviewed the current literature on 
monoclonal antibody (Ab) therapy in ovarian cancer.
This thesis describes our findings on site and time of disease recurrence and induced 
humoral immune response in ovarian cancer patients in complete clinical remission 
after a single intraperitoneal (i.p.) dose of 90Y-muHMFG. The murine monoclonal 
antibody muHMFG is directed towards the tumor-associated antigen MUC present 
on ovarian cancer cells. The patient population of this thesis is that of the international 
clinical trial which compared the effect on outcome of disease of a single i.p. dose 
of 90Y-muHMFG followed by standard treatment to standard treatment alone. No 
survival benefit was observed in the group of patients receiving the drug compared to 
patients undergoing only standard treatment. Nevertheless, we observed that patients 
receiving a single dose of i.p. 90Y-muHMFG had delayed and fewer intraperitoneal 
relapses than the patients in the standard treatment arm, suggesting a certain degree 
of local disease control (chapter ). However, this effect was offset by more and earlier 
extraperitoneal disease recurrence in the active treatment arm resulting in similar 
overall survival in both the active and standard treatment arm.
As the majority of the ovarian cancer patients mainly develop disease recurrence 
intra-abdominally, administering therapeutics directly into the peritoneal cavity 
seems an attractive treatment option. In chapter  we studied the biodistribution 
of a single i.p. dose of 90Y-muHMFG. Two out of the first three patients had 
extraperitoneal leakage of the i.p. medication to retroperitoneal spaces covering 
the upper and lower quadrant of the abdomen. Adjustments in the procedure, as 
described in chapter , reduced leakage considerably, as in the next 4 patients 
only  patients showed leakage of medication. 
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Additionally, the administration of murine monoclonal antibodies (Mab) may 
induce the development of human anti-mouse antibodies (HAMA). These 
antibodies may interfere in measurements of cancer antigen  (CA ) in 
serum. This tumor marker is used to monitor disease recurrence in ovarian cancer 
patients after primary therapy. The CA  assay uses a murine catcher antibody 
to which HAMA may react, resulting in falsely elevated CA  levels. In chapter 
4 we demonstrated that HAMA present in blood after a single injection of 90Y-
muHMFG transiently interfered in the CA assay.
We hypothesized that a single i.p. muHMFG administration leads to the production 
of anti-idiotypic Ab (Ab) directed to the hypervariable region of muHMFG, 
which in turn may induce the production of anti-anti-idiotypic Ab (Ab). To 
measure the HMFG-specific immune response after treatment of patients with 
90Y-muHMFG, we developed a reliable method to measure the human HMFG-
specific HAMA-IgG and IgM immune response (chapter ). The majority (9%) 
of patients receiving i.p. 90Y-muHMFG in the phase III trial developed HMFG-
specific HAMA-IgG and HAMA-IgM indicating induction of a humoral immune 
response. As was to be expected, these patients developed a rapid HMFG-specific 
HAMA-IgM peak (week 4 to 8), followed by a HAMA-IgG peak -4 weeks later 
(chapter 6). No direct relation could be found between HMFG-specific HAMA-
IgM or HAMA-IgG levels and location of disease recurrence.
In chapter 7, we studied the presence of anti-MUC IgG Ab in serial serum samples 
obtained from patients in the phase III trial, in order to investigate the induction 
of a MUC specific immune response (Ab). Anti-MUC IgG levels ranked 
significantly higher in the active treatment arm from week 4 to  after injection 
as compared to the standard treatment arm. To define a parameter that included 
time as well as levels of anti-MUC IgG, we calculated for each patient the area 
under the curve (AUC) from week 0 or  till week . Patients with highest levels of 
anti-MUC IgG ab had an improved disease-free and overall survival (chapter 7).
To test our hypothesis that injection of i.p. muHMFG leads to the production of 
Ab and Ab, we correlated HMFG-specific HAMA-IgG with the induced anti-
MUC IgG (Ab). Individual HMFG-specific HAMA-IgG AUC values did not 
significantly correlate with anti-MUC IgG AUC values. In conclusion, we were 
unable to determine a significant relationship between HMFG-specific HAMA-
IgG and anti-MUC IgG levels (chapter 8).
We correlated HMFG specific HAMA-IgG, IgM or anti-MUC IgG with site of 
disease recurrence, to evaluate whether the regional effect, as described in chapter 
, was mediated by the humoral immune response to i.p. muHMFG (chapter 8). 
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Analysis on relapse site and HMFG specific HAMA-IgG, IgM or anti-MUC IgG 
response did not show any significant correlation between antibody titres and 
site of disease recurrence. Thus, the observed regional effect in delayed and fewer 
intraperitoneal relapse in ovarian cancer patients receiving i.p. 90Y-muHMFG is 
most likely due to the effect of the radionuclide or perhaps a combination of both 
the effect of induced Ab and the radionuclide.
Based on the above findings we conclude that a single i.p. dose of 90Y-muHMFG 
in ovarian cancer patients in complete clinical remission achieves a degree of local 
disease control, and induces the production of Ab against MUC that potentially 
protects against disease progression. The presence of these Ab suggests the 
existence of an idiotypic network induced by muHMFG.
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Samenvatting
In Nederland sterven jaarlijks ongeveer 00 vrouwen aan eierstokkanker. De 
ziekte presenteert zich meestal laat en genezing is dan moeilijk te bewerkstelligen. 
De standaard therapie bestaat uit chirurgische reductie van de tumor gevolgd door 
chemotherapie. Ondanks deze intensieve primaire behandeling ontwikkelen veel 
patiënten een recidief. In het merendeel van de gevallen recidiveert de ziekte in de 
buikholte, waaraan patiënten uiteindelijk overlijden. Om (regionale) ziekte controle 
te bewerkstelligen zijn er nieuwe behandelmethoden nodig. Al enkele decennia 
wordt er intensief onderzoek gedaan naar de mogelijkheden van immunotherapie 
bij patiënten met eierstokkanker. Hierbij worden antilichamen gebruikt om de 
tumorcel te merken waardoor het immuun systeem de tumorcel kan herkennen. 
De gebruikte antilichamen zijn specifiek gericht tegen antigenen die aanwezig 
zijn op de celmembraan van de tumorcellen. Door het merken van de tumorcel 
kan het immuunsysteem geactiveerd worden tot herkenning en destructie van de 
specifieke tumorcellen. 
Een eerder verrichtte gerandomiseerde internationale fase III studie waarin 
eierstokkanker patiënten in complete klinische remissie werden gerandomiseerd 
tussen eenmalige intraperitoneale (i.p.) toediening van het Ytrium-90 gebonden 
murine HMFG (90Y-muHMFG) en de standaard behandeling liet geen verschil 
in overleving zien tussen beide behandelgroepen. HMFG is een muizen 
monoklonaal antilichaam gericht tegen het antigen MUC dat wordt gepresenteerd 
op eierstokkanker cellen. In dit proefschrift hebben wij de patiënten populatie 
van de internationale fase III studie gebruikt om het soort ziekte recidief en de 
humorale respons na eenmalige i.p. 90Y-muHMFG toediening te bestuderen. Wij 
observeerden dat patiënten na behandeling met i.p. 90Y-muHMFG significant 
minder intraperitoneale recidieven en significant meer extraperitoneale 
recidieven ontwikkelden. Helaas werd dit verschil teniet gedaan doordat de 
actieve behandelgroep significant vroeger en meer extraperitoneale recidieven 
ontwikkelde, welke uiteindelijke leidde tot gelijke overlevingscijfers. Echter het 
verschil in intraperitoneale en extraperitoneale recidieven in de twee groepen 
suggereert een zekere mate van regionale ziekte controle na behandeling met i.p. 
90Y-muHMFG.
Aangezien het merendeel van de eierstokkanker patiënten een recidief in de 
buikholte ontwikkelt, lijkt het voor de hand liggend om medicatie direct i.p. 
toe te dienen. In hoofdstuk  hebben we de biodistributie van een eenmalige 
i.p. toediening van 90Y-muHMFG bestudeerd. Bij  van de eerste  patiënten 
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werd er extraperitoneale lekkage van de medicatie gezien, verspreid over de 
retroperitoneale ruimte.  Hierop is de toedieningsprocedure aangepast waarna 
er een aanzienlijke vermindering van lekkage werd waargenomen. Van de daarop 
volgende 4 patiënten hadden slechts  patiënten extraperitoneale lekkage van de 
toegediende i.p. medicatie. 
De toediening van een murine monoklonaal antilichaam (Ab) kan gepaard gaan 
met het ontstaan van humane anti-muis antilichamen (HAMA). Uit de literatuur 
is bekend dat deze HAMA kunnen interfereren met metingen van o.a. tumor 
merkstoffen in serum. De tumor merkstof cancer antigen  (CA ) wordt in 
patiënten met eierstokkanker gebruikt om het ontstaan van een ziekte recidief te 
volgen na de primaire behandeling. De CA  test gebruikt een muizen ‘catcher’ 
antilichaam waaraan HAMA kan binden. Dit kan resulteren in vals verhoogde CA 
 waarden. In hoofdstuk 4 beschrijven wij dat de aanwezigheid van HAMA na 
i.p. 90Y-muHMFG toediening de CA  metingen tijdelijk kan verstoren. 
Zoals uit de literatuur bekend is, kan het toedienen van een monoklonaal 
antilichaam leiden tot de productie van specifieke antilichamen tegen dit 
monoklonale antilichaam. Wij stelden de hypothese dat eenmalige toediening 
van i.p. 90Y-muHMFG leidt tot de productie van anti-idiotypische antilichamen 
(Ab) gericht tegen het hypervariable deel op het muHMFG. Deze Ab kunnen 
door hun aanwezigheid weer de productie van anti-anti-idiotypische Ab (Ab) 
induceren. Het hypervariabele deel van Ab past op het MUC antigen aanwezig 
op eierstokkanker cellen waardoor het immuunsysteem deze tumorcellen kan 
herkennen. 
Om de immuunrespons na toediening van i.p. 90Y-muHMFG in eierstokkanker 
kanker patiënten te evalueren hebben we een test ontwikkeld om de specifieke 
muHMFG HAMA-IgG en HAMA-IgM concentraties in serum te meten. De 
test en de analytische chemische specificaties worden beschreven in hoofdstuk 
. Het merendeel (9%) van de patiënten uit de internationale fase III studie die 
i.p. 90Y-muHMFG ontvingen, ontwikkelden HMFG-specifieke HAMA-IgG and 
HAMA-IgM. Dit suggereert de inductie van een immuun respons. Zoals verwacht 
ontwikkelden de patiënten uit de actieve behandelgroep een snelle muHMFG 
specifieke HAMA-IgM piek (van week 4 tot week 8 na injectie) op de voet gevolgd 
door een muHMFG specifieke HAMA-IgG piek  tot 4 weken later (hoofdstuk 
6). Een significante relatie tussen HMFG-specifieke HAMA-IgM of HAMA-IgG 
waarden en het soort ziekte recidief (i.p. vs. extraperitoneaal) kon echter niet 
worden waargenomen. 
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De mogelijke aanwezigheid van anti-anti-idiotypische antilichamen (Ab) na 
eenmalige i.p. 90Y-muHMFG behandeling hebben wij bestudeerd in hoofdstuk 7. 
Hierin hebben we anti-MUC IgG Ab (Ab) waarden bepaald in serieel afgenomen 
bloedmonsters van patiënten in de internationale fase III studie. Anti-MUC IgG 
concentraties waren significant hoger in de actieve behandel groep van week 4 tot 
 na toediening van i.p. 90Y-muHMFG ten opzichte van de controle groep. Om 
een parameter te definiëren die zowel tijd als hoogte van de anti-MUC spiegels 
beschrijft, werd voor iedere patiënte de ‘oppervlakte onder de curve (area under 
the curve; AUC) van week 0 of  tot en met week  berekend. Patiënten met 
de grootste anti-MUC IgG Ab AUC hadden een langere ziektevrije periode en 
overleving in vergelijking met patiënten met kleinere anti-MUC IgG Ab AUCs 
(hoofdstuk 7).
Wij gingen ervan uit dat de eenmalige toediening van i.p. 90Y-muHMFG zou 
leiden tot de productie van Ab en Ab. Om dit te testen hebben we de HMFG-
specifeke HAMA-IgG gecorreleerd met de geïnduceerde anti-MUC IgG Ab (Ab). 
Individuele HMFG-specifieke HAMA-IgG AUC waarden waren niet significant 
gecorreleerd aan de individuele anti-MUC IgG AUC waarden (hoofdstuk 8).
In hoofdstuk  van dit proefschrift beschrijven wij een regionaal effect van de i.p. 90Y-
muHMFG behandeling. Om te onderzoeken of dit regionale effect bewerkstelligd 
wordt door een humorale immuun response hebben we de HMFG specifieke 
HAMA-IgG, IgM en anti-MUC IgG concentraties gecorreleerd met het soort 
ziekte recidief (i.p. vs. extraperitoneaal). Deze analyse liet geen significante relatie 
zien. Hieruit kunnen we concluderen dat het eerder geobserveerde regionale effect 
van minder intraperitoneale recidieven in de behandelde groep niet wordt verklaard 
door een humorale immuunrespons. Zeer waarschijnlijk wordt het regionale effect 
bewerkstelligd door straling van de radionuclide (90Y) of door een combinatie van 
de radionuclide en de productie van Ab. 
Op basis van de studies beschreven in dit proefschrift kunnen we concluderen 
dat een eenmalige i.p. 90Y-muHMFG toediening in eierstokkanker patiënten in 
complete klinische remissie leidt tot lokale ziekte controle zonder effect op de 
lange termijn overleving. Daarnaast induceert het de productie van Ab tegen 
MUC die mogelijk beschermen tegen ziekte progressie. Bovendien suggereert de 
aanwezigheid van deze antilichamen, Ab, de aanwezigheid van een idiotypisch 
netwerk dat wordt geïnduceerd door muHMFG. 

Dankwoord
Samen sterk is het motto achter dit proefschrift want dankzij een 
samenwerkingsverband tussen het oosten en het westen des lands en de inzet van 
vele mensen werd het mogelijk het project tot dit proefschrift te volbrengen. 
Beste Leon, boordevol enthousiasme wist je me te strikken voor dit geweldige 
doch ingewikkelde onderzoek. Daarbij wist ík je te strikken voor een potje squash, 
want dat had je ‘al jaren’ niet meer gedaan. Ik bewonder je eeuwige inzet voor 
kankerpatiënten, ze hebben een goede aan je. Dank voor je wetenschappelijke en 
menselijke begeleiding tijdens mijn promotie traject.
Beste Fred, altijd accuraat, kritisch en fris en van tijd tot tijd plek voor een grap. 
Goed om te zien dat de professor ook een mens is met kinderen en kippen. 
Bedankt voor je eeuwige inzet en nuchterheid rondom al die cijfertjes en daarnaast 
je persoonlijk belangstelling.
Beste Otto, wat was de Mab wereld af en toe ondoorzichtig voor mij. Gelukkig kon 
je mij meerdere malen het pad wijzen waardoor de stukjes toch op zijn plek kwamen. 
Dank voor je everlasting kom maar langs dan hebben we het er even over.
Beste Chris, samen hebben we wat Excel sheets voorbij zien komen waarin je me 
leerde hoe het berekenen van de MoM net wat makkelijker kon. Gelukkig was er 
nog tijd voor je mooie verhalen en schilderijen. Het was een aangename verrassing 
en een welkome afwisseling van het computer werk.
Beste Silvia, na lange werkdagen kwam ik bij jou om ook nog ‘even’ aan mijn 
promotie te werken. Die combinatie was soms teveel. Dank voor je oprechtheid, 
gastvrijheid en steun, daarin ben je een voorbeeld voor mij. 
Lieve Joanne de Hullu, dankzij jouw motiverende, enthousiaste inzet voor het 
onderzoek ben ik voor de bijl gegaan. Dank voor jouw spetterende begeleiding 
tijdens mijn eerste stappen in de wetenschappelijke wereld.
Beste kantoortuinbewoners van het eerste tijdperk en de vissekom. Met zijn 
allen in een tuin: wat was het wennen, maar eigenlijk ook wel erg gezellig. Anika, 
Alwin, Annemarie, Arno, Bea, Charlotte, Dennis, Godfried, Gwendolyn, Irene, Nel, 
Nienke, Sabine, Willianne, Wouter; dank jullie voor jullie steun en gezelligheid in 
de tuin en ten tijde van het memorabele onderzoekers weekend.
ACE laboratorium medewerkers: Anneke, Doorlène, André, Nicolai, Paul en alle 
andere medewerkers. Ik wil jullie bedanken voor de warme, flexibele en gezellige 
werkplek die jullie mij geboden hebben als ik weer eens met Doorlène in de vriezer 
6
had gezeten. Anneke dankzij jouw oplettend- en meedenkendheid konden we altijd 
weer een stapje verder komen. Doorlène, efficiëntie en accuratesse zijn twee woorden 
die je op het lijf zijn geschreven! André, dank voor de terugkerende uitleg die je me 
over FPLC hebt gegeven. Nicolai, je bent een bijzonder mens. Paul, statistieken is voor 
mij het toppunt van hersengymnastiek, dank voor je wijze raad in tijden van nood.
Beste leden van de maatschap gynaecologie JBZ. Dank jullie wel voor de steun ten 
tijde van mijn ANIOS tijd en de prettige en leerzame AIOS tijd bij jullie. Ik mis het 
JBZ, locatie GZG, forever!
Beste gynaecologen van het UMC St Radboud. Bedankt voor jullie steun en 
persoonlijke belangstelling. Het is leuk om AIOS bij jullie te zijn.
Lieve Bianca, Chantal, Esther, Ilham, Karen, Myrthe, Petra, Sylvie en Yvonne, wat 
hadden we het gezellig daar in het JBZ. Dank voor jullie steun op het werk, met de 
promotie maar ook privé.
Lieve AIOS gynaecologie: dank voor jullie steun en gezelligheid. Ik ga er nog een 
paar gezellige, ik bedoel, leerzame jaren van maken.
Lieve Ineke, maatje in de kantoortuin en goede vriendin. Gelukkig vulde je me aan 
met ME en begreep ik je everlasting WAAATTT. Dank!
Lieve Maartje, teman selalu. Vele reizen hebben we samen gemaakt, maar ik ben 
ervan overtuigd dat er nog meer gaan komen.
Lieve Anneke: fijn dat jij, jij bent en mijn vriendin!
Lieve vrienden en familie, met de opleiding tot gynaecoloog en een promotie is er 
van veel sociale activiteiten de laatste jaren niet veel gekomen. Hierdoor schitterde 
ik in afwezigheid. Gelukkig heb ik niet alles hoeven missen, maar vanaf het moment 
dat de promotie een feit is zal ik weer schitteren in áánwezigheid, of jullie het nu 
leuk vinden of niet….
Lieve mama, je blijven ontwikkelen hebben we van jou geleerd. Ik vind het 
bewonderenswaardig hoe jij er iedere keer weer vol passie voor gaat! Wat een geluk 
dat jij mijn mama bent.
Lieve papa, jij hebt ongekende discipline en doorzettingsvermogen tot het 
stronteigenwijze toe. Woorden zeggen gelukkig niet alles en we weten toch wel 
wat je bedoeld. Terimah kasih Ayah saya.
Lieve Steef, yo bro, mijn allerliefste broer. Dank voor wie je bent en hopelijk weten 
jij en Eli nu dat ik geen onderzoek doe naar baarmoederhalskanker.
Lieve Eli, lief zusje. Wat zit je toch ver weg. Gelukkig weet ik dat afstand niets zegt 
en je er eigenlijk altijd bij bent.
7
Lieve Hans, mijn lief. Makkelijk was anders met mij de afgelopen jaren. Dankbaar 
ben ik dat Kenia ons samen heeft gebracht. Met jou is echt alles leuker. So much 
better together (JJ)!!
Momenten van stilte en vreugde doen je beseffen dat dit het is. Het leven, jouw 
leven, mijn leven, ons leven.
Live Life!
8
Bibliography
Y.R.P. de Waal, C.M.G. Thomas, A.L.M. Oei, C.G.J. Sweep and L.F.A.G. 
Massuger. Secondary ovarian malignancies: frequency, origin and characteristics. 
International Journal of Gyn Cancer 009 accepted.
L.H. Gerritzen, N. Hoogerbrugge, A.L.M. Oei, F.M. Nagengast, M.A. van Ham, 
L.F.A.G. Massuger and J.A. de Hullu. Improvement of endometrial biopsy over 
transvaginal ultrasound alone for endometrial surveillance in women witgh Lynch 
syndrome. Fam Cancer 009 accepted.
A.L.M. Oei, C.G.J. Sweep, A. Geurts-Moespot, D. van Tienoven, S. von Mensdorff-
Pouilly, C.M.G. Thomas and L.F.A.G. Massuger. Human anti-mouse IgM and 
IgG responses in ovarian cancer patients after radioimmunotherapy with 90Y-
muHMFG. AntiCancer Research 008;8:7-6.
A.L.M. Oei, M. Moreno, R.H. Verheijen, C.G.J. Sweep, C.M.G. Thomas, L.F.A.G. 
Massuger and S. von Mensdorff-Pouilly. Induction of IgG antibodies to MUC and 
survival in patients with epithelial ovarian cancer. International Journal of Cancer 
008;:848-.
A.L.M. Oei, C.G.J. Sweep, C.M.G. Thomas, O.C. Boerman and L.F.A.G. Massuger. 
The use of monoclonal antibodies for the treatment of epithelial ovarian cancer 
(review). International Journal of Oncology 008;:4-7. 
A.L.M. Oei, C.G.J. Sweep, L.F.A.G. Massuger, A.J. Olthaar and C.M.G. Thomas. 
Transient human anti-mouse antibodies (HAMA) interference in CA  
measurements during monitoring of ovarian cancer patients treated with murine 
monoclonal antibody. Gynecologic Oncology 008;09:99-0.
A.L.M. Oei, O.C. Boerman, A. Geurts-moespot, JE van Eerd, D. van Tienoven, N. 
Courtenay-Luck, CM. Thomas,L.F.A.G. Massuger and F.C. Sweep. Development 
of ELISAs for quantification of HMFG-specific human anti-mouse IgG and IgM 
antibodies. International journal of biological Markers 007;:67-7. 
9
A.L.M. Oei, J.M. Grefte, B.P. Havenith and J.A. de Hullu. An enlarged groin node 
as first manifestation of a malignancy: don’t forget the ovaries. European Journal of 
Obstetrics & Gynecology and Reproductive Biology 007;:7-9.
A.L.M. Oei, L.F.A.G. Massuger and W.J.G. Oyen. Extraperitoneal leakage as 
possible explanation for failure of intraperitoneal treatment in ovarian cancer. 
Cancer Biotherapy and Radiopharmaceuticals 007:;08-4.
A.L.M. Oei, R.H. Verheijen, M.V. Seiden, B.B. Benigno, A. Lopes, J.T. Soper, A.A. 
Epenetos and L.F.A.G. Massuger. Decreased intraperitoneal disease recurrence in 
epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment 
with yttrium-90-labeled murine HMFG without improvement in overall survival. 
International journal of Cancer 007;0:70-4.
A.L.M. Oei, M.R.J. Salet-van de Pol, S.M. Borst, A.P. van de Berg and J.M.M. Grefte. 
‘Owl’s eye’ cells in a cervical smear of a transplant recipient: don’t forget to inform 
the referring physician. Diagnostic cytopathology 007:;7-9.
A.L.M. Oei, L.F.A.G. Massuger, H. Bulten, N. Hoogerbrugge, J.A. de Hullu. Familial 
ovarian screening: how to address abnormal TVU findings and what about the 
efficacy of screening? Letter to the Editor, British Journal of Cancer 006:9;6-7.
A.L.M. Oei, L.F.A.G. Massuger, H. Bulten, N. Hoogerbrugge, J.A. de Hullu. 
Surveillance of women at high risk for hereditary ovarian cancer is inefficient. 
British Journal of Cancer 006:94;84-9.
60
Abbreviations
Ab  antibody
ADCC   antibody-dependent cell-mediated cytotoxicity 
Anti-MUC IgG   IgG antibodies to MUC
AT   90Y-muHMFG plus standard treatment 
AUC   area under the curve
CR   complete remission
CI   confidence interval 
CV   coefficient of variation 
DFS   disease-free survival 
ELISA   Enzyme-linked immunosorbent assay
FIGO   Fédération Interationale de Gynécologie et d’Obstetrique
FPLC  Fast Protein Liquid Chromatography 
HAMA   human anti-mouse antibodies
HMFG   human milk fat globuline
HR   hazard ratio 
HRP   horseradish peroxidase Hu human
IFN   interferon 
i.v.   intravenous
i.p.   intraperitoneal
i.m.   intramuscular
Mab   monoclonal antibody
NC   not calculated
ND   not detectable
NS   not significant
NC   not calculated
OD   optical density
OS   overall survival 
PD   progressive disease
PFS   progression-free survival
PR   partial response
s.c   subcutaneous
SD   stable disease/ standard deviation
SEM  standard error of mean
SLL   second-look laparoscopy
ST   standard treatment 
TSH   thyroid stimulating hormone
vs.   versus
90Y-muHMFG  yttrium-90-labeled murine monoclonal antibody HMFG
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